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The innate immune response to bacterial products plays a critical role in host
defence against infection, yet this response can be of benefit or detriment to the host
depending on its magnitude. Lipopolysaccharide (LPS) or endotoxin, the major
component of the outer membrane of Gram-negative bacteria, is the archetypal
bacterial signal that activates innate immunity. LPS provides a potent and pleiotropic
stimulus for immune cells and has been implicated in the pathogenesis of various
clinical conditions. Most significantly, exposure to excessive levels of LPS in the
circulation can lead to Gram-negative septic shock, a clinical syndrome characterised
by fever, disseminated intravascular coagulation, multiple organ failure, and
potentially death. Thus, strategies aimed at modulating the effects of LPS on the
innate immune response are desirable.
Elafin is a cationic, low molecular weight elastase inhibitor produced locally
in the respiratory tract, in the skin and at mucosal sites in many tissues. Several
biochemical characteristics of elafin, such as low molecular weight, cationicity,
heavy disulphide bonding and tissue distribution at mucosal sites, suggested that it
may possess anti-endotoxin properties similar to defensins and other cationic
antimicrobial peptides.
Here we have demonstrated that elafin binds directly to LPS of both smooth-
form and rough-form type. This binding was shown to occur within the conserved
lipid A portion of the LPS molecule, and binding of elafin to LPS inhibited
subsequent interaction of LPS with LPS-binding protein (LBP). Moreover, both
terminal domains of elafin were shown to bind LPS and preclude this interaction.
Furthermore, elafin inhibited TNF-a secretion from LPS-stimulated
macrophages in serum-containing conditions in vitro, but enhanced TNF-a secretion
in serum-free milieu. These findings suggest that extracellular elafin may play
divergent roles in the innate immune response to LPS depending on the site of
infection, for example serum-rich bloodstream or serum-deficient mucosal sites. A
II
replication-deficient adenovirus vector encoding human elafin cDNA (Ad-elafin)
was used to extend these studies to demonstrate that elafin may also act
intracellularly to dampen macrophage responses to LPS.
This LPS-modulatory activity prompted us to study the antimicrobial
properties of elafin. Ad-elafin infection of primary murine tracheal epithelial cells ex
vivo conferred antimicrobial activity against Staphylococcus aureus, but
compromised the inherent ability of cells to kill Pseudomonas aeruginosa.
In summary, elafin may play a role in innate immunity by modulating host
responses to Gram-negative bacterial LPS. Elafin could function to enhance immune
responses in sites of local inflammation, such as the airways, but to down-regulate
potentially deleterious responses to LPS in the circulation.
Ill
ACKNOWLEDGEMENTS
I have received an enormous amount of help from numerous individuals in the completion of
this work, but several are worthy of special mention.
Most notably, I would like to thank my supervisor Dr Jean-Michel Sallenave for his
tremendous enthusiasm for this project, throughout both the laboratory research and the protracted
writing of this thesis, and also for his patience and invaluable advice.
I am also extremely grateful to the various members of the Gene Transfer Group, past and
present, who have provided help, suggestions and friendship over a number of years. In this regard,
Mr Mark Marsden, Mr Tom Brown, and Drs Peter Henriksen, Gerry McLachlan, Jason King, Grainne
Cunningham and Kinley Farmer are deserving of special mention. Without these people in particular
the execution of this work would have been considerably less fun. Also deserving of a particular
mention is Dr Yatish Lad of the LIG, who has been a tremendous help in many regards, but none
more so than in sorting out computer-related woes, and in being a mainstay in the pub (alongside Dr
Morag Martin).
During the course ofmy research, significant periods of time were spent working with other
research groups in a collaborative capacity. In this regard, many thanks are due to the research groups
of Professor John Govan, Dr Julia Dorin and Professor Ian Poxton for their invaluable assistance and
willingness to make me feel welcome. In particular, I would like to thank Dr Alison Maxwell (who
has provided me with both immense help in a working capacity, and great friendship, over a number
of years), Dr Cathy Doherty, Mrs Wendy Hannant and Dr Richard Gibbs. In all cases, it has been a
pleasure to work with these people.
My best friend Tony Lewis has campaigned relentlessly to be given a mention in my
acknowledgements, so in reward for his persistence I'd like to thank him for his loyal friendship
during the long publess nights over the past year (and for providing the further stress of a best man's
speech as I was struggling through Chapter 1!).
An immense thank-you goes to my parents, who have been tremendously supportive
throughout my countless years as a student, despite having absolutely no idea what I do!
My partner Julie Love is deserving of a special thank-you for her incredible patience and
support in the last few years, and no doubt she will also be delighted to see the back of this thesis!
Many thanks to all individuals who have provided assistance in the completion of this work.





Ad-elafin Adenovirus encoding human elafin cDNA
Ad-lacZ Adenovirus encoding the lacZ gene
AP-1 Activating protein-1
APS Ammonium persulphate
ASL Airway surface liquid
BAL Bronchoalveolar lavage
BPI Bactericidal/permeability-increasing protein
BSA Bovine serum albumin





CD Cluster of differentiation
cDNA Complementary deoxyribonucleic acid
CF Cystic fibrosis
CFTR Cystic fibrosis transmembrane conductance regulator
cfu Colony forming units






DMEM Dulbecco's Modified Eagle's Medium
DNA Deoxyribonucleic acid
E. coli Escherichia coli
ECL Enhanced chemiluminescence
v
EDTA Ethylene diamine tetraacetic acid
ELISA Enzyme-linked immunosorbent assay
FCS Foetal calf serum
GPI Glycosylphosphatidylinositol
H. influenzae Haemophilus influenzae
HBD Human p-defensin
HD Human defensin
HEK Human embryonic kidney
HNE Human neutrophil elastase
HNP Human neutrophil peptide
HRP Horseradish peroxidase
HSP Heat-shock protein
IkB Inhibitor of kB
IFN Interferon
IKK Inhibitor of kB kinase
IL Interleukin
IRAK Interleukin-1 receptor-associated kinase
IRF3 Interferon-regulatory factor 3
J1385 Pseudomonas aeruginosa strain J1385
JNK c-Jun N-terminal kinase
K. pneumoniae Klebsiella pneumoniae
kDa Kilodaltons
Kdo 2-keto-3-deoxyoctulosonic acid
LAL Limulus amoebocyte lysate
LBP Lipopolysaccharide-binding protein








MAPK Mitogen-activated protein kinase
mCD14 Membrane-bound CD14
MCMV Murine cytomegalovirus
MCP Monocyte chemoattractant protein
MD-2 Myeloid differentiation protein-2
MEEM Minimum Essential Eagle's Medium
MIF Macrophage migration inhibitory factor
MIP Macrophage inflammatory protein
moi Multiplicity of infection
MPC Multicatalytic proteinase complex
MRSA Methicillin-resistant Staphylococcus aureus
MyD88 Myeloid differentiation factor 88




NOD Nucleotide-binding oligomerization domain
O- O-polysaccharide antigen
O.D. Optical density
P. aeruginosa Pseudomonas aeruginosa
PAGE Polyacrylamide gel electrophoresis
PAMP Pathogen-associated molecular pattern
PAOl Pseudomonas aeruginosa strain PAOl
PBS Phosphate buffered saline
p/ Isoelectric pH
PIA Pseudomonas Isolation Agar
PRR Pattern-recognition receptor
RNA Ribonucleic acid
RSV Respiratory syncytial virus





SDS Sodium dodecyl sulphate
SLPI Secretory leukocyte proteinase inhibitor
TEMED N,N,N',N'-tetramethylethylenediamine
TGF Transforming growth factor
TICAM-1 TIR-containing adapter molecule-1
TIR Toll/interleukin-1 receptor
TIRAP TIR domain-containing adapter protein
TLR Toll-like receptor
TMB 3,3',5' 5 -tetramethylbenzidine
TNF Tumour necrosis factor
TRAF6 TNF receptor-associated factor 6
TRIF TIR-domain containing adapter inducing IFN-P
USG Ultroser G medium







TABLE OF CONTENTS IX
LIST OF FIGURES XVI
LIST OF TABLES XXI
CHAPTER 1: INTRODUCTION
1.1. OVERVIEW 1
1.2. INNATE IMMUNITY 3
1.3. BACTERIAL LIPOPOLYSACCHARIDES 6
1.3.1. Overview of LPS 6
1.3.2. General structure of LPS 8
1.3.2.1. O-polysaccharide 10
1.3.2.2. Core oligosaccharide 11
1.3.2.3. Lipid A 13
1.3.3. Activation of innate immunity by LPS 15
1.3.3.1. Severe sepsis and septic shock 17
1.4. LPS RECOGNITION AND SIGNALLING PATHWAYS 20
1.4.1. TOLL-LIKE RECEPTORS 20
1.4.1.1. Overview 20
1.4.1.2. Toll-like receptor 4 (TLR4) and LPS recognition 21
1.4.1.3. The LPS receptor complex 25
1.4.1.4. Myeloid-differentiation factor (MyD88)-dependent
TLR4 signalling 29
1.4.1.5. Myeloid-differentiation factor (MyD88)-independent
TLR4 signalling 31
1.4.2. TLR4-INDEPENDENT MECHANISMS OF LPS
RECOGNITION 33
1.4.2.1. Integrin CD11/CD18 33
IX
1.4.2.2. LPS-activation cluster 34
1.4.2.3. Cytosolic receptors - NOD proteins 34







1.5.4. Activities of defensins/cathelicidins distinct from antimicrobial
action 41
1.6. LOW MOLECULAR WEIGHT PROTEINASE INHIBITORS/
FOUR-DISULPHIDE CORE PROTEINS 44
1.6.1. Overview 44
1.6.2. Secretory leukocyte proteinase inhibitor (SLPI) 45
1.6.3. Elafin 48
1.7. SUMMARY 53
1.8. CENTRAL HYPOTHESES 54
CHAPTER 2: MATERIALS AND METHODS
2.1. MATERIALS 55
2.1.1. Source of chemicals and reagents 55
2.1.2. Synthetic human elafin peptides 55
2.1.3. Polyclonal rabbit anti-human elafin antibody 55
2.1.4. Adenoviral constructs 56




2.2.1. TECHNIQUES RELATED TO ELAFIN/LPS BINDING
STUDIES 58
X
2.2.1.1. LPS separation using Invitrogen NuPAGE
(polyacrylamide gel electrophophoresis) Novex Bis-Tris
electrophoresis system (minigels)
2.2.1.2. LPS separation using maxigel PAGE (pH 8.8)
2.2.1.3. Dot blotting
2.2.1.4. PAGE (pH 8.8) (minigel) system to investigate
binding of peptides to LPS
2.2.1.5. Acidic (pH 4.5) native PAGE (minigels)
2.2.1.6. Coomassie staining
2.2.1.7. ELISA technique to investigate inhibition of the
LPS-LBP interaction
2.2.1.8. ELISA technique to investigate elafin/LBP
competition for binding to LPS
2.2.2. CELL CULTURE
2.2.3. ELAFIN PEPTIDE/LPS CELL-BASED ASSAYS
2.2.3.1. Stimulation ofRAW 264.7 murine macrophages with
LPS
2.2.3.2. Investigation of the effects of elafin peptides on the
TNF-a response ofRAW 264.7 murine macrophages
To LPS
2.2.3.3. Investigation of the effects of elafin peptides on the
MIP-2 response ofmurine Clara cells to LPS
2.2.4. ADENOVIRUS/LPS CELL-BASED ASSAYS,
& RELATED TECHNIQUES
2.2.4.1. Infection ofRAW 264.7 murine macrophages with
adenoviral constructs (Ad-elafin, Ad-lacZ, Ad-ItcB,
Ad-dl70/3, Ad-m-eotaxin, Ad-mSLPI or vehicle alone)
2.2.4.2. Investigation of the effects of calcium phosphate
(CaPi) precipitates on the inflammatory responses
ofRAW 264.7 murine macrophages
2.2.4.3. Stimulation of adenovirally-infected RAW 264.7



















2.2.4.4. Staining for P-galactosidase in RAW 264.7
murine macrophages 67
2.2.4.5. Lysis of cells for measurement of intracellular elafin 68
2.2.4.6. Elafin ELISA 68
2.2.5. ANTIMICROBIAL STUDIES & RELATED TECHNIQUES 68
2.2.5.1. Infection of murine Clara cells with adenoviral
constructs (Ad-elafin, Ad-lacZ or vehicle alone)
and investigation of antimicrobial activity against
P. aeruginosa 68
2.2.5.2. SDS-PAGE & Western Blotting to detect elafin
in culture media from Ad-elafin-infected Clara cells 69
2.2.5.3. Isolation and culture ofprimary murine tracheal
epithelial cells 70
2.2.5.4. Infection of primary murine tracheal epithelium
with adenoviral constructs (Ad-elafin, Ad-lacZ or
vehicle alone) 71
2.2.5.5. Staining for p-galactosidase in primary murine
tracheal epithelium 72
2.2.5.6. Assay to investigate the effects of elafin gene
augmentation on the antimicrobial activity of primary
murine tracheal epithelium against Pseudomonas
aeruginosa and Staphylococcus aureus 72
2.2.6. STATISTICAL ANALYSIS 73




3.2.1. Preliminary experiments to visualise LPS serotype
ladders and establish conditions for initial interaction assays 74
3.2.2. Direct interactions of elafin with LPS 78
XII
3.2.3. Investigation of a potential elafin binding domain within
the LPS molecule 86
3.2.4. Effects of elafin on the interaction of LPS with LBP 96
3.3. DISCUSSION 103
3.3.1. Technical considerations - control proteins 103





CHAPTER 4: THE EFFECTS OF ELAFIN PEPTIDES ON THE
INFLAMMATORY RESPONSE OF MACROPHAGES AND CLARA
CELLS TO LPS IN VITRO
4.1. AIMS 123
4.2. RESULTS 124
4.2.1. Experiments to characterise LPS response and serum
requirements ofRAW 264.7 murine macrophages 124
4.2.2. The effects of elafin peptides on LPS-mediated TNF-a
secretion by RAW 264.7 murine macrophages 129
4.2.2.1. LPS stimulation ofmacrophages in medium
containing serum 129
4.2.2.2. LPS stimulation ofmacrophages in serum-free
medium 135
4.2.3. The effects of elafin peptides on LPS-mediated MIP-2
secretion by murine bronchiolar epithelial
cells (Clara cells) 141
4.2.3.1. LPS stimulation of Clara cells in medium
containing serum 141




4.3.1. Effects of elafin on LPS-mediated cellular activation in the
presence of serum 154
4.3.2. Effects of elafin on LPS-mediated cellular activation in the
absence of serum 156
4.3.3. Potential mechanisms and functions for elafin in vivo 157
4.4. SUMMARY 167
APPENDIX IV 168
CHAPTER 5: THE EFFECT OF ELAFIN GENE AUGMENTATION




5.2.1. Experiments to establish conditions for optimal Ad-elafin
infection ofRAW 264.7 murine macrophages 172
5.2.2. The effect of LPS on elafin production by Ad-elafin-infected
RAW 264.7 murine macrophages 177
5.2.3. Inflammatory response ofRAW 264.7 murine
macrophages to infection with adenovirus constructs 181
5.2.4. The effect of elafin gene augmentation on the inflammatory
response of RAW 264.7 murine macrophages to LPS 183
5.3. DISCUSSION 189
5.3.1. Adenoviral infection of the murine macrophage cell line
RAW 264.7 189
5.3.2. The effect of LPS on elafin production by Ad-elafin-infected
murine macrophages 191
5.3.3. The effect of elafin gene augmentation on the inflammatory




CHAPTER 6: THE EFFECT OF ELAFIN GENE AUGMENTATION
ON ANTIMICROBIAL ACTIVITY OF MURINE EPITHELIAL
CELLS
6.1. AIMS AND BACKGROUND 205
6.1.1. Pseudomonas aeruginosa 206
6.1.2. Staphylococccus aureus 209
6.2. RESULTS 211
6.2.1. The effects of elafin gene augmentation on the antimicrobial
activity of Clara cells against P. aeruginosa 211
6.2.2. Adenoviral infection of primary murine tracheal epithelium 214
6.2.3. The effects of elafin gene augmentation on the antimicrobial
activity of primary murine tracheal epithelium against
P. aeruginosa 217
6.2.4. The effects of elafin gene augmentation on the antimicrobial
activity of primary murine tracheal epithelium against
S. aureus 222
6.3. DISCUSSION 227
6.3.1. The effects of elafin gene augmentation on the antimicrobial
activity of primary murine tracheal epithelium against
P. aeruginosa 228
6.3.2. The effects of elafin gene augmentation on the antimicrobial
activity of primary murine tracheal epithelium against
S. aureus 234
6.4. SUMMARY 237





Figure 1. Cell wall architecture of Gram-negative bacteria.
Figure 2. General structure of LPS from Gram-negative enterobacteria.
Figure 3. Structures of the five known outer core oligosaccharides from the
LPS of E. coli (A), and the chemical structure of E. coli lipid A (B).
Figure 4. The pleiotropic effects of LPS-mediated macrophage activation
Figure 5. Biological activities of tumour necrosis factor (TNF)-a
Figure 6. Schematic diagram of the LPS receptor complex.
Figure 7. Schematic diagram of TLR4-dependent LPS recognition and
signalling, and proposed mechanisms of TLR4-independent
LPS recognition.
CHAPTER 3
Figure 1. LPS serotypes separated as characteristic 'ladder' pattern
Figure 2. SDS in electrode buffer is critical for the resolution of LPS structure
by PAGE
Figure 3. Elafin and SLPI inhibit migration of LPS in a pH 8.8 native gel system
Figure 4. Elafin N-terminal and C-terminal domains inhibit migration of LPS in
a pH 8.8 native gel system
Figure 5. Non-specific binding of antibodies hinders investigation of
elafin-LPS interaction by dot-blot
Figure 6. Direct binding of elafin to smooth-form LPS and comparison with
the effects of SLPI
Figure 7. Direct binding ofN-terminal and C-terminal elafin domains to
smooth-form LPS
Figure 8. Binding of elafin to rough-form LPS serotypes and comparison
with SLPI

















K12 rough-form LPS 88
Figure 10. Elafin binds to lipid A-core portion of LPS 90
Figure 11. Binding of polymyxin B to lipid A-core portion of LPS 91
Figure 12. LBP peptide bound to LPS inhibits subsequent binding of
full-length elafin 93
Figure 13. LBP peptide bound to LPS inhibits subsequent binding ofN-terminal
and C-terminal elafin domains 94
Figure 14. Polymyxin B bound to LPS inhibits subsequent binding of elafin
peptides 95
Figure 15. Standard curve of binding of LBP to LPS 97
Figure 16. Effects of 0.625-1 OmM elafin peptides on the binding of LPS to LBP 98
Figure 17. Elafin peptides in the concentration range 9.75-156nM inhibit the
binding of LPS to LBP 101
Figure 18. Elafin binding to LPS is out-competed by LBP 102
CHAPTER 4
Figure 1. LPS stimulation ofRAW 264.7 murine macrophages in serum-free
and serum-rich conditions 126
Figure 2. Natural human LBP reproduces the effects of serum on
LPS-mediated stimulation ofRAW 264.7 murine macrophages 127
Figure 3. TNF-a response ofRAW 264.7 murine macrophages to 50ng/ml
LPS is enhanced by FCS concentrations as low as 0.2% 128
Figure 4. Elafin peptides have no significant effect on secretion ofTNF-a
by RAW 264.7 murine macrophages
(medium containing serum) 131
Figure 5. Full-length elafin down-regulates LPS-mediated TNF-a secretion
by RAW 264.7 murine macrophages, in medium
containing serum 132
Figure 6. N-terminal elafin domain has no significant effect on LPS-mediated
TNF-a secretion by RAW 264.7 murine macrophages,
in medium containing serum 133
XVII
Figure 7. C-terminal elafin domain down-regulates LPS-mediated TNF-a
secretion by RAW 264.7 murine macrophages, in medium
containing serum 134
Figure 8. Elafin peptides have no significant effect on secretion ofTNF-a by
RAW 264.7 murine macrophages (serum-free medium) 137
Figure 9. Full-length elafin enhances LPS-mediated TNF-a secretion by
RAW 264.7 murine macrophages, in serum-free medium
Figure 10. N-terminal elafin domain enhances LPS-mediated TNF-a
secretion by RAW 264.7 murine macrophages, in serum-free
medium
Figure 11. C-terminal elafin domain enhances LPS-mediated TNF-a
secretion by RAW 264.7 murine macrophages, in serum-free
medium
Figure 12. Elafin peptides have no significant effect on secretion of
MIP-2 by murine Clara cells (medium containing serum)
Figure 13. Full-length elafin enhances LPS-mediated MIP-2 secretion
by murine Clara cells, in medium containing serum
Figure 14. N-terminal elafin domain enhances LPS-mediated MIP-2
secretion by murine Clara cells, in medium containing serum
Figure 15. C-terminal elafin domain enhances LPS-mediated MIP-2
secretion by murine Clara cells, in medium containing serum
Figure 16. Elafin peptides have no significant effect on secretion of
MIP-2 by murine Clara cells (serum-free medium)
Figure 17. Full-length elafin has no significant effect on LPS-mediated
MIP-2 secretion by murine Clara cells, in serum-free medium 149
Figure 18. N-terminal elafin domain has no significant effect on LPS-mediated
MIP-2 secretion by murine Clara cells, in serum-free medium 150
Figure 19. C-terminal elafin domain enhances LPS-mediated MIP-2











Figure 1. Calcium phosphate (CaPi) precipitates enhance the efficiency of
adenoviral infection ofRAW 264.7 murine macrophages 174
• • 2T • • • •
Figure 2. Increasing the concentration of Ca in infection medium augments
elafin production by Ad-elafm-infected RAW 264.7
macrophages 175
Figure 3. Increasing the multiplicity of infection (moi) of Ad-elafm augments
elafin production by RAW 264.7 macrophages 176
Figure 4. Calcium phosphate (CaPi) induces a more pronounced
inflammatory response from RAW 264.7 macrophages
thanDMEM 178
Figure 5. Incubation ofRAW 264.7 macrophages with calcium phosphate (CaPi)
has little effect on their inflammatory response to LPS 179
Figure 6. LPS upregulates elafin production by Ad-elafin-infected
RAW 264.7 macrophages 180
Figure 7. Infection ofRAW 264.7 macrophages with adenoviral constructs
induces a significant inflammatory response, compared with
uninfected cells 182
Figure 8. Ad-elafin-infected RAW 264.7 macrophages are hyporesponsive
to LPS, and this effect is more pronounced when conditioned
medium is replaced with fresh medium prior to stimulation 186
Figure 9. Conditioned medium from Ad-elafin-infected RAW 264.7
macrophages does not confer LPS-hyporesponsiveness to
uninfected cells 187
Figure 10. Elafin levels produced by RAW 264.7 macrophages
during LPS stimulation assays 188
XIX
CHAPTER 6
Figure 1. Elafin secreted by Ad-elafin-infected murine Clara cells is
eradicated by Pseudomonas aeruginosa PAO1 213
Figure 2. Adenovirus efficiently infects primary murine tracheal epithelial cells
and infection is enhanced by calcium phosphate (CaPi)
precipitates 215
Figure 3. Ad-elafin-infected primary murine tracheal epithelial cells
secrete high levels of elafin 216
Figure 4. Ad-elafin infection of primary tracheal epithelial cells derived from
C57B1/6J mice compromises their ability to kill Pseudomonas
aeruginosa PAOl, and enhances bacterial survival 219
Figure 5. Ad-elafin-infected primary tracheal epithelial cells, derived from
C57B1/6J mice, significantly enhance survival of Pseudomonas
aeruginosa PAOl, compared with uninfected or
Ad-lacZ-infected cells 220
Figure 6. Ad-elafin infection ofprimary tracheal epithelial cells derived from
both C57B1/6J and BALB/c mice compromises their ability to
kill Pseudomonas aeruginosa J1385, and enhances
bacterial survival 221
Figure 7. Ad-elafin infection of primary tracheal epithelial cells derived
from C57B1/6J mice enhances their antimicrobial activity
against Staphylococcus aureus C1705 223
Figure 8. Ad-elafin-infected primary tracheal epithelial cells, derived from
C57B1/6J mice, exhibit significantly greater antimicrobial activity
against Staphylococcus aureus C1705 than Ad-lacZ-infected cells 224
Figure 9. Ad-elafin-infected primary tracheal epithelial cells, derived from
BALB/c mice, exhibit significantly greater antimicrobial activity
against Staphylococcus aureus CI705 than either uninfected or
Ad-lacZ-infected cells 225
Figure 10. Staphylococcus aureus C1705 up-regulates elafin secretion from




Table 1. Pattern recognition molecules (PRRs) of the innate immune system,
and their associated PAMPs 5






The immune system detects and eliminates invading pathogenic
microorganisms by discriminating between self and infectious non-self. In mammals,
the immune system can be segregated into two branches: the innate immune response
and the adaptive immune response. Adaptive immunity relies on gene rearrangement
and clonal expansion upon detection of specific antigens of the invading pathogen;
this arm of the immune response is mediated by the activity of T and B cells, which
engage non-self via antigen receptors to generate antigen-specific effector cells that
specifically target the pathogen, and memory cells that prevent subsequent infection
with the same organism. While the effectors of adaptive immunity may take weeks
to generate, innate immune responses are mobilised within hours of exposure to a
pathogen. Innate immune responses are therefore largely responsible for containing
and limiting the spread of infection, and stimulating the adaptive immune response.
Innate immunity is not pathogen-specific as it does not involve clonal expansion of
antigen-specific lymphocytes, but rather relies on recognition of conserved molecular
patterns exhibited by invading microorganisms.
Of particular importance in this regard is lipopolysaccharide (LPS) or
endotoxin, a ubiquitous component of the outer membrane of Gram-negative
bacteria. LPS is a potent agonist of the innate immune system. The rapid response
against LPS can be of benefit to the host in local sites of infection and in moderate
levels by promoting inflammation and priming the immune system to eradicate the
invading pathogens; however, an excessive or systemic response to LPS (for
example when LPS enters the bloodstream) can lead to sepsis, a systemic
inflammatory condition characterised by multiple organ failure, shock and
potentially death. The discovery of novel strategies aimed at modulating the
inflammatory response to LPS are therefore of great interest.
1
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One potential approach to addressing therapeutically the pathophysiological
sequelae induced by LPS is to target this molecule directly, by using an agent
capable of binding to it and sequestering its agonistic activities. In this regard,
cationic antimicrobial peptides of the innate immune system are of particular interest,
since they can interact with LPS and suppress many of its biological effects.
Our group is interested in the activities of elafin, a low molecular weight
proteinase inhibitor (or 'four-disulphide core' protein) produced locally in the
respiratory tract, in the skin and at mucosal sites in many tissues, that can exert
antimicrobial activity against Gram-positive and Gram-negative bacterial pathogens.
Several biochemical characteristics of elafin, such as low molecular weight,
cationicity, heavy disulphide bonding and tissue distribution at mucosal sites,
suggested that it may possess LPS-binding properties similar to those described for
other antimicrobial peptides. Moreover, the low molecular weight anti-proteinase
SLPI (secretory leukocyte proteinase inhibitor), with which elafin shares sequence
homology, has been shown to bind to LPS and modulate its activity.
The work described in this thesis was thus stimulated by the following
questions: Firstly, can the low molecular weight proteinase inhibitor elafin bind
directly to Gram-negative LPS? If so, how does this interaction affect the ability of
LPS to activate immune cells? Finally, can genetic augmentation of elafin modulate
cellular responses to LPS and whole bacteria?
Against this background, the following sections will provide a brief overview
of innate immunity, before going on to discuss the structure and activities of LPS,
with emphasis on the pathophysiology of sepsis. These sections will be followed by
a discussion of major components of the innate immune response, with particular
reference to those involved in responses to LPS (such as the mechanisms of LPS
recognition, Toll-like receptors (TLRs) and cationic antimicrobial peptides). Finally,
endogenous proteinase inhibitors will be described in the latter part of this chapter,





The innate immune system is a phylogenetically conserved, ancient
mechanism of host defence that is present in virtually every multicellular organism,
from plants to humans (reviewed by Medzhitov and Janeway, 2000). In
invertebrates, innate immunity is the only mechanism of defence. By contrast with
adaptive immunity, innate immune recognition is mediated by germline-encoded
receptors, meaning that the specificity of each receptor is genetically pre-determined.
These receptors have evolved by natural selection to possess defined specificities for
infectious microorganisms. Such receptors are known as pattern-recognition
receptors (PRRs), which identify highly conserved molecules present in bacteria and
other pathogens. PRRs may be strategically expressed on cells that are first to
encounter pathogens during infection, such as surface epithelia, and on effector cells
of the innate immune system, such as macrophages and dendritic cells, which may
act as antigen-presenting cells (APCs) for activation of acquired immune responses
(Medzhitov and Janeway, 1997). The structures recognised by PRRs are known as
pathogen-associated molecular patterns (PAMPs); prominent examples of PAMPs
include bacterial LPS, lipoteichoic acid, peptidoglycan, flagellin, bacterial (CpG)
DNA, lipoarabinomannans, phosphoglycolipids and viral double-stranded RNA
(Medzhitov and Janeway, 2000; Singh et al., 2003).
Although these molecular targets are structurally distinct, all PAMPs share a
number of common features. Firstly, they are usually only expressed by microbial
pathogens and are therefore distinct from self-antigens. Secondly, PAMPs
demonstrate little variation among microorganisms of a given class. For example, all
Gram-negative bacteria possess a form of LPS in their outer membrane. Finally,
these patterns are generally essential components for the survival or pathogenicity of
the microbe, and are thus not prone to antigenic variability.
Functionally, pattern-recognition receptors can be divided into three classes:
secreted receptors (such as collectins), which function as opsonins by binding to
microbial cell walls and marking them for recognition by the complement system
and for phagocytosis (reviewed by Epstein et al., 1996; Hickling et al., 2004);
3
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endocytic receptors (such as the macrophage mannose receptor and the macrophage
scavenger receptor), which mediate uptake and delivery of the pathogen into
lyosomes for destruction, and subsequent antigen presentation via major-
histocompatibility-complex (MHC) molecules on the cell surface (Fraser et al., 1998;
Thomas et al., 2000); and signalling receptors (such as the Toll-like receptor (TLR)
family and NOD (nucleotide-binding oligomerization domain) proteins), which
recognise PAMPs and activate intracellular signal-transduction pathways, leading to
expression of a variety of immune-response genes (reviewed by Takeda et al., 2003
and Inohara and Nunez, 2003, respectively). Table 1 describes the protein families
believed to play a central role in forming PRRs.
A wealth of recent work has highlighted the prominent role played by the
TLR family of receptors in the recognition of infectious microorganisms, and the
subsequent initiation of immune and inflammatory responses. Moreover, TLR
signalling pathways have been shown to be crucial in regulating cellular responses to
LPS. Prior to examining the roles played by TLRs in the innate immune response and
particularly in LPS recognition, it seems prudent to begin by discussing the structure
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1.3. BACTERIAL LIPOPOLYSACCHARIDES
1.3.1. Overview of LPS
Bacterial lipopolysaccharides (LPS) or endotoxins are the major outer surface
membrane components of Gram-negative bacteria, and are extremely powerful
stimulators of the innate immune system. LPS is vital to both the structural and
functional integrity of the Gram-negative outer membrane, and is expressed
ubiquitously (in some form) by all Gram-negative bacteria (Erridge et al, 2002).
Figure 1 provides a schematic representation of the location of LPS in the Gram-
negative bacterial cell wall.
As a primary target of innate immunity, recognition of LPS by cells such as
monocytes and macrophages provides the host with a rapid and vigorous response to
Gram-negative infection. Endotoxins can affect the functions of numerous cells and
organs, alter blood enzyme levels, modify sugar, fat and protein metabolism, raise or
lower body temperature, induce blood coagulation, tissue damage and organ failure,
and in extreme cases can lead to death of the host (Haeffner-Cavaillon et al., 1998).
The majority of these effects result from the ability of LPS to induce the release of a
gamut of pro-inflammatory mediators, such as tumour necrosis factor (TNF)-a,
interleukin (IL)-6 and IL-1(3. As mentioned in section 1.1., the reaction of the
immune system to the presence of LPS can be of benefit or detriment to the host,
depending on the site or magnitude of the response. Agonistic LPS may either induce
an increase in the general immune resistance against microbial infections, or evoke
serious pathologic symptoms such as those observed during sepsis syndromes related
to Gram-negative bacteraemia and endotoxaemia (Alexander and Rietschel, 2001).
With this is mind, the following sections will discuss the general structural
features of the LPS molecule, the relationship of these features to biological activity
of the holo-molecule, and the consequences of an over-vigorous or unregulated























Figure 1. Cell wall architecture of Gram-negative bacteria.
Gram-negative bacterial cell walls are characterised by the presence of two lipid
bilayers, the outer and inner (or cytoplasmic) membranes, which are separated by the
periplasmic space containing peptidoglycan. In contrast, Gram-positive bacteria do
not possess an outer membrane in their cell wall, and do not elaborate LPS. In Gram-
negative bacteria, the lipid portion of the outward directed membrane leaflet is
formed predominantly by lipid A of LPS molecules, which make up around 75% of
total membrane surface and form contacts to integral outer membrane proteins (such
as porins Omp A or Omp F/C, or the bacterial ferric hydroximate uptake receptor
FhuA). In addition to LPS, the outer membrane polysaccharide coat of enterobacteria
is formed by the enterobacterial common antigen and, in some species and strains, by
capsular polysaccharides. In the physiological situation, divalent cations are tightly
associated to the highly anionic membrane-proximal LPS moieties. The inner layer
of the outer membrane, as well as the lipid layers of the cytoplasmic membrane, are
predominantly composed of phospholipids. The membrane-inserted acyl moieties of
bacterial lipoproteins also anchor the outer membrane to the periplasmic
peptidoglycan network.
(taken from Alexander and Rietschel, 2001).
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1.3.2. General structure of LPS
The historical discovery and elucidation of the general structure of LPS is a
story which began in the late 19th century, following observations made by Pfeiffer in
the laboratory of Robert Koch at the Institute for Infectious Diseases in Berlin.
Pfeiffer discovered that lysates of heat-killed Vibrio cholerae could cause toxic
shock reaction in guinea pigs, and postulated that this toxic substance was associated
with the insoluble part of the bacterial cell wall; he named this substance endotoxin,
from the Greek 'endo' meaning 'within' (Pfeiffer, 1892). The term
Tipopolysaccharide' has been adopted due to the later discovery that endotoxin
consists of both lipid and carbohydrate (Erridge et al., 2002). A recent review by
Beutler and Rietschel (2003) provides a fascinating summation of the story of LPS
discovery and its subsequent structural elucidation.
It is now known that all forms of LPS are comparable and conform to a
common general structural architecture. Figure 2 provides a schematic diagram of
this basic general structure, as described below. Variations of this basic arrangement
account for the lipopolysaccharides of all Gram-negative bacteria so far investigated,
and can be classified as containing three distinct regions: (i) lipid A, the highly
hydrophobic and endotoxically active part of the molecule that is embedded in the
outer membrane unless bacteria are lysed. (ii) core oligosaccharide, which is
covalently attached to lipid A and can be further divided into inner and outer core.
The inner core is proximal to lipid A, and contains a high proportion of unusual
sugars such as 2-keto-3-deoxyoctulosonic acid (Kdo) and L-glycero-D-manno-
heptose (Hep) (Alexander and Rietschel, 2001; Erridge et al., 2002). The outer core
extends further from the bacterial surface and mainly consists of more common
hexose sugars such as glucose, galactose, V-acetyl glucosamine and V-acetyl
galactosamine (Alexander and Rietschel, 2001; Erridge et al., 2002). (iii) a serotype-
specific polysaccharide (O-polysaccharide or O-specific chain) that extends outward





















































































































The O-polysaccharide is not ubiquitous as it can be truncated or absent in Gram-
negative strains; for example, some bacterial strains may express LPS with a reduced
non-repeating O-chain known as lipo-oligosaccharide (LOS) (Erridge et al., 2002).
Moreover, certain strains exhibit mutations in the 'rfb' locus, which contains several
genes involved in O-polysaccharide synthesis and attachment, and these strains are
termed 'rough (R) mutants' to distinguish them from the wild-type 'smooth-form
(S)' strains whose LPS contains O-polysaccharide (Erridge et al., 2002).
1.3.2.1. O-polysaccharide
In LPS from most Gram-negative bacteria, the O-polysaccharide comprises
up to 50 repeating oligosaccharide subunits, each formed with 2-8 monosaccharide
moieties, in a highly species- and strain-specific manner (Alexander and Rietschel,
2001). The O-polysaccharides differ between strains by way of the individual sugars,
sequence, chemical linkage, substitution, and ring forms utilised. This leads to an
incredibly high structural diversity, even within a bacterial species, and therefore the
necessity for classifying LPS by serotype according to the O-polysaccharide
determinants. As the major Gram-negative bacterial antigen targeted by host
antibody responses, the O-chain is often referred to as O-antigen and is a useful tool
in typing strains and LPS (Erridge et al., 2002).
As mentioned above, rough-mutant bacterial strains do not synthesise O-
polysaccharide; as a consequence, these strains are less able to persist and survive in
vivo since the O-chain protects bacteria from uptake by phagocytes, and prevents
penetration of the complement membrane attack complex (Joiner et al., 1984; Joiner
et al., 1986). However, many wild-type species of pathogenic Gram-negative
bacteria have been identified which lack the O-polysaccharide moiety but can
colonise mucosal surfaces in vivo, for example Neisseria meningitidis, Haemophilus
influenzae and Bordetella pertussis (Peppier, 1984; Schneider et al., 1984; Inzana et
al., 1985; Griffiss et al., 1987). Interestingly, the LPS or LOS of organisms such as
N. meningitidis and H. influenzae have also been found to contain terminal
oligosaccharide structures that closely resemble human glycosphingolipids, due to
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the presence of common host carbohydrates (Moran et al., 1996). This mimicry of
host glycoconjugates has been shown to contribute to increased resistance of the
organism to phagocytosis and bactericidal activities (Verheul et al., 1993; Jarvis,
1995; Estabrook et al., 1997). Moreover, in terms of resistance to host immunity, the
variable O-polysaccharide domain provides a protective shield against access to the
more conserved inner core and lipid A domains by antibacterial agents such as bile
acids and cationic antimicrobial peptides (to be discussed in a later section), or by
lipid A recognition proteins (Alexander and Rietschel, 2001).
1.3.2.2. Core oligosaccharide
While the O-polysaccharide region is extremely variable, the oligosaccharide
structures in the core domain are far more limited, with some regions being highly
conserved between different strains and species. For example, and of relevance to
this thesis which predominantly involves the use of LPS derived from the
enterobacterium Escherichia coli, there are now over 160 identified E. coli O-
serotypes but only 5 unique core structures (R1-R4 and K12; organisms containing
these structures but no O-polysaccharide are therefore rough-form) (Amor et al.,
2000). These structures are presented diagrammatically in Figure 3A and will be
discussed in more detail in Chapter 3 of this thesis, in which various E. coli LPS
serotypes have been investigated experimentally.
The outer core (also known as the 'hexose region') is generally more variable
than the inner core. The inner core is characterised by more unusual sugars,
particularly Kdo and heptose; Kdo has been demonstrated in virtually every
identified LPS, and is a-bound to the carbohydrate backbone of lipid A. The only
exceptions known are the LPS of Acinetobacter and Burkholderia cepacia, which
exhibit 2-keto-D-glycero-D-talo-octonic acid (Ko) in its place (Erridge et al., 2002).
While the O-chain and majority of the core are dispensable in some viable mutants,
Kdo is required for bacterial viability. The smallest saccharide moiety observed in
the LPS of any organism is that of the deep rough mutant ofH. influenzae, which has
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Figure 3. Structures of the five known outer core oligosaccharides from the
LPS of E. coli (A), and the chemical structure of E. coli lipid A (B).
A. While there are over 160 identified E. coli O-serotypes, only 5 unique core structures have been
determined. Although all 5 share a structural theme, with a tri-hexose carbohydrate backbone and two
side chain residues, the order of hexoses in the backbone and the nature, position and linkage of the
side chain residues can all vary. HepII is the last residue of the inner core oligosaccharide. * indicates
the point of attachment of O-antigen, but this has only been determined experimentally for R1 and R2
(diagram adapted from Amor et al., 2000). B. The structural format of E. coli lipid A is widely
considered to be close to that optimally recognised by human cellular LPS receptors
(bisphosphorylated diglucosamine backbone substituted with 6 acyl chains) (diagram adapted from
Erridge et al., 2002). Abbreviations: Glc, glucose; Hep, D-glycero-D-/wa««o-heptose; Gal, galactose,
GlcNAc, jV-acetyl glucosamine; Pi, phosphate.
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naturally occurring bacteria the smallest core seen is that of Chlamydia species,
which consists of only a triplet of Kdo units (Brade et al., 1987).
Both inner and outer core sugar residues may be substituted with anionic
groups such as phosphate, diphosphate or diphosphoethanolamine (Hoist et al.,
1996). In the inner core, these substituents associate closely with divalent cations
9+ 9+ • •
such as Ca and Mg , which are required for membrane structure and function
(Rietschel et al., 1994). Interestingly, these cations may potentially be targeted for
displacement by innate defence molecules such as cationic antimicrobial peptides,
which can then interact electrostatically with the negative charges of the bacterial
outer membrane prior to microbial killing (Koczulla and Bals, 2003).
1.3.2.3. Lipid A
Decades of research into the role played by lipid A in the endotoxicity of LPS
have demonstrated that this domain harbours the endotoxic activity of the holo-
molecule (reviewed by Alexander and Rietschel, 2001). Figure 3B provides a
representation of the chemical structure of E. coli lipid A. Structurally, lipid A is
typically composed of a pi,6-linked D-glucosamine (D-GlcN) disaccharide (p-D-
GlcN-(l-6)-a-D-GlcN) carrying two phosphoryl groups at positions 1 and 4'; these
phosphates can be further substituted with groups such as phosphate, ethanolamine,
ethanolamine phosphate, ethanolamine diphosphate, GlcN, 4-amino-4-deoxy-L-
arabinopyranose and D-arabino-furanose (Erridge et al., 2002). To this structure are
attached up to four acyl chains by ester or amide linkage, and these chains can in turn
be substituted by further fatty acids to produce up to seven acyl substituents which
may vary considerably between species in nature, number, length, order and
saturation (Erridge et al., 2002). These may be attached to lipid A either
symmetrically (e.g. 3+3 as in N. meningitidis LPS) or asymmetrically (e.g. 4+2 as in
E. coli) (Erridge et al., 2002). The attachment site for the polysaccharide component
of the molecule is invariably provided by a linking Kdo residue at position 6'
(Beutler and Rietschel, 2003). A phosphorylated diglucosamine backbone attached to
13
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at least one Kdo residue represents the most highly conserved region between LPS
molecules (Erridge et al., 2002).
Several studies have indicated that the major factors contributing to LPS
endotoxicity are the number and lengths of acyl chains, and the phosphorylation state
of the disaccharide backbone. Interestingly, a number of studies (reviewed by
Erridge et al., 2002) have additionally provided the conclusion that the optimal lipid
A structure recognised by the host immune system to express maximal endotoxic
responses is the structure exhibited by E. coli: a biphosphorylated hexa-acylated lipid
A containing two p (l-6)-linked D-glucosamine residues, as shown by Figure 3B;
deviations from this structure reduce the activity of the molecule (Rietschel et al.,
1994). However, it is important to note that the optimum structure for cellular
activation appears to differ from that required for optimum cell binding: the criteria
for cell binding are much less strict, requiring only a biphosphorylated disaccharide
together with a minimum of two fatty acid substituents in no defined arrangement
(Erridge et al., 2002).
It is interesting to note that some lipid A structures can in fact exhibit
pronounced inhibitory effects. For example, a structural variation known as
compound 406, which is virtually identical to E. coli lipid A except it is tetra-
acylated rather than hexa-acylated, completely lacks endotoxic activity and is also
capable of inhibiting normal lipid A signalling in human cells (Wang et al., 1990;
Wang et al., 1991; Wang et al., 1992). It has further been suggested that E. coli lipid
A may be detoxified by macrophages by a pathway involving biodegradation to a
product resembling the endotoxically-inactive compound 406 (Erridge et al., 2002).
Having described the prominent structural features of LPS and the roles they
play in the architecture and activity of the molecule, the following section will




1.3.3. Activation of innate immunity by LPS
LPS is capable of inducing a broad spectrum of biological effects in the
mammalian host. The primary target cells of LPS in mammalian species are the
professional phagocytes of innate immunity (peripheral monocytes, tissue
macrophages and neutrophils) which constitutively express the membrane-bound
form of CD14 as well as TLR4 (these molecules are discussed in depth in section
1.4.) (Alexander and Rietschel, 2001). Dendritic cells have also been identified as a
myeloid cell type that is strongly activated by LPS, in response to which these cells
mature to play a key role as primary antigen-presenting cells (Cella et al., 1997;
Verhasselt et al., 1997). LPS is also known to induce specific and rapid activation of
humoral serine protease cascades such as the mammalian complement system
(Galanos et al., 1971; Cooper and Morrison, 1978). Moreover, LPS can directly or
indirectly (via induction of early inflammatory cytokines) upregulate the production
of local epithelial antimicrobial molecules such as human P-defensin-2 (HBD-2) and
the low molecular weight proteinase inhibitors elafin and secretory leukocyte
proteinase inhibitor (SLPI) (Sallenave et al., 1994; Jin et al., 1998; Becker et al.,
2000; Harder et al., 2000). These antimicrobial molecules will be discussed in later
sections.
Mononuclear cells react with tremendous sensitivity to the presence of LPS
and secrete a range of endogenous mediators, including the pro-inflammatory
cytokines TNF-a, macrophage migration inhibitory factor (MIF), interleukins IL-ip,
IL-6, IL-8, IL-12, IL-15, and IL-18, the colony-stimulating factors G-CSF, M-CSF
and GM-CSF, lipid-derived mediators such as platelet-activating factor (PAF),
prostaglandin E2 (PGE2), thromboxane A2 (TXA2), leukotrienes, and reduced oxygen
species such as the superoxide anion (O2"), hydroxyl radicals (OH) and nitric oxide
(NO); Figure 4 provides a diagrammatic representation of these pleiotropic effects of









































Figure 4. The pleiotropic effects of LPS-mediated macrophage activation
This diagram depicts the central extracellular route for LPS-mediated activation of peripheral
monocytes or tissue macrophages (see section 1.4.), and the major inflammatory spectrum of cellular
responses. In normal physiological conditions, reasonable and balanced concentrations of the above
mediators lead to activation of general antimicrobial, antiviral and antitumoural defence mechanisms,
but during pathological situations dysregulated and unbalanced release of mediators may lead to life-
threatening effects such as those observed in severe forms of sepsis. Key mediators which either
reinforce or suppress the pro-inflammatory activity of monocytes/macrophages are highlighted in red
and blue, respectively. In T-lymphocytes, natural killer (NK) cells and other cell types, IL-12 and 1L-
18 induce release of IFN-y, which hypersensitises mononuclear phagocytes to LPS. Diagram is
adapted from Alexander and Rietschel (2001).
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1.3.3.1. Severe sepsis and septic shock
While the response to the presence of Gram-negative bacteria and/or LPS can
be of benefit to the host by activating mechanisms aimed at eradicating the invading
pathogen (such as phagocytosis of bacteria, activation of the classical complement
pathway by lipid A and the alternate or lectin pathway by polysaccharide, or release
of antimicrobial peptides), an over-zealous response can lead to overt inflammation,
tissue damage and possibly even death (see Figure 4). The most extreme
consequence of an overtly vigorous and uncontrolled response to the presence of
Gram-negative bacteria and LPS is severe sepsis leading to shock; this condition is
the principal cause of death in non-cardiac intensive care units (ICUs) (Lolis and
Bucala, 2003). Sepsis can be defined as 'severe' when organ dysfunction develops,
such as acute renal failure, and 'septic shock' describes severe sepsis associated with
hypotension that is unresponsive to fluid resuscitation (Lolis and Bucala, 2003).
Septic diseases affect more than 50% of all patients in ICUs (Brun-Buisson, 2000). It
is important to note that Gram-negative bacteria currently account for roughly half of
the reported cases of sepsis, while Gram-positive bacteria and fungal organisms are
contributing to a progressively higher proportion (Martin et al., 2003).
Particularly high risks for septic syndromes are patients in ICUs suffering
from polytrauma, burn injuries or following major surgery and organ transplantation
under high-dose immunosuppression (Alexander and Rietschel, 2001). In healthy
humans, the maintenance of low systemic levels of LPS is normally guaranteed by
the effective external barriers of innate immunity, and an efficient physiological
clearance system for the small dose of gastrointestinal LPS that constitutively enters
the circulation with nutritional lipids (Jacob et al., 1977). Accordingly, most cases of
Gram-negative sepsis are caused by the enterobacteria E. coli and Klebsiella species
(Bochud and Calandra, 2003). Normal concentrations of LPS detectable in human
peripheral blood are around 3-10pg/ml, while levels higher than 300pg/ml are




Whilst cytokines such as MIF (for which a role in the pathogenesis of sepsis
has been suggested by studies demonstrating that MIF-deficient mice are highly
resistant to endotoxaemia (Bozza et al., 1999)) may be important mediators during
sepsis, TNF-a and IL-ip are the prototypic inflammatory cytokines that mediate
many of the immunopathological features of LPS-induced shock (Dinarello, 1997).
They are released during the first 30-90 minutes following LPS exposure and in turn
activate a second level of inflammatory cascades including cytokines, lipid mediators
and reactive oxygen species, in addition to upregulating cell adhesion molecules that
result in initiation of inflammatory cell migration into tissues (Cohen, 2002). TNF-a
in particular appears to be a key mediator in endotoxaemia, since passive
immunisation against this cytokine was shown to substantially attenuate the lethal
effects of LPS in mice (Beutler et al., 1985), and the effects of LPS could be
mimicked by administration of recombinant TNF-a to animals in high doses (Tracey
et al., 1986). Figure 5 describes the biological activities and cell and tissue targets of
TNF-a, relevant to its role as a mediator of sepsis. It is important to note that, while
TNF-a may instigate a range of potentially damaging inflammatory sequelae, a
number of studies using TNF-a deficient mice have demonstrated that it also plays a
crucial role in defence against microbial pathogens (reviewed by Mannel and
Echtenacher, 2000). However, with regards to the pathogenesis of sepsis, strategies
to downregulate the pro-inflammatory effects of TNF-a may be beneficial.
Much work is currently concerned with uncovering novel strategies for the
treatment of sepsis, including the potential use of antimicrobial peptides that display
anti-endotoxin activity (Koczulla and Bals, 2003). Cationic antimicrobial peptides
will be discussed in a later section. However, other approaches currently under
investigation for potential use in the treatment of sepsis will not be discussed here;
several authors have provided recent detailed reviews of past and ongoing studies
into such strategies, to which the reader is referred (Bochud and Calandra, 2003;
Hotchkiss and Karl, 2003; Lolis and Bucala, 2003; Marshall, 2003; Riedemann et al.,
2003). Suffice to say that the discovery of novel approaches aimed at dampening the





















Figure 5. Biological activities of tumour necrosis factor (TNF)-a
Although TNF-a is produced by several cell types, including neutrophils, T cells and
mast cells, the main source of this cytokine is monocytes/macrophages. TNF-a
induces a range of pro-inflammatory changes in endothelial cells, including cytokine
production, adhesion molecule expression, release of pro-coagulatory substances and
induction of inducible nitric oxide synthase (iNOS). These alterations may ultimately
lead to septic shock. TNF-a also stimulates T and B cells, induces fever in the brain,
suppresses lipoprotein lipase in adipocytes (contributing to cachexia or tissue
wasting, hence the alternative name for TNF-a, 'cachectin') and stimulates
hepatocytes to produce acute phase proteins. Fibroblasts and osteoclasts are target
cells for TNF-a in rheumatoid arthritis. Diagram is adapted from Eigler et al. (1997).
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Having examined the structural features and biological activities of LPS, the
following sections will discuss the current knowledge surrounding the mechanisms
by which the innate immune system recognises and responds to LPS. In this regard,
the Toll-like receptors are now known to play a major role in LPS recognition and
signalling.
1.4. LPS RECOGNITION AND SIGNALLING PATHWAYS
1.4.1. TOLL-LIKE RECEPTORS
1.4.1.1. Overview
Toll-like receptors comprise a family of type I transmembrane proteins that
are evolutionarily conserved between insects and humans (Medzhitov et al., 1997;
Rock et al., 1998). Toll was first identified as an essential molecule for embryonic
dorsoventral patterning in the Drosophila fruitfly (Hashimoto et al., 1988), and was
subsequently shown to be important for Drosophila immunity via induction of the
antifungal peptide Drosomycin (Lemaitre et al., 1996). The discovery of a
mammalian homologue of the Drosophila Toll by Medzhitov et al. (1997), now
designated TLR4, has led to a rapid increase in the knowledge surrounding the roles
of these receptors in mammalian immunity.
TLRs are characterised by an amino-terminal extracellular leucine-rich repeat
(LRR) domain, and a carboxy-terminal intracellular tail containing a conserved
region known as the Toll/interleukin-1 (IL-1) receptor (TIR) domain (Rock et al.,
1998). The extracellular LRR domain of TLRs is involved in ligand-binding, and
may also be necessary for TLR dimerisation (Singh et al., 2003); LRRs are found in
a diverse set of proteins in which they are involved in ligand recognition and signal
transduction (Kobe and Deisenhofer, 1995). While the extracellular LRR domain of
TLRs displays a high degree of polymorphism in order to confer ligand specificity,
the intracellular TIR domain is a conserved module which mediates protein-protein
interactions between the TLRs and signal-transduction components; thus the TIR
domain promotes intracellular signalling and transcription of genes involved in
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immune activation (Takeda et al., 2003). The TIR domain is also present in the
cytoplasmic portions of members of the IL-1 receptor (IL-1R) family, including IL-
1R and IL-18R (Medzhitov, 2001). In mammals, the TIR domain can also be found
in several cytoplasmic proteins, including two signalling adapters known as MyD88
(myeloid differentiation factor 88) (Medzhitov et al., 1998) and TIRAP (TIR
domain-containing adapter protein) (Horng et al., 2001); both of these molecules
function in TLR signal transduction and will be discussed in a later section.
To date, the mammalian TLR family is known to consist of ten members
(TLR1-TLR10) (Takeda et al., 2003). Each of these TLRs seems to have a distinct
function in innate immune recognition of microbial components, and ligands have
been identified for most of these receptors (Table 2). It is evident that the TLRs are
responsible for modulation of immune responses to a variety of stimuli, although the
overall innate immune response to infection is likely to represent the sum of signals
generated by the interaction ofmultiple TLRs.
Of particular relevance to this study, the first- and best-characterised member
of the TLR family, TLR4, has been identified as the crucial receptor for recognition
of LPS. The following sections will discuss the role of TLR4 in regulation of LPS
responses.
1.4.1.2. Toll-like receptor 4 (TLR4) and LPS recognition
As mentioned previously, TLR4 was the first characterised mammalian Toll
(Medzhitov et al., 1997). The study by Medzhitov et al. (1997) demonstrated that a
dominant active form of this receptor induced cytokine expression and NF-kB
activation when expressed in monocytic cell lines. Since that seminal study, TLR4
has been shown to function as the signal-transducing receptor for LPS.
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TLR family Ligands (origin)
TLR1 Tri-acyl lipopetides (bacteria, mycobacteria)
Soluble factors (Neisseria meningitidis)
TLR2 Lipoprotein/lipopeptides (variety of pathogens)
Peptidoglycan (Gram-positive/-negative bacteria)
Lipoteichoic acid (Gram-positive bacteria)
Lipoarabinomannan (mycobacteria)





Atypical LPS (.Leptospira interrogans)
Atypical LPS (Porphyromonas gingivalis)
HSP70 (host)
TLR3 Double-stranded RNA (virus)
TLR4 LPS (Gram-negative bacteria)
Taxol (plant)
Fusion protein (respiratory syncytial virus)




Type III repeat extra domain A of fibronectin (host)
Oligosaccharides of hyaluronic acid (host)
Polysaccharide fragments of heparan sulphate (host)
Fibrinogen (host)
TLR5 Flagellin (bacteria)
TLR6 Di-acyl lipopeptides (mycoplasma)




TLR9 CpG DNA (bacteria)
TLR10 ?
Table 2. Toll-like receptors and their ligands
(adapted from Takeda et al. (2003))
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This discovery was made as a result of the work carried out by two independent
groups, who strove to identify the genes responsible for the LPS-hyporesponsive
phenotype of the classical mouse strains C3H/HeJ and C57BL/10ScCr. These studies
found that the defective Lps gene, associated with profound LPS-hyporesponsiveness
in these strains, was in fact identical to the TLR4 gene (Poltorak et al., 1998; Qureshi
et al., 1999). The C3H/HeJ mouse strain has a point mutation in the intracellular TIR
domain of TLR4, leading to a dominant-negative mutant containing a proline to
histidine substitution in position 712 (Poltorak et al., 1998; Qureshi et al., 1999). The
mutant TLR4 from C3H/HeJ mice has since been shown to be defective in binding to
the adapter protein MyD88, thus failing to activate central downstream signalling
pathways (Rhee and Hwang, 2000). Transfection of this missense mutant Tlr4 into
the RAW 264.7 murine macrophage cell line was shown to inhibit LPS-induced NF-
kB activation (Rhee and Hwang, 2000). The C57BL/10ScCr mouse strain was found
to harbour a homozygous null mutation in the Tlr4 gene (Poltorak et al., 1998;
Qureshi et al., 1999) correlating with a deletion in the third exon (Poltorak et al.,
2000). TLR4-deficient mice generated by gene targeting were also hypo-responsive
to LPS, confirming the role for TLR4 in mediating inflammatory signals from LPS
(Hoshino et al., 1999). Moreover, TLR4 mutations have also been found to be
associated with endotoxin hyporesponsiveness in humans (Arbour et al., 2000;
Schwartz, 2001).
TLR4 is expressed predominantly in immune cells of the myeloid lineage,
such as dendritic cells (DCs) and monocytes/macrophages (Akashi et al., 2000;
Muzio et al., 2000; Kadowaki et al, 2001; Visintin et al., 2001b). Mast cells, which
play a role in phagocytosing pathogens, processing antigens and releasing
inflammatory cytokines (Malaviya and Abraham, 2001), also recognise Gram-
negative bacteria via TLR4 (McCurdy et al., 2001; Supajatura et al., 2001).
However, TLR4 expression has been observed in most human tissues (Zarember and
Godowski, 2002) and, in addition to professional innate immune cells, TLR4 is
expressed in several other cells types that contribute to inflammatory responses. For
example, TLR4 is found in endothelial cells (Faure et al., 2000; Zeuke et al., 2002),
fibroblasts (Wang and Ohura, 2002), adipocytes (Lin et al., 2000) and in cells of
23
Chanter 1: Introduction
epithelial origin, such as those of the pulmonary (Monick et al., 2003; Guillot et al.,
2004), intestinal (Cario et al., 2000; Hornef et al., 2002; Hornef et al., 2003), renal
(Wolfs et al., 2002), bladder (Backhed et al., 2002), colonic and gingival epithelia
(Uehara et al., 2001).
Recent studies have provided interesting findings with regards to the
expression and localisation of TLR4 in both intestinal and pulmonary epithelial cells.
These cells are constantly exposed to bacterial-related antigens, whether pathogenic
or commensal, and yet in normal circumstances exhibit only minimal immunological
responses (Boman, 2000). Several studies have documented very low or absent
surface expression of TLR4 in intestinal epithelial cells (Abreu et al., 2001; Naik et
al., 2001), and also lack of production of CD14 (Cario et al., 2000) and the adapter
protein MyD88 (Abreu et al., 2001); Abreu et al. (2001) further demonstrated that
LPS responsiveness could be enhanced by co-transfection of TLR4-MD-2 (myeloid
differentiation protein-2, an accessory molecule for TLR4; see following section).
While surface expression of TLR4 is relatively low in normal intestinal epithelium,
Cario and Podolsky (2000) found that TLR4 expression is augmented in
inflammatory bowel diseases such as Crohn's disease and ulcerative colitis,
providing a rationale for the exaggerated inflammatory responses to bacterial flora in
these conditions. Similarly, pulmonary epithelial cells of alveolar and
tracheobronchial origin have been shown to lack surface expression of TLR4 under
normal conditions (Monick et al., 2003; Tsutsumi-Ishii, 2003). The relative tolerance
of normal airway epithelial cells to foreign antigens is altered in individuals with
asthma and following respiratory syncytial virus (RSV) infection, and subsequent
development of asthma has been linked to severe infection with RSV during the first
year of life (Stein et al., 1999; Welliver, 1999); the study by Monick et al. (2003)
provided a possible basis for this observation, by demonstrating that RSV up-
regulates TLR4 expression and membrane localisation in airway epithelial cells, and
consequently sensitises the airway epithelium to LPS-mediated inflammation.
While observations regarding surface expression of TLR4 in these epithelial
cells have been relatively discordant, recent studies have further demonstrated that
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TLR4 resides intracellularly in the Golgi apparatus in intestinal epithelial cells
(Hornef et al., 2002; Hornef et al., 2003). These studies suggest that, in contrast to
the situation in macrophages, LPS recognition in intestinal epithelial cells relies upon
co-localisation of TLR4 and LPS in Golgi apparatus following LPS internalisation
(Hornef et al., 2002; Hornef et al., 2003); previous work has demonstrated delivery
of LPS to the Golgi apparatus following internalisation (Thieblemont and Wright,
1999). A role for intracellular TLR4 in LPS recognition in intestinal epithelial cells
was supported by the observation that monoclonal antibodies directed against the
TLR4-MD-2 complex failed to block TLR4-mediated signalling (Hornef et al., 2002;
Suzuki et al., 2003), while the same strategy was successful in neutralising LPS
response in macrophages (Schimazu et al., 1999; Akashi et al., 2000). Similarly, a
recent study by Guillot et al. (2004) demonstrated that TLR4 was not detectable on
the surface of pulmonary epithelial cells, but was constitutively expressed and
localised intracellularly; these findings were again supported by the inability of an
anti-TLR4 monoclonal antibody to inhibit cellular activation by LPS (Guillot et al.,
2004).
Interestingly, the potently pro-inflammatory cytokine interferon-y (IFN-y),
which has long been known to play a role in priming cells for inflammatory
responses to PAMPs such as LPS, has recently been shown to augment the LPS
activation of cell types such as monocytes/macrophages, intestinal epithelial cells
and renal epithelial cells by enhancing the expression of TLR4 and MD-2 (Bosisio et
al., 2002; Wolfs et al., 2002; Suzuki et al., 2003).
1.4.1.3. The LPS receptor complex
In addition to TLR4, recognition of LPS requires the cooperative involvement
of a number ofmolecules known collectively as the 'LPS receptor complex' (Figure
6) (reviewed by Fujihara et al., 2003).
LPS is firstly bound by the 60 kilodalton (kDa) acute phase serum
glycoprotein LPS-binding protein (LBP), via specific recognition of the lipid A
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domain of LPS (Tobias et al., 1986; Tobias et al., 1989; Schumann et al., 1990).
LBP functions to extract single LPS molecules from aggregated structures and
catalyse the transfer of these monomers to CD 14, a 55kDa glycoprotein present
either as a glycosylphosphatidylinositol (GPI)-anchored form on the surface of
myeloid cells (mCD14), or circulating in serum as a soluble form lacking the GPI tail
(sCD14) (Haziot et al., 1988; Wright et al., 1990; Hailman et al., 1994; Tobias et al.,
1995; Hailman et al., 1996). Besides LPS, CD14 is also required for the recognition
of other bacterial products including peptidoglycan, lipoteichoic acid and
lipoarabinomannan (Pugin et al., 1994; Gupta et al., 1996; Savedra et al., 1996).). In
addition to their critical roles in provision of monomerised LPS to the surface of
phagocytes for initiation of signal activation, both LBP and m/sCD14 have been
shown to mediate rapid cellular internalisation of LPS aggregates and phagocytosis
of intact Gram-negative bacteria (Gegner et al., 1995; Schiff et al., 1997; Kitchens
and Munford, 1998; Thieblemont and Wright, 1999; Vasselon et al., 1999). Within
the group of professional human phagocytes, CD14 is constitutively expressed at
high levels by monocytes and tissue macrophages (approximately 105
molecules/cell), and to a much lower extent by neutrophils (approximately 3x10
molecules/cell) (Antal-Szalmas et al., 1997).
The important catalytic role of LBP in LPS-induced cell activation has been
underlined by the observation that blood from mice with a targeted deletion of the
LBP gene was hyporesponsive to LPS by at least 1000-fold (Wurfel et al., 1997).
Similarly, CD14-deficient mice are highly resistant to endotoxic shock, and
monocytes derived from CD14-deficient mice are hyporesponsive to LPS (Haziot et
al., 1996). Soluble CD14 accepts LPS from LPS/LBP complexes and facilitates LPS-
dependent activation of CD14-negative cells, such as endothelial and epithelial cells
(Pugin et al., 1993; Backhed et al., 2002); interestingly, several studies have recently
demonstrated CD14 on the surface membrane of intestinal and airway epithelial cells
(Becker et al., 2000; Hornef et al., 2002; Tsutsumi-Ishii and Nagaoka, 2003), and
therefore the roles of mCD14/sCD14 in LPS-mediated activation of these cells
currently requires further definition. Furthermore, work has shown that LBP is
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Figure 6. Schematic diagram of the LPS receptor complex.
LPS is recognised by a complex of three proteins: CD 14, TLR4 and MD-2. The serum
glycoprotein LPS-binding protein (LBP) disaggregates LPS and transfers it to CD 14, which
exists in two forms: mCD14, anchored on the surface of myeloid cells such as
monocytes/macrophages, and sCD14 which circulates in plasma. The LPS/sCD14 complex
can activate cells that lack mCD14, such as endothelial and epithelial cells. CD14 presents
LPS to TLR4-MD-2. MD-2 plays a role in LPS recognition and regulates cellular
distribution of TLR4. TLR4 is a transmembrane protein characterised by an extracellular
domain containing multiple leucine-rich repeats (LRRs), a transmembrane domain, and an
intracellular TIR domain. TLR4 also plays a role in LPS recognition and functions as the
signal-transducing receptor for LPS. Three adapter proteins are responsible for TLR4-




produced not only by liver cells but also locally by epithelial cells in the lung
(Dentener et al., 2000).
LPS stimulation is followed by increased physical proximity between CD 14
and TLR4, suggesting that CD14 and TLR4 may interact in order to activate LPS
signalling (Jiang et al., 2000; Correia et al., 2001). An interesting observation to note
at this point is that, while it is now recognised that TLR4 represents the principal
LPS signal-transducing molecule, atypical LPS such as that exhibited by
Porphyromonas gingivalis is recognised by TLR2 (Hirschfeld et al., 2001).
Conformational differences in the shape of the lipid A portion in these LPS types
have recently been suggested to provide the basis for this disparity: if the lipid A
portion is conical in shape (as in E. coli LPS) it will be recognised by TLR4, whereas
if it is cylindrical (as in P. gingivalis LPS) it will be recognised by TLR2 (Netea et
al., 2002).
TLR4 is essential for LPS signalling; however, overexpression ofTLR4 alone
does not confer LPS responsiveness on LPS-unresponsive cell lines such as HEK
(human embryonic kidney) 293 cells (Kirschning et al., 1998). MD-2, a small
(18kDa) protein that lacks a transmembrane domain, was identified as a molecule
that associates with the extracellular portion of TLR4 and enhances LPS
responsiveness (Shimazu et al., 1999; Akashi et al., 2000). Notably, Chinese hamster
ovary (CHO) cell lines that are hyporesponsive to LPS have mutations in the MD-2
gene, and this phenotype could be reversed on transfection of MD-2 cDNA or by
addition of soluble MD-2 (Schromm et al., 2001). Moreover, as is the case for
TLR4-deficient mice, MD-2-deficient mice are resistant to LPS-induced shock;
macrophages, dendritic cells and B cells from these mice also display severely
impaired responses to LPS (Nagai et al., 2002). However, MD-2 (-/-) mice were
found to be susceptible to Salmonella typhimurium infection (Nagai et al., 2002).
MD-2 associates with TLR4 in the endoplasmic reticulum/Golgi apparatus before the
TLR4/MD-2 complex moves to the cell surface, where excess MD-2 is secreted
(Visintin et al., 2001a). MD-2 has additionally been shown to play an essential role
in the distribution of TLR4 since, whereas in wild-type cells TLR4 is normally
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located on the cell surface, it was found in the Golgi apparatus in cells lacking MD-2
(Nagai et al., 2002).
1.4.1.4. Myeloid-differentiation factor (MyD88)-dependent TLR4 signalling
Since the TLRs share sequence homology with the IL-1 receptor (IL-1R) in
their cytoplasmic 'TIR' domains, it is considered that TLRs and the IL-1R use
homologous signalling pathways. The downstream events are mediated by common
components: the adapter protein MyD88, a family of IL-1 receptor-associated
kinases (IRAK) and another adapter protein, TNF receptor-associated factor 6
(TRAF6). MyD88, which contains an N-terminal death domain and a C-terminal TIR
domain, is recruited to TLR4 following ligation of TLR4 with LPS. The TIR domain
ofMyD88 then associates with the TIR domain of TLR4, whereas the death domain
interacts with the N-terminal death domain of the serine/threonine kinase IRAK and
recruits IRAK to the receptor complex (Muzio et al., 1997; Wesche et al., 1997;
Burns et al., 1998; Medzhitov et al., 1998) (the IRAK family is reviewed by Fujihara
et al., 2003). IRAKs are subsequently phosphorylated, become dissociated from the
receptor complex and interact with TRAF6 (Cao et al., 1996; Muzio et al., 1998).
TRAF6 activates mitogen-activated protein kinases (MAPK), and also the inhibitors
of kB (IkB) kinase (IKK) complex. The IKK complex is composed of two catalytic
subunits, IKKa and IKKp, and one regulatory subunit, IKKy (Takeda et al., 2003).
This complex induces phosphorylation of the inhibitory protein IkB, which functions
to sequester NF-kB in the cytoplasm; phosphorylation is followed by
polyubiquitination of the IkBs and their 26S proteasome/multicatalytic proteinase
complex (MPC) -mediated degradation, allowing NF-kB to translocate to the nucleus
and activate transcription of a multitude of genes, including TNF-a and IkBoc
(reviewed by Baldwin, 1996, and Hilt and Wolf, 1996). The latter provides a
negative feedback loop whereby newly synthesised IkB binds to NF-kB and
terminates its activity (Silverman and Maniatis, 2001). Figure 7 provides a schematic
diagram of the TLR4 signalling pathway activated by LPS, as described in this
section and the section below (section 1.4.1.5). This diagram also includes proposed
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Figure 7. Schematic diagram of TLR4-dependent LPS recognition and
signalling, and proposed mechanisms of TLR4-independent LPS recognition.
LPS activates inflammatory gene transcription via signalling pathways downstream of TLR4. TLR4-
independent mechanisms of LPS recognition have also been proposed. These pathways are described
in detail in sections 1.4.1.4, 1.4.1.5 and 1.4.2.
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The involvement of signalling molecules such as MyD88, IRAK-1, IRAK-2
and TRAF6 in the LPS-mediated activation of NF-kB was confirmed in a study
which demonstrated that the dominant-negative construct of each molecule could
block LPS-induced activation of NF-kB in human monocytes and endothelial cells
(Zhang et al., 1999). Moreover, MyD88-, IRAK-1- and TRAF6-deficient mice are
hyporesponsive to LPS (Kawai et al., 1999; Lomaga et al., 1999; Swantek et al.,
2000). Macrophages of MyD88-deficient mice were also shown to be unable to
activate IRAK-1, and did not produce the inflammatory cytokines TNF-a, IL-6 and
IL-ip on stimulation with LPS (Kawai et al., 1999).
However, an interesting observation arising from the study by Kawai et al.
(1999) was that nuclear translocation of NF-kB and phosphorylation of MAPK
following stimulation with LPS remained intact in macrophages from MyD88-
deficient mice, albeit with delayed kinetics compared with macrophages from wild-
type mice. Furthermore, another study by the same group showed that TLR4 (but not
TLRs 1, 2, 5 or 6) could induce interferon-regulatory factor 3 (IRF3), a transcription
factor essential for the production of IFN-P and the antiviral response (Kawai et al.,
2001). These findings suggest that TLR4 can also activate pathways independent of
the activity of MyD88.
The MyD88-dependent signalling pathway described above is shared by all
members of the TLR family, and results in the induction of a core set of responses.
However, TLR4 is capable of inducing certain signalling pathways independent of
this adapter, and these are described in the following section.
1.4.1.5. Myeloid-differentiation factor (MyD88)-independent TLR4 signalling
Evidence is accumulating that MyD88-independent activation of the LPS-
TLR4 signalling pathway is of biological importance. For example, dendritic cells
from MyD88-deficient mice showed enhanced expression of co-stimulatory
molecules and increased T-cell stimulatory activity in response to LPS, suggesting
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that LPS-induced DC maturation depends on a MyD88-independent pathway
(Kaisho et al., 2001).
A second adapter molecule known as TIR domain-containing adapter protein
(TIRAP) or MyD88-adapter-like (Mai) was identified by two independent groups,
and a dominant-negative form of this adapter was shown to selectively inhibit TLR4
signalling (Fitzgerald et al., 2001; Horng et al., 2001). TIRAP-deficient mice were
found to be impaired in NF-kB and MAP kinase activation, and in cytokine
production, but their expression of DC maturation markers and induction of IRF3
were intact in response to LPS (Horng et al., 2002; Yamamoto et al., 2002a),
suggesting the involvement of yet another adapter protein. The precise role of
TIRAP/Mal in TLR4 signalling remains to be determined.
A third TIR-containing adapter molecule, known as TIR-domain containing
adapter inducing IFN-P (TRIF) or TIR-containing adapter molecule (TICAM)-l, has
recently been identified (Yamamoto et al., 2002b; Oshiumi et al., 2003). The
dominant-negative TRIF/TICAM-1 was shown to inhibit activation of NF-kB by
TLR2, TLR3, TLR4 and TLR7, and also IFN-P promoter activation by TLR3
(Yamamoto et al., 2002b). Indeed, a study carried out using TRIF/TICAM-1
knockout mice has indicated that this adapter is physiologically essential for TLR3-
mediated signalling pathways (Yamamoto et al., 2003). With regard to TLR4-
medated signalling, TRIF/TICAM-1 has been shown to be involved in the LPS-
induced MyD88-independent pathway, since cells from TRIF/TICAM-1-deficient
mice are defective in TLR-4 mediated IFN-P expression and IRF3 activation in
response to LPS (Yamamoto et al., 2003). It has been proposed that the MyD88-
dependent pathway leads to early activation of NF-kB and MAPK, while the
MyD88-independent pathway causes delayed activation of NF-kB and MAPK
(Fujihara et al., 2003). In support of this concept, Yamamoto et al. (2003)
demonstrated that TRIF/TICAM-1-deficient macrophages show normal activation of
NF-kB and MAPK in response to LPS, whereas cells deficient in both
TRIF/TICAM-1 and MyD88 showed complete loss of activation of NF-kB and
MAPK (Yamamoto et al., 2003).
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At the time of writing, research surrounding these novel TLR4-associated
adapter proteins is very much in its infancy, and future work will help elucidate the
pathways downstream of the TLR4-LPS receptor complex.
1.4.2. TLR4-INDEPENDENT MECHANISMS OF LPS RECOGNITION
Although TLR4 has now been established as an essential component in the
recognition of LPS, several reports have indicated that LPS can also be recognised
independently of TLR4. These mechanisms are discussed briefly in the following
sections.
1.4.2.1. Integrin CD11/CD 18
The CD11/CD18 P2 integrins are a family of heterodimeric glycoproteins
expressed on leukocytes such as monocytes, macrophages and neutrophils. The
CD18 P-subunit associates noncovalently with 1 of 3 subunits: CDlla (LFA-1),
CDllb (membrane attack complex (MAC)-l or complement receptor (CR) 3) or
CDllc (CR4) (Hynes, 1987). A study by Ingalls and Golenbock (1995)
demonstrated that LPS non-responsive CHO cells acquired serum-independent
responses to Gram-negative bacteria and LPS when transfected with CDllc/CD18,
suggesting that this integral membrane protein may function as a receptor for LPS. In
comparison to CHO cells transfected with CD14, responses in CHO/CDllc cells
were slower and required higher LPS concentrations for maximal response (Ingalls
and Golenbock, 1995). More recently, Perera et al. (2001) have suggested that
interaction of CD1 lb/CD18 with TLR4 and CD14 in murine macrophages is
required in order to induce the full panel of LPS-inducible genes; this study proposed
that, in the absence of either CD1 lb/CD 18 or CD 14, the engagement of TLR4 by
LPS delivers some, but not all (e.g. absence of cyclooxygenase 2), of the signals
necessary for optimal gene expression (Perera et al., 2001). This model postulates
that individual receptors (TLR4, CD14 and CD1 lb/CD 18) converge to form a





A recent study carried out by Triantafilou et al. (2001) identified a
structurally heterogeneous complex of four receptors that can bind LPS. This
complex is composed of heat shock proteins (HSP) 70 and 90, chemokine receptor 4
(CXCR4) and growth differentiation factor 5 (GDF5) (Triantafilou et al., 2001).
Incubation with antibodies against any of the four identified receptors before LPS
stimulation abrogated LPS-induced TNF-a secretion, likely due to sterical
interference with other components of the receptor complex (Triantafilou et al.,
2001). This group of investigators have proposed the following model: LBP transfers
LPS to mCD14, and the intercalated LPS is released into lipid membrane; the LPS
then binds to the four-receptor complex as above, and signal-transducing molecules
such as TLR4-MD-2 and CD11/CD18 are recruited into the activation cluster,
triggering multiple signalling cascades (Triantafilou and Triantafilou, 2002). This
new model of LPS recognition suggests that the mechanisms of action of a couple of
receptor molecules may be an over-simplified model of LPS-induced activation, and
may provide some interesting new insights in the future.
1.4.2.3. Cytosolic receptors - NOD proteins
In addition to TLRs, another family of cytoplasmic proteins known as NOD
(nucleotide-binding oligomerisation domain) proteins have recently been implicated
as cytosolic receptors for specific bacterial components, including LPS (reviewed by
Inohara and Nunez, 2003).
NODs show structural homology to a class of proteins (R proteins) that are
encoded by plant disease-resistance genes. The two mammalian NOD proteins,
NODI (also known as caspase-recruitment domain (CARD) 4) and NOD2 (also
known as CARD 15), are highly homologous. They are composed of a variable
amino-terminal effector-binding domain (EBD) containing CARD, a centrally
located NOD that mediates self-oligomerisation (shown to be required for activation
of downstream effector molecules (Inohara and Nunez, 2001)), and a carboxy-
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terminal ligand-recognition domain (LRD) containing leucine-rich repeats, a motif
also present in TLRs (Inohara and Nunez, 2003). The major structural difference
between NODI and NOD2 is the presence of two amino-terminal CARDs in NOD2,
compared with one in NODI (Ogura et al., 2001b). The expression of NODI is
ubiquitous in adult tissues (Bertin et al., 1999; Inohara et al., 1999), while NOD2
expression has been demonstrated in myelomonocytic, dendritic and epithelial cells
(Ogura et al., 2001b; Gutierrez et al., 2002). Interestingly, mutations in the gene
encoding NOD2 have been identified as the defects at the IBD1 locus that are
associated with the chronic inflammatory bowel disease Crohn's disease (Ogura et
al., 2001a).
Both NODI and NOD2 utilise a common downstream molecule known as
RICK (also called RIP2 or CARDIAK), a CARD-containing protein kinase; both
NODs physically associate with RICK through homophilic CARD-CARD
interactions (Bertin et al., 1999; Inohara et al., 1999; Ogura et al., 2001b). An
intermediate region that is located between the CARD and the kinase domain of
RICK has been shown to interact with IKKy, the regulatory subunit of the IKK
complex, thereby linking NODI and NOD2 to the IKK complex (Inohara et al.,
2000).
Expression of NODI or NOD2 was shown to confer LPS responsiveness
(NF-kB activation) in HEK cell lines which do not normally respond to LPS, without
the need for TLR4, MyD88 and TRAF-6 (Inohara et al., 2001; Ogura et al., 2001a).
Moreover, NODI mediated the activation of NF-kB and c-Jun N-terminal kinase
(JNK) by the invasive Gram-negative organism Shigella flexneri (Girardin et al.,
2001). NODI and NOD2 have also been shown to recognise LPS and/or
peptidoglycan through their carboxy-terminal LRRs (Inohara et al., 2001; Ogura et
al., 2001a; Bonen et al., 2003). It has been suggested, however, that findings related
to LPS recognition may be unreliable due to contamination of commercial LPS
preparations with other bacterial cell wall components (Royet and Reichhart, 2003).
With this in mind, several studies have recently demonstrated that NOD2 recognises
muramyl dipeptide derived from peptidoglycan of Gram-negative and Gram-positive
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bacteria (Girardin et ah, 2003b; Inohara et ah, 2003), and that NODI detects a
muropeptide present in Gram-negative but not Gram-positive peptidoglycan
(Chamaillard et ah, 2003; Girardin et ah, 2003a). Additionally, Chamaillard et ah
(2003) demonstrated that HEK cells transfected with TLR4, but not NODI or NOD2,
responded to purified intact E. coli lipid A with activation of NF-kB. These results
indicate that NODI, NOD2 and TLR4 may recognise different bacterial PAMPs, and
at the time of writing a role for the mammalian NODs in LPS recognition is the
subject of much debate. However, it is possible that intracellular detection of LPS by
NOD proteins could represent a novel pathogen recognition pathway distinct from
TLR4-mediated LPS recognition.
1.5. ANTIMICROBIAL PEPTIDES - EFFECTOR MOLECULES
OF INNATE IMMUNITY
1.5.1. Overview
Antimicrobial peptides (AMPs) are now recognised as one of the most
important elements of the innate immune system. The term 'antimicrobial peptides'
describes a diverse and evolutionarily ancient group of molecules which are
ubiquitous among all eukaryotes, including mammals, amphibians, insects, plants
and protozoa (Hancock and Diamond, 2000). AMPs are ribosomally-synthesised,
gene-encoded peptides, meaning that one gene encodes one peptide (Koczulla and
Bals, 2003). Although the existence of these molecules has been known for decades,
interest in their roles in immunity has recently accelerated rapidly. Moreover, the
increase in bacterial resistance to conventional antibiotics has accentuated the
requirement for a novel class of drugs to treat infections, and AMPs have been
considered as interesting candidates for drug discovery. AMPs represent attractive
candidates since they are active against antibiotic-resistant bacteria, and rarely induce
bacterial resistance themselves (Hancock and Scott, 2000). However, while these
peptides do not rapidly induce resistance in vitro, a variety of resistance mechanisms
have been reported in clinical isolates; these mechanisms will not be discussed here,




The definition of an AMP has been loosely applied to any peptide with the
capacity to inhibit microbial growth (Gallo and Nizet, 2003), although more
specifically to any polypeptide of fewer than 100 amino acids (aa) that displays
antimicrobial activity at physiological concentrations, under conditions prevailing in
the tissues of origin (Ganz, 2003). Although larger antimicrobial molecules such as
lysozyme, lactoferrin, bacteridal/permeability-increasing protein (BPI), and the four-
disulphide core proteins elafin and SLPI also play important roles in innate immune
defence, they cannot by definition be regarded as antimicrobial 'peptides' and as
such are not discussed in this section. However, BPI is discussed in more depth in
Chapter 3, while elafin and SLPI are described in section 1.6. of this chapter.
AMPs may exhibit potent killing or inhibition of a broad spectrum of
microorganimsms, including Gram-negative and Gram-positive bacteria, fungi and
certain viruses. In this regard, AMPs have emerged as key factors for inhibition of
microbial proliferation prior to recruitment of cellular immune defence mechanisms
such as macrophages and neutrophils (Gallo and Nizet, 2003). Most of these peptides
are highly cationic, a property which is important for the initial interaction between
the peptide and the anionic microbial membrane preceding membrane disruption and
cell lysis, and have a structure that organises charged residues separately from
hydrophobic residues. Four main mechanisms of peptide-mediated membrane
permeabilisation have been described: the barrel-stave model, worm-hole model, the
carpet model, and selective ion channel formation (Ganz and Lehrer, 1999).
Moreover, the selectivity of AMPs for prokaryotic cells seems to depend on
fundamental differences in the lipid composition of microbial and host cell
membranes (Yeaman and Yount, 2003).
AMPs are now known to contribute to innate immunity via activities distinct
from antimicrobial activity, such as binding to and modulating the activity of LPS
(Gough et al., 1996); as mentioned in section 1.3.2.2., cationic peptides can
completely displace the LPS-associated divalent cations which stabilise the structure
of the bacterial outer membrane (Hancock and Chappie, 1999). Additionally, these
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peptides may act as multifunctional mediators of immunity, inflammation and wound
repair.
In humans and other mammals, the two main AMP families are defensins and
cathelicidins; these two families are discussed in the following sections.
1.5.2. Defensins
Defensins are a family of evolutionarily related vertebrate peptides (typically
30-45 residues) with a characteristic P-sheet-rich fold and a framework of six
disulphide-linked cysteine residues (Lehrer and Ganz, 2002; Ganz, 2003). The two
main defensin subfamilies, a- and P-defensins, can be distinguished based on the
localisation and pairing of the six cysteines in the disulphide bridges. A third
defensin subfamily, characterised by a cyclic structure, has recently been identified
in rhesus macaque monkey leukocytes and named the 0-defensins (Tang et al.,
1999). However, this subfamily is inactive in humans due to gene mutations that
encode premature stop codons (Cole et al., 2002).
1.5.2.1. a-defensins
a-defensins contain three disulphide bridges in a Cysl-Cys6, Cys2-Cys4,
Cys3-Cys5 alignment (Koczulla and Bals, 2003). Six a-defensins have been
identified in humans to date. Human neutrophil peptides 1-4 (HNP 1-4) are localised
in azurophilic granules of neutrophils, in which they are the principal protein and
contribute to the oxygen-independent killing of phagocytosed microorganisms (Ganz
et al., 1985). Moreover, they may be secreted by neutrophils and thus accumulate to
high concentrations in the extracellular milieu during infection and inflammation
(Aarbiou et al., 2002b). The two other a-defensins, human defensins 5 and 6 (HD-5
and -6), are primarily expressed in Paneth's cells of the small intestinal crypts (Jones
and Bevins, 1992). An important role for Paneth cell defensins in host defence
against intestinal infection has been demonstrated by two key studies: mice deficient
in matrilysin (matrix metalloproteinase (MMP) 7), a tissue metalloproteinase
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involved in the processing of mouse Paneth cell defensins (cryptdins), displayed
increased sensitivity to intestinal infections (Wilson et al., 1999), while HD-5
transgenic mice showed enhanced resistance against enteric salmonellosis (Salzman
et al. 2003).
a-defensins are generally encoded as a 90-100 amino acid prepropeptide,
containing an N-terminal signal sequence (~19aa), an anionic propiece (~45aa), and
a C-terminal mature cationic defensin (~30aa) (Ganz, 2003). After signal peptide
cleavage, the anionic propiece neutralises the cationic mature peptide, which may be
important for folding and prevention of interaction with the host membrane (Valore
et al., 1996).
1.5.2.2. p-defensins
P-defensins contain three disulphide bridges in a Cysl-Cys5, Cys2-Cys4,
Cys3-Cys6 alignment, and are generally slightly larger than a-defensins (36-42aa in
length) (Koczulla and Bals, 2003). Four human p-defensins have been characterised
to date, namely human P-defensins (HBD)-l to -4. Based on recent genomic studies
which revealed additional defensin gene clusters, it is likely that several more HBDs
exist and play a role in innate defence (Schutte et al., 2002; Kao et al., 2003). In
comparison to a-defensins, the structure of P-defensin precursors is simpler,
consisting of a signal sequence, a short or absent propiece, and the C-terminal mature
defensin peptide (Ganz, 2003). The processing of P-defensins is likely similar to that
of a-defensins, but has not been clarified to date.
The majority of studies on P-defensin expression have centred on their
expression in epithelial tissues such as the mucosa of the lung, gastrointestinal tract
and the skin (Schutte and McCray, 2002). For example, HBD-1 and HBD-2 have
been detected in airway secretions in concentrations reaching the pg/ml range (Bals
et al., 1998b; Singh et al., 1998). However, HBDs may also be expressed by other
cell types such as monocytes/macrophages and dendritic cells (Duits et al., 2002).
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Interestingly, epithelial expression of HBD-1 appears to be constitutive, while the
expression of HBDs 2-4 has been shown to be inducible by bacteria, viruses,
neutrophil elastase and inflammatory cytokines, providing further evidence for their
important role in the initial stages of innate immunity (Garcia et al., 2001a, 2001b;
Harder et al., 2000; Harder et al., 2001; Duits et al., 2003a; Griffin et al., 2003).
Recent studies have also suggested that, while epithelial cells may display a low
responsiveness to microbial products, this response may be augmented by
macrophages to boost the local antimicrobial shield; TNF-a and IL-1 (3 secreted by
LPS-stimulated macrophages markedly enhanced the expression of HBD-2 by skin
and pulmonary epithelial cells (Liu et al., 2003; Tsutsumi-Ishii et al., 2003).
A range of murine p-defensins have also been identified and characterised
(Morrison et al., 2003); these will be discussed in more detail in Chapter 6 of this
thesis.
1.5.3. Cathelicidins
Cationic peptides of the cathelicidin family are approximately 12-100 aa in
length and, similar to the defensins, are produced as an inactive precursor; these pre-
pro-peptides consist of an N-terminal signal peptide, a highly conserved prosequence
and a structurally variable C-terminal mature antimicrobial peptide (Zanetti et al.,
1995). The prosequence (99-114aa) is known as the 'cathelin' domain due to its
homology with cathelin, a porcine neutrophil protein that inhibits the protease
cathepsin L (Bals and Wilson, 2003; Nizet and Gallo, 2003). The cathelin pro¬
peptide must be removed from the mature peptide in order to unleash the
antimicrobial activity, and in the case of the human peptide LL-37 this is achieved by
extracellular cleavage of its precursor hCAP-18 by proteinase 3 in neutrophils
(Sorensen et al., 2001) or by gastricsin in seminal plasma (Sorensen et al., 2003).
Interestingly, however, a recent study has demonstrated that the cathelin pro-peptide
of hCAP-18/LL-37 also possesses antimicrobial activity, in addition to cathepsin L-
inhibitory activity (Zaiou et al., 2003).
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Whereas a range of cathelicidins have been identified in species such as cattle
and pigs, hCAP-18/LL-37 represents the only known human cathelicidin, while a
homologue of LL-37 known as CRAMP (cathelin-related antimicrobial peptide) is
the sole murine cathelicidin (Gallo et al., 1997; Nizet and Gallo, 2003). The
important antimicrobial activities of these molecules has been demonstrated by
several studies. Firstly, adenovirus-mediated overexpression of hCAP-18/LL-37 in a
cystic fibrosis xenograft model restored the disease-specific defect in antimicrobial
activity to normal levels (Bals et al., 1999b). Secondly, murine models of pneumonia
and endotoxic shock further demonstrated that adenovirus-mediated hCAP-18/LL-37
overexpression could reduce pulmonary bacterial load, inflammation and
endotoxaemia-induced mortality (Bals et al., 1999c). Finally, mice deficient in
CRAMP were found to have an increased susceptibility to skin infections by Group
A Streptococci (Nizet et al., 2001).
In humans, hCAP-18/LL-37 appears to be produced predominantly by
neutrophils, but is also expressed in various squamous epithelia, respiratory epithelia,
keratinocytes in inflamed skin, specific lymphocyte and monocyte populations, and
mast cells (Frohm et al., 1997; Sorensen et al., 1997; Bals et al., 1998c; Frohm et al.,
1999; Agerberth et al., 2000; Di Nardo et al., 2003). Expression of hCAP-18/LL-37
can be upregulated in several cell types by inflammatory mediators, such as IL-6
(Frohm et al., 1997). Conversely, studies have suggested that Shigella species may
protect themselves from enteric innate immunity by downregulating expression of
both HBD-1 and hCAP-18/LL-37 (Islam et al., 2001).
1.5.4. Activities of defensins/cathelicidins distinct from antimicrobial action
In addition to antimicrobial activity, cationic antimicrobial peptides have also
been found to play a number of further roles in the immune response.
As mentioned previously, antimicrobial peptides (including defensins and
cathelicidins) can bind directly to LPS (Larrick et al., 1995; Gough et al., 1996;
Turner et al., 1998; Scott et al., 1999b; Scott et al., 2000b) and are capable of
blocking the ability of LPS to stimulate the production of TNF-a, IL-6 and other
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inflammatory mediators in vitro (Gough et al., 1996; Scott et al., 2000b; Nagaoka et
al., 2001). Studies have also suggested that these effects may be mediated, at least in
part, by the ability to inhibit binding of LPS to LBP, or of LPS to CD14-positive
cells (Scott et al., 2000b; Nagaoka et al., 2001). Furthermore, LL-37 and LL-37
analogues can neutralise the effects of LPS in vivo, decreasing TNF-a production
and protecting mice against the lethal effects of endotoxaemia (Kirikae et al., 1998;
Bals et al., 1999c; Nagaoka et al., 2001; Scott et al., 2002).
Antimicrobial peptides have also been shown to activate epithelial cells.
Neutrophil defensins (HNP 1-3) induce release of the neutrophil-attractant
chemokine IL-8 from human alveolar A549 and bronchial epithelial cells (van
Wetering et al., 1997b), and also of the low molecular weight proteinase
inhibitor/four-disulphide core protein SLPI from bronchial epithelial cells (van
Wetering et al., 2000a). Similarly, LL-37 has been found to increase IL-8 production
by A549 cells, and also to augment expression of the chemokine monocyte
chemoattractant protein (MCP)-l and chemokine receptors CXCR-4, CCR2 and IL-
8RB in macrophages (Scott et al., 2002). The latter study also demonstrated that LL-
37 can effectively downregulate the LPS-mediated release of TNF-a in
macrophages, suggesting that this cathelicidin could prevent overwhelming
macrophage-mediated inflammation, while promoting local leukocyte responses to
infection (Scott et al., 2002).
HNPs have been implicated in repair of injured airway epithelium, since HNP
1-3 can induce lung epithelial cell proliferation in vitro via an epidermal growth
factor receptor (EGFR)-independent MAP kinase signalling pathway (Aarbiou et al.,
2002a). HNPs are also mitogenic for retinal epithelial cells and fibroblasts (Murphy
et al., 1993). However, high (pM) concentrations of neutrophil defensins have been
shown to be cytotoxic to epithelial cells, and decrease proliferation (Okrent et al.,
1990; van Wetering et al., 1997a; Aarbiou et al., 2002a). It has also been
demonstrated that LL-37 can activate epithelial cells by activation of the MAP
kinase/extracellular signal-regulated kinase (ERK1/2) pathway, although LL-37's
effects are mediated via metalloproteinase-dependent transactivation of EGFR
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(Tjabringa et al., 2003). Additionally, LL-37 may play a role in angiogenesis and
arteriogenesis by inducing proliferation and formation of vessel-like structures in
endothelial cells, through interaction with the G protein-coupled, seven
transmembrane receptor formyl peptide receptor-like 1 (FPRL1) (Koczulla et al.,
2003).
Further modulation of the innate immune response by defensins and
cathelicidins is evidenced by the observations that HNPs can upregulate TNF-a and
IL-ip production, and downregulate production of the anti-inflammatory cytokine
IL-10, by S. aureus-activated monocytes (Chaly et al., 2000), while FfNPs, HBD2
and LL-37 induce the activation and degranulation of mast cells, resulting in release
of histamine and prostaglandin D2 (PGD2) (Befus et al., 1999; Niyonsaba et al.,
2001). These effects may serve to amplify local inflammatory defences against
microbial invasion.
Interestingly, findings regarding roles for defensins and cathelicidins in
cellular chemotaxis have suggested that they may also play a role in linking innate
immunity with the adaptive immune response to infection. Human neutrophil
defensins have been shown to be chemotactic for human monocytes, T cells and
immature dendritic cells (Territo et al., 1989; Chertov et al., 1996; Yang et al.,
2000a), while the P-defensins appear to act as chemoattractants for immature
dendritic cells, memory T cells and macrophages (Yang et al., 1999; Garcia et al.,
2001a, 2001b). The receptor used by P-defensins to mediate their chemotactic effects
has been identified as the CC chemokine receptor 6 (CCR6) (Yang et al., 1999),
whereas a specific receptor for the HNPs has not yet been identified. Also of interest
in this regard is the recent observation that murine P-defensin 2 may act directly on
immature dendritic cells as an endogenous ligand for TLR4, inducing up-regulation
of co-stimulatory molecules and dendritic cell maturation (Biragyn et al., 2002). LL-
37 exhibits chemotactic activity towards human monocytes, T cells and neutrophils
through binding to the aforementioned FPRL1 (Yang et al., 2000b), and also
chemoattracts mast cells (Niyonsaba et al., 2002). Another cathelicidin, porcine PR-
39, has been shown to be chemotactic for neutrophils (Huang et al., 1997).
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The use of chemotactic receptors by defensins and cathelicidins suggests that
they may provide a functional overlap with chemokines, and it is interesting to note
that recent findings have described defensin-like antimicrobial activities of
chemokines (Durr and Peschel, 2002).
It can therefore be concluded that AMPs play a variety of roles in the innate
immune response besides their antimicrobial function, and these activities may
encompass modulation of inflammatory processes, cell proliferation, wound repair
and immune cell chemotaxis.
1.6. LOW MOLECULAR WEIGHT PROTEINASE INHIBITORS/
FOUR-DISULPHIDE CORE PROTEINS
1.6.1. Overview
During inflammatory responses instigated by bacterial products such as LPS,
excessive or unregulated release of proteolytic enzymes (normally utilised in defence
against microbial pathogens) by inflammatory and stromal cells can lead to severe
tissue damage and dysfunction (Hubbard et al., 1991). The major source of serine
proteases is the neutrophil, and human neutrophil elastase (HNE) is a significant
instigator of tissue degradation (Weiss, 1989). Its potential substrates include almost
all components of the extracellular matrix, such as elastin, collagen (types I-IV) and
proteoglycan (Kawabata et al., 2002). Other serine proteases released from the
azurophilic granules of neutrophils during inflammatory processes include
proteinase-3 and cathepsin G (Hubbard et al., 1991). Accordingly, inhibitors of
proteinase activity comprise an important part of the innate immune system. For
example, three distinct anti-elastases are known to comprise the 'anti-elastase shield'
in the lung: a1-proteinase inhibitor (al-PI), SLPI and elafin. While al-PI is
synthesised principally in the liver by hepatocytes and released into the circulation,
SLPI and elafin are produced locally at mucosal sites (Sallenave et al., 1999b). SLPI
and elafin together form the antileukoprotease (ALP) family, and are often referred
to as Tow molecular weight proteinase inhibitors' or 'four-disulphide core proteins'
(Sallenave, 2000). SLPI and elafin are structurally similar, and in fact share
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approximately 40% sequence homology (Wiedow et al., 1990; Sallenave and Ryle,
1991; Sallenave and Silva, 1993). These molecules are now known to possess
activities distinct from their roles as inhibitors of proteolytic enzymes. The following
sections will discuss these two molecules in more depth, with particular emphasis on
the current knowledge surrounding elafin, since the work described in this thesis was
primarily concerned with investigating novel roles for elafin in the innate immune
response.
1.6.2. Secretory leukocyte proteinase inhibitor (SLPI)
SLPI (which has also been known as antileukoprotease, mucus proteinase
inhibitor and bronchial mucus inhibitor) is a 107 amino acid, single-chain, non-
glyosylated cationic protein, with a molecular weight of 11.7kDa (Seemuller et al.,
1986; Thompson and Ohlsson, 1986). The SLPI molecule is arranged in a compact,
'boomerang' shape, and characteristically contains two structural domains each
containing four disulphide bridges (Grutter et al., 1988). The NLL-terminal domain is
composed of residues 1-54, while the COOH-terminal domain consists of residues
55-107 (Seemuller et al., 1986). The antiproteinase active site resides in the COOH-
terminal domain; the active residue is leucine at position 72, while the methionine
residue at position 73 has been shown to be susceptible to oxidation, which renders
SLPI inactive towards HNE (Rudolphus et al., 1991). SLPI is capable of inhibiting
HNE, cathepsin G, trypsin, chymotrypsin and mast cell chymase, but does not inhibit
proteinase 3 (reviewed by Sallenave et al., 1999b). The size and compact structure of
SLPI may contribute to its ability to access the gap between neutrophil and substrate
(Rice and Weiss, 1990), and human SLPI has been detected in association with
elastic fibres in pulmonary connective tissue (Willems et al., 1986).
SLPI has been shown to be widely distributed in human tissues, and is
produced at mucosal sites in respiratory, nasal, salivary, cervical and semenal
secretions (reviewed by Sallenave et al., 1999b), as well as by inflammatory cells
such as macrophages and neutrophils (Jin et al., 1997; Sallenave et al., 1997; Mihaila
and Tremblay, 2001). Along with elafin, SLPI may be regarded as an inducible
'alarm' defence molecule, since its production is enhanced by early inflammatory
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signals such as LPS, TNF-a, IL-ip, HNE, cathepsin G and also by neutrophil
defensins (Sallenave et al., 1994; Jin et ah, 1998; van Wetering et al., 2000a; van
Wetering et al., 2000b). Conversely, anti-inflammatory cytokines such as
transforming growth factor (TGF)-P can down-regulate the production of SLPI
(Jaumannn et al., 2000).
While protection of tissues from protease-mediated damage at inflammatory
sites is considered to be a major physiological role of SLPI, recent studies have
shown that this molecule functions as more than just a protease inhibitor.
It has been demonstrated that SLPI possesses broad spectrum antimicrobial
activity against a range of pathogens, including Gram-negative bacteria (Escherichia
coli, Pseudomonas aeruginosa), Gram-positive bacteria (Staphylococcus aureus, S.
epidermidis), fungi (Aspergillus fumigatus, Candida albicans), and retroviruses
(HIV-1) (McNeely et al., 1995; Hiemstra et al., 1996; Tomee et al., 1997; Wiedow et
al., 1998). Hiemstra et al. (1996) have further indicated that the anti-bacterial activity
of SLPI resides in its NH2-terminal domain.
SLPI may also play a role in normal wound healing, since skin wounds in
SLPI-deficient mice healed slowly with impaired matrix accumulation, and
persistence of inflammatory cells (Ashcroft et al., 2000).
Furthermore, anti-inflammatory functions for SLPI have been described by a
number of studies. Firstly, Mulligan et al. (1993) used in vivo rat models to
demonstrate that exogenous SLPI could suppress IgG immune complex-induced
alveolitis, which is characterised by neutrophil accumulation and lung vascular leak.
Using the same model of acute lung injury, it has since been shown that the anti¬
inflammatory effects of SLPI may be due to inhibition of intrapulmonary activation
ofNF-kB, coupled with augmentation of the levels of IkBP (Lentsch et al., 1999a).
Mulligan et al. (2000) have further suggested that these effects are related to the
trypsin-inhibiting activity of SLPI, and may be directed at the intracellular proteases
involved in degradation of IkB proteins by the 26S proteasome/MPC (Mulligan et
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al., 2000). Additionally, similar immune complex models have suggested that
endogenous rat SLPI may play a role in preventing lung injury by inhibiting
generation of the neutrophil-chemotactic inflammatory mediator, C5a (Gipson et al.,
1999). In a murine model of hepatic ischemia/reperfusion injury, SLPI also reduced
lung and liver damage and diminished neutrophil accumulation, accompanied by
decreased serum levels of TNF-a and the CXC chemokine macrophage
inflammatory protein (MIP)-2 (Lentsch et al., 1999b); moreover, SLPI suppressed
NF-kB activation in liver in this model (Lentsch et al., 1999b).
Of particular relevance to the work in this thesis are observations concerning
the activity of SLPI in modulating LPS-mediated inflammatory responses.
Interestingly, SLPI has been shown to bind directly to LPS, prevent binding of LPS
to sCD14, and slow the uptake of LPS-sCD14 complexes by macrophages (Ding et
al., 1999).
SLPI was also shown to inhibit the signalling pathways leading to generation
of matrix metalloproteinases in LPS-stimulated monocytes (Zhang et al., 1997). The
work ofDing and colleagues has subsequently been instrumental in delineating a role
for SLPI in dampening the LPS-mediated activation of macrophages. Having
demonstrated that SLPI is inducible by LPS and is constitutively overexpressed in
LPS-hyporesponsive macrophages, their work also indicated that transfection of
macrophages with SLPI could suppress LPS-induced activation of NF-kB and
production of nitric oxide and TNF-a (Jin et al., 1997; Jin et al., 1998). In an
extension of the latter, Zhu et al. (1999) demonstrated that transfection of
macrophages with a non-secretory from of SLPI effectively suppressed macrophage
nitrite and TNF-a secretion in response to LPS, while exogenous SLPI had no effect;
these data have suggested that SLPI's anti-inflammatory effects are mediated
intracellularly (Zhu et al., 1999). These observations have been supported by Sano
and colleagues, who showed that, while exogenous SLPI could augment production
of the anti-inflammatory cytokines IL-10 and TGF-|3 by LPS-stimulated
macrophages, secretion of TNF-a was not inhibited (Sano et al., 2000; Sano el al.,
2003). In this regard, Taggart et al. (2002) recently demonstrated that SLPI can
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prevent NF-kB activation in LPS-stimulated monocytes by precluding degradation of
IRAK, IicBa and IkB|3, and have suggested that this effect is educed via inhibition of
the ubiquitin-proteasome pathway (Taggart et ah, 2002).
Finally, a role for SLPI in attenuating excessive LPS-mediated inflammatory
responses has been suggested by a recent study carried out using SLPI-deficient
mice, which showed a higher mortality from endotoxic shock than did wild-type
mice (Nakamura et ah, 2003). This study made the additional observation that SLPI7"
macrophages released higher levels of IL-6 in response to LPS, and demonstrated
increased activation of NF-kB, when compared with SLPI+/+ macrophages
(Nakamura et ah, 2003). It is also interesting to note that serum levels of SLPI are
elevated in human sepsis and experimental endotoxaemia, suggesting a role in
regulation of LPS-mediated inflammation in humans in vivo (Grobmyer et ah, 2000).
SLPI levels are additionally increased in the bronchoalveolar lavage (BAL) fluid of
patients with sepsis-associated acute respiratory distress syndrome (ARDS), an acute
lung inflammatory condition characterised by a predominantly neutrophilic alveolitis
(Sallenave et ah, 1999a).
The LPS-modulating activities of SLPI will be discussed in more detail
within the 'Results' sections to follow.
1.6.3. Elafin
Elafin (which has also been known as elastase-specific inhibitor (ESI), skin-
derived antileukoprotease (SKALP) or trappin-2) was first identified by Hochstrasser
et ah (1981) and Kramps and Klasen (1985) as a low molecular weight anti-elastase
present in bronchial secretions. The elastase-specific inhibitor was subsequently
isolated and purified from the sputum of patients with chronic bronchitis, and
characterised as a fast-acting inhibitor of FINE and porcine pancreatic elastase (PPE)
(Sallenave and Ryle, 1991). ESI/elafin shared considerable homology with SLPI,
although the scissile bond forming the active inhibitory site of ESI was shown to be
Ala-Met (compared with Leu-Met in SLPI), and this difference is thought to be
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important for the disparity in these molecules' proteinase-inhibitory spectra
(Sallenave and Ryle, 1991). At around the same time, two groups independently
described an elastase inhibitor purified from psoriatic skin scales and human
keratinocytes, which they named elafin and SKALP in parallel but was later shown
to represent the same molecule (Wiedow et al., 1990; Schalkwijk et al., 1990;
Schalkwijk et al., 1991).
The moiety isolated from sputum by Sallenave and Ryle (1991) was found to
cross-react immunologically with the species described by Kramps and Klasen
(1985), and to have almost complete sequence homology with the molecules purified
from skin (Sallenave et al., 1992). The gene encoding elafin was consequently
cloned and sequenced, and shown to code for a 117 amino acid protein, ofwhich the
first 22 amino acids represent a hydrophobic signal peptide (Sallenave and Silva,
1993). The sequence of the gene for elafin, which is located on chromosome 20,
showed that it is approximately 2.3kb long, is composed of three exons and two
introns, and contains 5' regulatory sequences such as AP-1 and NF-kB sites
(Sallenave and Silva, 1993; Molhuizen et al., 1994; Schalkwijk et al., 1999).
Elafin has been shown to be a more specific inhibitor of elastolytic
proteinases than SLPI, since it inhibits FINE, PPE and proteinase 3 (Wiedow et al.,
1990; Sallenave and Ryle, 1991; Wiedow et al., 1991; Ying and Simon, 2001), but
does not inhibit cathepsin G, trypsin or chymotrypsin (Wiedow et al., 1990; Tsunemi
et al., 1992). It is produced in a variety of epithelial and mucosal sites throughout the
human body, such as the skin, the oral cavity, the small intestine, and the lung
(Molhuizen et al., 1993; Sallenave et al., 1993; Nara et al., 1994; Pfundt et al.,
1996). Lung expression of elafin may be associated with alveolar epithelium, Clara
(bronchial) cells, or tracheal epithelium (Sallenave et al., 1993; Nara et al., 1994;
Suzuki et al., 2000), and elafin has been found to constitute approximately 20% of
the total anti-elastase antigen retrieved from bronchoalveolar lavage fluid during
health (Tremblay et al., 1996). Moreover, elafin production has also been described
in inflammatory cells such as neutrophils and macrophages (Sallenave et al., 1997;
Mihaila and Tremblay, 2001; Simpson et al., 2001a). Similar to SLPI, early
49
Chapter 1: Introduction
inflammatory 'alarm signals', such as LPS, TNF-a, IL-1(3 and HNE, can switch on
production of elafin (Sallenave et al., 1994; Reid et al., 1999; Tanaka et al., 2000;
van Wetering et al., 2000b; Simpson et al., 2001a), suggesting a role in the initial
stages of the innate immune response to infection.
The elafin molecule is a 9.9kDa non-glycosylated cationic protein which, as
mentioned previously, has approximately 40% sequence homology with SLPI
(Wiedow et al., 1990; Sallenave and Ryle, 1991; Sallenave and Silva, 1993). The
elafin molecule has two distinct structural domains. The COOH-terminal domain is
compact due to the presence of four disulphide bonds, and contains the Ala-Met
active inhibitory site (Sallenave and Ryle, 1991; Tsunemi et al., 1996). As is the case
with SLPI, the methionine in the active site of elafin may become oxidised with loss
of function (Rudolphus et al., 1991). Elafin's inhibitory activity has previously been
shown to be inactivated by PPE and sputum from patients with cystic fibrosis
(Sallenave et al., 1995). The COOH-terminal domain of elafin is also often termed
the whey acid protein (WAP) domain, leading Schalkwijk et al. (1999) to classify
elafin as a member of the 'trappin' family, hence the name trappin-2.
The NH2-terminal domain of elafin is characterised by repeated VKGQ
motifs (Sallenave and Silva, 1993). This sequence (also termed 'cementoin' (Nara et
al., 1994)) acts as a substrate domain for transglutaminase, with the resultant
formation of covalent isopeptide bonds between lysine and glutamine (Schalkwijk et
al., 1999). Transglutaminase has been shown to instigate polymerisation of elafin
and the covalent binding of elafin to laminin in vitro (Nara et al., 1994), suggesting
that tissue transglutaminase may anchor elafin to extracellular matrix in vivo and
prolong its local activity. In this regard, elafin has been identified cross-linked to
keratin 1 and loricrin in human cornified cell envelope (Steinert and Marekov, 1995),
while transglutaminase type 1 has been co-localised with elafin in stratified epithelia
(Schalkwijk et al., 1999).
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Although inhibition of elastolytic activity has historically been considered to
be the primary role of elafin, recent work has highlighted further properties of this
molecule which propose it as a 'defensin-like' entity.
Simpson et al. (1999) demonstrated that elafin has antibacterial activity
against Gram-negative P. aeruginosa and Gram-positive S. aureus, and further
established that, while anti-elastase activity resides exclusively in the COOH-
terminal domain, the majority of elafin's antimicrobial activity resides in its NH2-
terminal domain (Simpson et al., 1999). The demonstration of elafin's antimicrobial
activity was corroborated by Meyer-Hoffert et al. (2003), who showed that elafin
could inhibit the growth of P. aeruginosa, but not E. coli (Meyer-Hoffert et al.,
2003). In an extension of these studies, augmentation of elafin in murine lungs (using
an adenovirus vector encoding human elafin cDNA (Ad-elafin)) was shown to confer
significant protection against injury mediated by P. aeruginosa in vivo, and also
reduced bacterial numbers (Simpson et al., 2001b). Moreover, the same study found
that elafin overexpression could protect pulmonary epithelial cells against HNE and
activated human neutrophils in vitro (Simpson et al., 2001b).
Furthermore, similar to the antimicrobial peptides described previously,
elafin may exhibit chemotactic activity for neutrophils. Adenovirus-mediated over-
expression of elafin enhanced neutrophil migration in vitro, and this effect could be
reduced by incorporating an anti-elafin antibody (Simpson et al., 2001a). In addition,
infection of murine airways with Ad-elafin significantly augmented LPS-mediated
neutrophil migration in vivo, and was also shown to enhance LPS-induced levels of
TNF-a and MIP-2 in BAL fluid (Simpson et al., 2001a). Elafin has been postulated
to function in this model by providing local antimicrobial protection and enhancing
neutrophil influx, while protecting host tissues from subsequent HNE-mediated
damage (Simpson et al., 2001a). Interestingly, work carried out using transgenic
mice expressing human elafin has demonstrated that these mice exhibit lower serum-
to-BAL fluid ratios of pro-inflammatory cytokines (TNF-a, MIP-2 and MCP-1) than
wild-type mice, following LPS administration to the lungs; this was associated with
an increase in neutrophil and macrophage influx, suggesting priming of innate
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responses in the lungs (Sallenave et al., 2003). Conversely, when LPS was given
systemically, mice expressing elafin had lower levels of serum TNF-a than wild-type
mice, while peritoneal macrophages from elafin mice were hypo-responsive to LPS
(Sallenave et al., 2003). In this transgenic mouse model, elafin similarly appears to
function to promote local immunity, but reduce systemic inflammation. The
aforementioned studies will be discussed in more depth during later chapters.
In another animal model, Vachon et al. (2002) contrastingly showed that
recombinant elafin could reduce neutrophil influx, gelatinase activity, and levels of
MIP-2 and TNF-a in lung following intranasal LPS administration. These findings
would suggest that elafin may play a role as a potent anti-inflammatory mediator in
the lung; the discrepancies between this study and those described above may reflect
differences in elafin concentration, dose of LPS administered, route of
administration, and duration of the experiments. Future studies may be required to
clarify these differing observations.
Other in vivo models have further indicated that exogenous (human) elafin
can play an anti-inflammatory role by inhibiting HNE-induced acute lung injury in
hamsters (Tremblay et al., 2002), protecting against vein graft degeneration in
rabbits by reducing the early inflammatory response associated with serine elastase
activity (O'Blenes et al., 2000), inhibiting smooth muscle proliferation and
inflammatory cell invasion after arterial injury in mice (Zaidi et al., 2000),
attenuating post-cardiac transplant coronary arteriopathy and myocardial necrosis in
rabbits (Cowan et al., 1996), and inhibiting intimal hyperplasia caused by serine
elastase activity following balloon angioplasty in rabbits (Barolet et al., 2001).
At this point it seems important to note that, while recent work by Simpson et
al. has striven to unearth possible applications for elafin gene therapy in vivo with the
use of adenoviral vectors, the work in this thesis has been concerned primarily with
in vitro techniques aimed at delineating elafin's activities. Adenovirus-mediated gene
transfer has, however, been used here in order to facilitate genetic augmentation of
elafin in primary cells and cell lines. While the author acknowledges the potential
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application of gene therapy techniques to treatment of bacterial and/or LPS-mediated
inflammation, strategies such as those involving the use of adenoviral vectors will
not be discussed in detail here. The reader is instead referred to recent reviews on
this subject by Simpson et al. (2000), Factor (2001) and Thomas et al. (2003).
1.7. SUMMARY
This introduction has outlined the importance of Gram-negative bacterial LPS
in induction of inflammatory responses, and has described the major mechanisms for
its recognition by the innate immune system. Small cationic molecules such as
antimicrobial peptides and the low molecular weight proteinase inhibitors elafin and
SLPI may play an important role in modulation of inflammatory responses in vivo.
Several biochemical characteristics of elafin, such as low molecular weight,
cationicity, heavy disulphide bonding and tissue distribution at mucosal sites,
together with its antimicrobial and neutrophil-chemotactic activities, have suggested
that elafin may share further properties with antimicrobial peptides. In particular,
antimicrobial peptides can bind to LPS and modify its biological effects. Taken
together with the previous description of SLPI's anti-endotoxin activities, these
observations led us to investigate potential roles for elafin in modulating LPS-
mediated inflammatory responses, using in vitro models. These principles generated




The initial hypothesis driving this work was that elafin may be capable of
interacting directly with bacterial lipopolysaccharide, and that this property could
confer to elafin the ability to modulate the pro-inflammatory activity of LPS. The
hypothesis that elafin may bind directly to LPS was tested using a series of
polyacrylamide gel-based assays, while the effects of elafin-LPS interaction on the
binding of LPS to LBP were studied by ELISA. The results of these experiments are
presented in Chapter 3.
Taking into consideration the findings of Chapter 3, the hypothesis that
interaction of elafin with LPS could modulate the pro-inflammatory activity of LPS
was tested in vitro. The model chosen to test this hypothesis involved stimulation of
murine macrophages or bronchial epithelial cells with LPS, in the presence or absence of
synthetic elafin peptides. The effects of elafin on the LPS-mediated activation of cells
were assessed by measuring cytokine or chemokine production, respectively. The data
generated by these assays are described in Chapter 4.
To further investigate the LPS-modulatory activities of elafin in vitro, the
hypothesis that elafin gene augmentation could modulate the inflammatory response
of macrophages to LPS was tested. The model used to test this hypothesis involved
infection of murine macrophages with an adenovirus vector encoding human elafin
cDNA, followed by stimulation with LPS. The results are described in Chapter 5.
The findings of Chapters 3, 4 and 5, in conjunction with elafin's characteristics
as a low molecular weight cationic protein expressed primarily at epithelial sites and up-
regulated in response to early inflammatory stimuli, prompted the further hypothesis that
elafin gene augmentation could enhance the antimicrobial activity of murine
epithelial cells. The model employed to test this centred around infection of primary
murine tracheal epithelium with adenovirus encoding human elafin, followed by
challenge with Pseudomonas aeruginosa or Staphylococcus aureus. Results from this
model are presented in Chapter 6.
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2.1.1. Source of chemicals and reagents
Unless otherwise stated, chemicals and reagents were obtained from Sigma
(Poole, Dorset, UK).
2.1.2. Synthetic human elafin peptides
Elafm peptides were produced synthetically by Albachem (Edinburgh, UK)
using standardised techniques described elsewhere (Morrison et al., 1998). The
established gene sequence for human elafm (Sallenave and Silva, 1993) was used to
derive amino acid sequences. The peptides used in this work were available in-house
from the outset, and have been described previously by Simpson et al. (1999). Three
peptides were used for these studies, namely full-length elafin (fUN-'AVT 95Q-
COOH), the NH2-terminal domain (fUN-'AVT 50K-COOH) and the COOH-
terminal domain (H2N-51PGS 95Q-COOH). The molecular weights of elafin
moieties, determined by mass spectrometry (Albachem), were 9925 Da for full-
length elafin, 5172 Da for the NH2-terminal domain and 4776 Da for the COOH-
terminal domain.
2.1.3. Polyclonal rabbit anti-human elafin antibody
Polyclonal rabbit anti-human elafin IgG, prepared from antiserum raised
against a COOH-terminal 2.5kDa fraction of human elafm (Sallenave et al., 1992),
was available in-house from the outset of this work. Biotinylated rabbit anti-human
elafin IgG was also available in-house.
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2.1.4. Adenoviral constructs
Six E1-, partially E3-deleted adenoviral vector constructs of serotype 5 were
used, and these vectors were available in-house from the outset of this work. The
vectors used were: Ad-elafin, encoding the cDNA for human elafin; Ad-lacZ,
encoding the lacZ reporter gene; Ad-mSLPI, encoding the cDNA for murine SLPI;
Ad-dl70/3, an empty vector encoding no transgene; Ad-IxB, encoding the cDNA for
an NF-kB super-repressor mutant of the cytoplasmic protein IicBa; and Ad-m-
eotaxin, encoding the cDNA for the murine CC chemokine eotaxin. The techniques
used to generate these adenovirus vectors have been described in detail elsewhere
(Hitt et al., 1995; Addison et al., 1997; Jobin et al., 1998; Sallenave et al., 1998;
Wang and Huang, 2000). With the exception of Ad-IxB, which incorporates the
human cytomegalovirus (CMV) promoter (Jobin et al., 1999), the transgene in each
vector is located downstream of a fragment of the murine cytomegalovirus (MCMV)
immediate early promoter (Dorsch-Hasler et al., 1985). While the Ad-elafin, Ad-
lacZ, Ad-dl70/3 and Ad-m-eotaxin vectors encode a single transgene driven by a
1,4kb fraction of the MCMV promoter, Ad-mSLPI is a bi-cistronic vector encoding
both murine SLPI (followed by an internal ribosomal entry site (IRES)) and green
fluorescent protein (GFP), under the control of a 531 bp fraction of the MCMV
promoter.
The Ad-elafin vector was originally constructed by Dr. Jean-Michel
Sallenave in Professor Jack Gauldie's laboratory at McMaster University, Hamilton,
Ontario, Canada (Sallenave et al., 1998). Ad-lacZ was originally constructed by Dr.
Christina Addison and colleagues in Professor Frank Graham's laboratory at
McMaster University (Addison et al., 1997). Ad-mSLPI was constructed in-house in
our laboratory. Ad-dl70/3 was a kind gift from Professor Gauldie and Dr Mary Hitt
(McMaster University). Ad-m-eotaxin was kindly provided by Professor Zhou Xing
(McMaster University). Ad-IxB was a kind gift from Dr R. Balfour Sartor,
University ofNorth Carolina, NC, USA (Jobin et al., 1998).
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2.1.5. LPS and reagents related to LPS-binding studies
Escherichia coli 055:B5 LPS (smooth-form serotype) and polymyxin B sulphate
were from Sigma.
Biotinylated E. coli 055:B5 LPS, recombinant human LPS-binding protein (LBP)
and anti-LBP monoclonal antibody (mAb) HM2 were kind gifts from Dr. Anita
Vreugdenhil (University ofMaastricht, The Netherlands).
E. coli 06, 012, 015, 018 and Pseudomonas aeruginosa 02 LPS (smooth-form
serotypes) and E. coli K12, R2 and R3 LPS (rough-form serotypes) were kind gifts
from Dr. Richard Gibbs (Department of Medical Microbiology, University of
Edinburgh, UK).
Human LBP peptide (1.8kDa), natural human LBP and monoclonal murine antibody
to polymyxin B were obtained from HyCult Biotechnology, Uden, The Netherlands.
Human neutrophil elastase (HNE) was from Elastin Products, Owensville, MO,
USA.
Recombinant human SLPI was from R&D Systems (Abingdon, UK).
2.1.6. Bacteria
P. aeruginosa strains PA01 and J1385, and Staphylococcus aureus strain
CI705 were available in-house, and were kindly provided by Professor John Govan,
Department ofMedical Microbiology, University of Edinburgh. Bacteria were stored
at -70°C in 1ml of 10% w/v skim milk (Oxoid, Basingstoke, UK). After thawing,
bacterial isolates were inoculated onto either Pseudomonas Isolation Agar (PIA)
(45g/l agar base (Difco Laboratories, Detroit, MI, USA) plus 2% (v/v) glycerol) or
Columbia agar (39g/l agar base (Oxoid)) and incubated overnight at 37°C. Bacteria
were subcultured every 3-4 days thereafter. All media were prepared using distilled
water and sterilised by autoclaving at 121°C at 15psi (pounds per square inch) for
15mins.
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2.1.7. Mice
Male C57BL/6J and BALB/c mice aged between 6 and 8 weeks were
obtained from Charles River UK, Margate, UK.
2.2. METHODS
2.2.1. TECHNIQUES RELATED TO ELAFIN/LPS BINDING STUDIES
2.2.1.1. LPS separation using Invitrogen NuPAGE (polyacrylamide gel
electrophophoresis) Novex Bis-Tris electrophoresis system (minigels)
LPS samples were subjected to electrophoresis using the NuPAGE Novex
Bis-Tris electrophoresis system (Invitrogen, Paisley, UK) according to the
manufacturer's instructions. LPS was diluted to the appropriate concentration in
dL^O, and mixed with reducing sample buffer to a total sample volume of 20fj.l.
Electrophoresis was performed at 200V for 35 minutes in SDS (sodium dodecyl
sulphate)-free Bis-Tris-HCl buffered (pH 6.4) polyacrylamide gels with a
concentration gradient of 4-12%, using denaturing SDS electrode buffer. Pre-stained
markers were provided with the kit (Invitrogen). Bands were then detected using a
Bio-Rad Silver Stain kit (Bio-Rad, Hemel Hempstead, UK).
2.2.1.2. LPS separation using maxigel PAGE (pH 8.8)
A maxigel PAGE technique was used to investigate the effects of varying the
SDS content of electrode and sample buffers on the resolution of LPS banding.
Samples of LPS were mixed 1:1 with sample buffer (± SDS) to a total volume of
10pl, and 25pg of each LPS serotype was separated. Electrophoresis was performed
on SDS-free 14% gels at 60V-150V for 3 hours in a vertical maxigel electrophoresis
tank, using Tris-Glycine electrode buffer ± SDS. LPS banding was detected by silver
staining (Bio-Rad).
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Formulations. 2x PAGE sample buffer. 0.125M Tris-HCl, 20% (v/v) glycerol, ± 4%
(w/v) SDS, 0.002% (v/v) bromophenol blue and 2% (v/v) mercaptoethanol.
Polyacrylamide gels: Separating gel (pH 8.8) - 0.375M Tris-HCl, 14% (v/v)
acrylamide (Life Technologies, Paisley, UK), 0.075% (v/v) ammonium persulphate
(APS) and 0.14% (v/v) N,N,N',N'-tetramethylethylenediamine (TEMED) (Bio-Rad).
Stacking gel (pH 6.8) - 0.125M Tris-HCl, 4% (v/v) acrylamide, 0.075% (v/v) APS
and 0.2% (v/v) TEMED. Electrode buffer: 0.025M Tris, 0.192M glycine, ± 0.1%
(w/v) SDS.
2.2.1.3. Dot blotting
Briefly, 2pg of LPS or HNE were spotted onto Genescreen Plus nylon
membrane (NEN Life Science Products, Boston, MA, USA) and allowed to dry.
Alternatively, 25ng to 200ng of synthetic full-length elafin were spotted as positive
controls. Synthetic full-length elafin from 25ng to 200ng was then dotted onto the
LPS, HNE or onto an area to which no LPS or HNE had been added. The membrane
was dried, and non-specific protein binding sites blocked for 1 hour at 4°C with
PBS/0.1% Tween 20 containing 5% skim milk (Marvel, Wirral, UK). The
membrane was then incubated in a 1:1000 dilution of rabbit anti-elafm IgG in
blocking solution for 1 hour at room temperature (RT), and washed thoroughly with
PBS/0.1% Tween. HRP-conjugated goat anti-rabbit immunoglobulin (Dako,
Glostrup, Denmark) diluted 1:2000 in blocking solution was added for 30 minutes at
RT, and then the membrane was washed as above. Finally, elafin was detected by
enhanced chemiluminescence (ECL) (Amersham Pharmacia, Amersham, UK) as per
manufacturer's instructions, and membrane developed on X-omat film (Kodak,
Chalon, France).
2.2.1.4. PAGE (pH 8.8) (minigel) system to investigate binding of peptides to LPS
Interaction between peptides (full-length elafin, MU-terminal elafin domain,
COOH-terminal elafin domain, SLPI and polymyxin B) and LPS was investigated in
two variations of pH 8.8 PAGE. In these assays, sample buffer and gels were SDS-
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free and non-denaturing, while SDS was included in electrode buffer only when
stated specifically in figure legends. In experiments using completely SDS-free
systems, peptides were incubated alone or with E. coli 015 LPS overnight at 37°C in
PBS containing ImM EDTA, and mixed with sample buffer to a total volume of
25pi prior to electrophoresis. In separate experiments where SDS was added to
electrode buffer, peptides were incubated alone or with E. coli 055:B5 LPS for 30
minutes at 37°C in dLLO, and mixed with sample buffer to a total volume of 25pl
prior to electrophoresis. Differences between the assays (in terms of sample
incubation period, reaction mixture and LPS serotype) are as a result of observations
made during these studies concerning conditions required for binding, and
availability of LPS.
Electrophoresis was performed on 15% gels at 70V-110V for 2-3 hours in a
vertical electrophoresis tank Mini Protean II system (Bio-Rad). Bands were detected
either by silver stain (Bio-Rad) or by immunoblotting. In the latter case, proteins
were transferred onto Hybond ECL nitrocellulose membrane (Amersham Pharmacia)
at 110V for 1 hour. Non-specific protein binding sites were blocked overnight at 4°C
with PBS/0.1% Tween 20 containing 5% skim milk. Elafin was then detected with
rabbit anti-elafin IgG, followed by HRP-conjugated goat anti-rabbit
immunoglobulin, as described under 'Dot blotting' in section 2.2.1.3. above.
Polymyxin B was detected with a murine anti-polymxin B monoclonal antibody,
followed by goat anti-mouse immunoglobulin (Dako). Membranes were developed
as per section 2.2.1.3.
Formulations. 4x PAGE sample buffer. 0.5M Tris-HCl, 40% (v/v) glycerol, 0.2M
EDTA and 0.5% (v/v) bromophenol blue. Polyacrylamide gels: Separating gel (pH
8.8) - 0.375M Tris-HCl, 2mM EDTA, 15% (v/v) acrylamide, 0.1% (v/v) APS and
0.05% (v/v) TEMED. Stacking gel (pH 6.8) - 0.125M Tris-HCl, 2mM EDTA, 4.5%
(v/v) acrylamide, 0.1% (v/v) APS and 0.06% (v/v) TEMED. Electrode buffer (±
SDS): 0.6% (w/v) Tris base, 2.9% (w/v) glycine, 0.7% (w/v) EDTA, ± 0.1% (w/v)
SDS. Transfer buffer: 24.7mM Tris base, 210mM glycine, and 20% (v/v) methanol.
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2.2.1.5. Acidic (pH 4.5) native PAGE (minigels)
Peptides and LPS were diluted to the appropriate concentration in dLLO, and
incubated together for 30 minutes at 37°C. Where one peptide was incubated with
LPS prior to the addition and incubation of a second peptide with reaction mixture,
each incubation was performed for 30 minutes at 37°C. In all cases, final sample
volume was 24pL 6pi of sample buffer was added to each sample before
electrophoresis. Electrophoresis was performed on 15% potassium hydroxide-acetic
acid gels at 80V for 2-3 hours in a vertical electrophoresis tank Mini Protean II
system, using a procedure modified from Reisfeld et al. (1962). Protein bands were
detected by coomassie staining.
Formulations. 5x sample buffer. 480mM potassium hydroxide, 40% (v/v) glycerol,
2.9% (v/v) glacial acetic acid, 0.5% (w/v) methyl green. Polyacrylamide gels:
Separating gel (pH 4.5) - 240mM potassium hydroxide, 2.15% (v/v) glacial acetic
acid, 0.5% (v/v) TEMED, 15% (v/v) acrylamide and 0.14% (v/v) APS. Stacking gel
(pH 6.8) - 63mM potassium hydroxide, 0.38% (v/v) glacial acetic acid, 0.06% (v/v)
TEMED, 2.5% (v/v) acrylamide and 0.15% (v/v) APS. Electrode buffer. 3.12%
(w/v) P-alanine and 0.8% (v/v) glacial acetic acid. Transfer buffer. 24.7mM Tris
base, 210mM glycine, and 20% (v/v) methanol.
2.2.1.6. Coomassie staining
Gels were incubated for 30 minutes at room temperature in fixative (10%
(v/v) glacial acetic acid and 20% (v/v) methanol), followed by 30 minute incubation
in coomassie stain (0.25% (w/v) coomassie blue, 7.5% (v/v) glacial acetic acid and
50% (v/v) methanol). Gels were then destained overnight at RT in destaining
solution (7% (v/v) glacial acetic acid and 10% methanol).
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2.2.1.7. ELISA technique to investigate inhibition of the LPS-LBP interaction
This technique measures the binding of biotinylated LPS to immobilised
LBP. The method was carried out according to Scott et al. (2000b). Briefly, the anti-
LBP mAb HM21 was diluted to lOmg/ml in PBS and adsorbed onto a 96-well assay
plate (Corning Costar, High Wycombe, UK) overnight at 4°C. The plate was then
blocked with PBS containing 1% bovine serum albumin (BSA) (Sigma) for 1 hour at
RT and washed with 0.1% Tween 20 in dH20. Recombinant LBP (25ng/ml) diluted
in PBS/0.1% BSA was added to the plate for 1.5 hours at RT. Following washing,
biotinylated E. coli 055:B5 LPS was added in the presence or absence of peptides.
The peptides were pre-incubated with biotinylated LPS for 30 minutes at 37°C in
PBS prior to addition to the wells. Following lhour incubation at RT and washing,
binding of biotinylated LPS to immobilised LBP was detected using horseradish
peroxidase (HRP)-conjugated streptavidin (Dako) diluted 1:2000 in PBS/0.1% BSA.
The plate was incubated for 1 hour at RT, washed, and 3,3',5'5-tetramethylbenzidine
(TMB) (Boehringer Mannheim UK, Lewes, UK) added 1:50 in ^Ch/sodium acetate
citrate (pH 4.9) for 15 minutes. The reaction was stopped by addition of 1M H2SO4
(BDH, Poole, UK) and the O.D. read at 490nm (MRX II microplate reader, Dynex
Technologies, Billinghurst, UK).
2.2.1.8. ELISA technique to investigate elafin/LBP competition for binding to LPS
An ELISA technique was devised to measure binding of elafin to
immobilised LPS. LPS alone binds poorly to assay plates, therefore LPS was pre-
bound to polymyxin B to form complexes which are stable when coated onto
microplates; this method was adapted from Scott and Barclay (1987). Briefly, equal
volumes of 36pg/ml E. coli 055:B5 LPS and 20pM polymyxin B (both diluted in
dH20) were mixed with continuous shaking for 30 minutes at room temperature. The
mixture was then dialysed overnight against dH20 using a 3.5kDa pore size, in order
to remove excess unbound polymyxin B.
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50pl/well of this mixture was coated onto a 96-well assay plate overnight at
4°C. The plate was then blocked with PBS containing 1% BSA for 1 hour at RT and
washed with 0.1% Tween 20 in dHaO. 156nM full-length elafin was added for 1.5
hours at RT. Alternatively, 25ng/ml LBP was added to wells simultaneously with
elafin, or LBP was added 45 minutes after addition of elafin and then incubated for a
further 45 minutes. Following washing, rabbit anti-elafin IgG diluted 1:1000 in
PBS/0.1% BSA was added and incubated for 1 hour at RT. The plate was washed,
then incubated for 1 hour at RT with HRP-conjugated goat anti-rabbit
immunoglobulin diluted 1:2000 in PBS/0.1% BSA. Following washing, the plate
was developed and read as described previously in section 2.2.1.7.
2.2.2. CELL CULTURE
The RAW 264.7 murine macrophage cell line was obtained from the
American Type Culture Collection (Manassas, VA, USA). Cells were cultured in
Dulbecco's Modified Eagle's Medium (DMEM) (Sigma) supplemented with 0-10%
(v/v) foetal calf serum (FCS; heat-inactivated at 57°C for 1 hour prior to use)
(Labtech, Ringmer, UK), 100 U/ml penicillin (Gibco BRL, Paisley, UK), lOOpg/ml
streptomycin (Gibco), 4mM L-glutamine (Gibco), 4.5g/l glucose and 1.5g/1 sodium
bicarbonate. For all following methods involving use of the RAW 264.7 macrophage
cell line, 'DMEM' is used to describe this culture medium with no FCS added,
unless otherwise indicated.
The murine Clara (bronchial epithelial) cell line DJS2-2 was a kind gift from
Dr Franco DeMayo (Baylor College of Medicine, Houston, TX, USA). Cells were
cultured in DMEM supplemented with 0-10% (v/v) FCS, 100 U/ml penicillin,
100pg/ml streptomycin, and 4mM L-glutamine. For all following methods involving
the use of Clara cells, 'DMEM' is used to describe this culture medium with no FCS
added, unless otherwise indicated.
All cells were maintained at 37°C in a humidified incubator containing 5%
CO2, and used for assays at the lowest possible passage number. Estimation of the
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number of cells in each monolayer was performed by washing cells with phosphate
buffered saline (PBS) (Sigma), incubating with trypsin (Gibco) at 37°C to facilitate
detachment, and counting of cells using a haemocytometer (Sigma). Cell viability
was assessed by staining with trypan blue (Sigma), with exclusion indicating
viability.
2.2.3. ELAFIN PEPTIDE/LPS CELL-BASED ASSAYS
2.2.3.1. Stimulation ofRAW 264.7 murine macrophages with LPS
Macrophages were seeded at 5 x 105 cells/well of a 48-well plate (Corning
Costar) and incubated overnight at 37°C. Cells were washed twice with PBS and
500pl of fresh DMEM added; depending on the experiment, DMEM contained
varying concentrations of FCS between 0 and 10% (v/v), and in one assay was
replaced with 25ng/ml natural human LBP (approximately equivalent to the
concentration of LBP present in 0.5% serum). E. coli 055:B5 LPS in the
concentration range 0 to 5pg/ml was incubated with cells for 4 hours at 37°C, and
supernatant retrieved.
2.2.3.2. Investigation of the effects of elafin peptides on the TNF-a response of
RAW 264.7 murine macrophages to LPS
Macrophages were seeded at 5 x 105 cells/well of a 48-well plate (Corning
Costar) and incubated overnight at 37°C. Cells were washed twice with PBS, and
500pl of either serum-free DMEM or DMEM containing 0.2% serum added.
50ng/ml E. coli 055:B5 LPS was incubated with cells for 4 hours at 37°C either
alone or in the presence of elafin peptides. In the latter case, 2.5pl samples of LPS
were either incubated with 5pi samples of elafin peptides for 30 minutes at 37°C
prior to addition to cells, or LPS and elafin peptides were added to cells
simultaneously. Total sample volume was 7.5pl, and both LPS and elafin were
diluted to test concentrations in dFLO. When cells were stimulated with LPS in the
absence of elafin, 2.5pi LPS was added with 5pl dELO. In alternative experiments
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designed to investigate the effects on TNF-a secretion of elafin peptides alone,
peptides were incubated with cells for 4 hours at 37°C as above. In all cases, cell
supernatants were analysed by TNF-a ELISA using a commercial ELISA kit
(Duoset, R&D Systems) in accordance with the manufacturer's instructions. The
standard curve measured between 15.6pg/ml and lOOOpg/ml protein, and test
samples were diluted accordingly in PBS containing 1% BSA.
2.2.3.3. Investigation of the effects of elafin peptides on the MIP-2 response of
murine Clara cells to LPS
Clara cells were seeded at 3 x 105 cells/well of a 48-well plate and incubated
overnight at 37°C. Cells were washed twice with PBS, and 500pl of either serum-
free DMEM or DMEM containing 0.2% serum added. 50ng/ml (in medium
containing serum) or lpg/ml (in serum-free medium) E. coli 055:B5 LPS was
incubated with cells for 4 hours at 37°C either alone or in the presence of elafin
peptides. In the latter case, samples of LPS were either incubated with 5pi samples of
elafin peptides for 30 minutes at 37°C prior to addition to cells, or LPS and elafin
peptides were added to cells simultaneously. 50ng/ml LPS was made up in 2.5pi
samples, while lpg/ml LPS was made up in 5pi. Total sample volume was therefore
7.5pl or lOpl, and both LPS and elafin were diluted to test concentrations in dFEO.
When cells were stimulated with LPS in the absence of elafin, LPS was added with
5pi dFEO. In alternative experiments designed to investigate the effects on MIP-2
secretion of elafin peptides alone, peptides were incubated with cells for 4 hours at
37°C as above. In all cases, cell supernatants were analysed by MIP-2 ELISA using a
commercial ELISA kit (Duoset, R&D Systems) in accordance with the
manufacturer's instructions. The standard curve measured between 15.6pg/ml and
lOOOpg/ml protein, and test samples were diluted accordingly in PBS containing 1%
BSA.
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2.2.4. ADENOVIRUS/LPS CELL-BASED ASSAYS, & RELATED
TECHNIQUES
2.2.4.1. Infection of RAW 264.7 murine macrophages with adenoviral constructs
(Ad-elafin, Ad-lacZ, Ad-IicB, Ad-dl70/3, Ad-m-eotaxin, Ad-mSLPI or
vehicle alone)
Macrophages were seeded at 5 x 105 cells/well of a 48-well plate and
incubated overnight at 37°C. Adenoviral constructs of known concentration were
diluted in Minimum Essential Eagle's Medium (MEEM) (see Formulations below)
with or without the addition of CaCE (to form calcium phosphate (CaPi)
precipitates), or in DMEM, and incubated for 20 minutes at room temperature to
allow formation of Ad:CaPi coprecipitates where applicable (Fasbender et al., 1998).
Adenovirus was applied to cells at various multiplicities of infection (mois) in a total
volume of 250pl for 45 minutes at 37°C (macrophages were infected at moi 100 for
the purpose of the LPS stimulation assays described in Chapter 5). Cells were
washed twice with PBS, and incubated overnight at 37°C in DMEM containing 0.2%
FCS.
• 9+
Formulations. MEEM: (M2279; Sigma). This medium contains 1.8mM Ca and
0.86mM Pi. Addition of CaCE to this medium facilitates formation of CaPi
precipitates; for example, addition of 4mM CaCE allows formation of precipitates
with a total of 5.8mM Ca2+ and 0.86mM Pi.
2.2.4.2. Investigation of the effects of calcium phosphate (CaPi) precipitates on the
inflammatory responses ofRAW 264.7 murine macrophages
Macrophages were seeded at 5 x 105 cells/well of a 48-well plate and
incubated overnight at 37°C. Cells were then incubated for 45 minutes at 37°C with
either 250pl DMEM or 250pl MEEM containing 4mM CaCl2 (forming CaPi
9-F •
precipitates with 5.8 mM Ca and 0.86 mM Pi, as described in 'Formulations' in
section 2.2.4.1.); these media were incubated at room temperature for 20 minutes
prior to addition to cells. Cells were washed twice with PBS and 500pil DMEM
containing 0.2% FCS, added. Cells were then incubated at 37°C for lhour or 23
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hours, and media analysed by TNF-a ELISA. Alternatively, following 23-hour
incubation, cells were stimulated with 50ng/ml E. coli 055:B55 LPS for 4 hours at
37°C, and media analysed by TNF-a ELISA. Cell viability was also assessed by
light microscopy, trypan blue exclusion and cell counting.
2.2.4.3. Stimulation of adenovirally-infected RAW 264.7 murine macrophages with
LPS
Macrophages were infected with adenovirus constructs as described in
section 2.2.4.1., and incubated overnight at 37°C in DMEM containing 0.2% FCS.
For experiments investigating the effects of LPS on elafin production by Ad-elafin-
infected macrophages, cells were incubated for 4 hours at 37°C with concentrations
of E. coli 055:B5 LPS ranging between 0 and 5pg/ml; cell supernatants or lysates
were then analysed by elafin ELISA. For experiments investigating the LPS-
responsiveness of Ad-infected macrophages, cells were incubated for 4 hours at 37°C
with 50ng/ml E. coli 055:B5 LPS, either in conditioned media or following washing
with PBS and addition of fresh DMEM containing 0.2% FCS. Alternatively,
conditioned media were removed from Ad-infected cells 4-hours or 23-hours post-
viral infection, media added to 5 x 105 uninfected, washed cells and then these cells
were incubated for 4 hours with 50ng/ml LPS as above. Cell supernatants were
analysed by TNF-a ELISA.
2.2.4.4. Staining for P-galactosidase in RAW 264.7 murine macrophages
Macrophages, infected with Ad-lacZ as described in section 2.2.4.1., were
fixed for 10 minutes at room temperature in a solution comprising 0.2%
glutaraldehyde, 0.8% formaldehyde and 2mM MgCL in PBS. Fixative was discarded
and 200pl of staining solution added for 5 hours at 37°C (staining solution comprised
5mM K4Fe(CN)6, 5mM K3Fe3(CN)6, 2mM MgCl2, 0.05% Triton X-100, 0.5mg/ml
X-gal, in PBS). Cells were washed with PBS to remove residual stain, air-dried and
photographed.
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2.2.4.5. Lysis of cells for measurement of intracellular elafin
Ad-elafin-infected cells were washed once with cold PBS and lysed using a
buffer containing 1% (v/v) NP-40, 0.5% (w/v) sodium deoxycholate and 1% (w/v)
SDS in PBS. One protease inhibitor tablet (Boehringer Mannheim) was added per
10ml of lysis buffer. Cells were scraped into an eppendorf, incubated on ice for 30
minutes and then centrifuged at 13000rpm for 20 minutes at 4°C. Supernatants
(representing total cell lysates) were removed and stored at -40°C until analysis by
elafin ELISA, as described in section 2.2.4.6. below.
2.2.4.6. Elafin ELISA
Concentrations of human elafin in supernatants and lysates of Ad-elafin-
infected cells were determined using a sandwich ELISA available in-house. This
technique has previously been described in detail by Reid et al. (1999). Samples
were diluted according to the range of the standard curve (0.5-1Ong/ml).
2.2.5. ANTIMICROBIAL STUDIES & RELATED TECHNIQUES
2.2.5.1. Infection of murine Clara cells with adenoviral constructs (Ad-elafin, Ad-
lacZ or vehicle alone) and investigation of antimicrobial activity against P.
aeruginosa
Clara cells were grown to confluence in 96-well plates in DMEM containing
10% FCS, and then incubated for 45 minutes at 37°C with adenoviral vectors (moi
100) in a total volume of 100pi DMEM/ 10% FCS. Cells were washed twice with
PBS, and incubated for 2-6 days at 37°C in lOOpl DMEM/ 10% FCS lacking
penicillin and streptomycin. P. aeruginosa strain PAOl was inoculated into 10ml
nutrient broth (Oxoid) containing 5% yeast extract (Difco) and incubated overnight
at 37°C in an orbital shaker at 200 rev/min (Gallenkamp, Fisher Scientific,
Loughborough, UK). The culture was centrifuged at 4500rpm for 10 minutes at room
temperature (Biofuge, Heraeus Instruments, Kendro, Bishops Stortford, UK),
supernatant discarded and the pellet resuspended in 8 ml phosphate buffer (0.008M
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K2HPO4/ 0.002M KH2PO4, pH 7.4). The suspension was adjusted with phosphate
buffer to an absorbance of 1.45 read at 590nm (M330 UV-visible spectrophotometer,
Camspec, Cambridge, UK), yielding an estimated bacterial concentration of 2.2 x
1011 colony forming units (cfu)/ml. Serial dilutions of this suspension were made in
DMEM/ 10% FCS lacking penicillin and streptomycin, and lOOpl aliquots were
incubated with cells for 5 hours at 37°C. Following incubation, media were serially
diluted and lOOpl of samples plated onto PIA. Plates were incubated for 16 hours at
37°C and colonies counted. Remaining cell culture media were retained and frozen at
-20°C.
2.2.5.2. SDS-PAGE & Western Blotting to detect elafin in culture media from Ad-
elafin-infected Clara cells
Culture media from the antimicrobial assays described in section 2.2.5.1.
were analysed to detect secreted elafin. Briefly, 22.5pl samples of media were
resolved on 15% SDS-polyacrylamide gels using a vertical electrophoresis tank Mini
Protean II system. Samples were electrophoresed at 70V-110V using SDS-Tris-
Glycine electrode buffer for 2-3 hours beside pre-stained molecular weight markers
(Life Technologies), and using 40ng of synthetic full-length elafin as a control.
Following separation, proteins were transferred onto Hybond ECL
nitrocellulose membrane at 110V for 1 hour. Non-specific protein binding sites were
blocked overnight at 4°C with PBS/0.1% Tween 20 containing 5% skim milk. The
membrane was then incubated in a 1:1000 dilution of rabbit anti-elafin IgG in
blocking solution for 1 hour at room temperature, and washed thoroughly with
PBS/0.1% Tween. HRP-conjugated goat anti-rabbit immunoglobulin diluted 1:2000
in blocking solution was added for 30 minutes at room temperature, and then the
membrane was washed as above. Finally, immunoreactive bands were detected by
ECL, and membrane developed on X-omat film.
Formulations. 4x SDS-PAGE sample buffer. 0.5M Tris-HCl, 40% (v/v) glycerol, 8%
(w/v) SDS, 0.2M EDTA, 0.5% (v/v) bromophenol blue and 4% (v/v)
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mercaptoethanol. SDS-polyacrylamide gels\ Separating gel (pH 8.8) - 0.375M Tris-
HC1, 2mM EDTA, 0.1% (w/v) SDS, 15% (v/v) acrylamide, 0.1% (v/v) APS and
0.05% (v/v) TEMED. Stacking gel (pH 6.8) - 0.125M Tris-HCl, 2mM EDTA, 0.1%
(w/v) SDS, 4.5% (v/v) acrylamide, 0.1% (v/v) APS and 0.06% (v/v) TEMED.
Electrode buffer. 0.6% (w/v) Tris base, 2.9% (w/v) glycine, 0.7% (w/v) EDTA, 0.1%
(w/v) SDS. Transfer buffer. 24.7mM Tris base, 210mM glycine, and 20% (v/v)
methanol.
2.2.5.3. Isolation and culture of primary murine tracheal epithelial cells
All work complied with the UK Animal (Scientific Procedures) Act 1986.
The method used followed approximately that described in the paper by Davidson et
al. (2000). Mice were killed by asphyxiation with CO2, and doused with 70%
ethanol. Tracheae were excised and severed at the proximal surface of the thyroid
cartilage and at the junction of the bronchi. The thyroid glands and other adherent
tissue were removed before cutting tracheae lengthways, rinsing in PBS and
transferring to collection medium at 37°C (see Formulations). Batches of eight
tracheae were removed to 20ml aliquots of dissociation medium containing DNase
and Pronase (see Formulations) and incubated for 60 mins at 37°C. 5ml of FCS was
added to halt enzymatic activity, and samples carefully inverted 12 times each to
dissociate epithelial cells. Tracheae were transferred to 10ml of fresh culture medium
(see Formulations) and gently agitated a further 12 times to facilitate additional
release of epithelial cells. The resultant cell suspensions were pooled and centrifuged
at 1300 rpm for 6 mins at 24°C, supernatants removed and pellets resuspended in
10ml culture medium. Samples were again centrifuged at 1300rpm for 6 mins at
24°C, and pellets resuspended in 5ml of culture medium. Cell suspensions were
incubated at 37°C for 2 hours in 10cm culture dishes (Premaria, Becton Dickinson
UK, Oxford, UK) to remove adherent non-epithelial cells. Media were removed to
collect unattached cells, centrifuged at 1300rpm for 6 mins, and resuspended in
200pl culture medium per two tracheae. Dissociated cells from two tracheae
(approximately 4 x 105 cells) were seeded onto one tissue culture insert semi¬
permeable support membrane (Costar Transwell clear, tissue culture-treated
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polyester membrane 24-well plate inserts, 0.4pm pore; Corning Costar) in 200pl of
culture medium, with 600pl outside the insert. Inserts were pre-coated with lOOpl of
type VI human placental collagen solution (0.5mg/ml collagen in df^O with 0.2%
glacial acetic acid), air-dried overnight, and washed twice with PBS before use. Cells
were incubated at 37°C in 6% CO2 for 3 days. On day 4, medium bathing the apical
cell surface was removed along with any cell debris, and the medium on the outside
of the insert replaced with 600pl of Ultroser G (USG) medium (see Formulations).
Medium bathing the basolateral surface was replaced twice weekly.
Formulations. Collection medium-. 1:1 mix of DMEM and Ham's F-12 medium
(Gibco) containing 100 U/ml penicillin and lOOpg/ml streptomycin. Dissociation
medium-, calcium- and magnesium-free MEEM containing 60 U/ml penicillin,
60pg/ml streptomycin, 1.4mg/ml Pronase (Boehringer Mannheim) and O.lmg/ml
DNase (Sigma). Culture medium-, collection medium containing 5% FCS and 120 U/l
insulin (Nova Human Actrapid, AAH Pharmaceuticals, Glasgow, UK). USG
medium: collection medium containing 2% USG serum substitute (Gibco).
2.2.5.4. Infection of primary murine tracheal epithelium with adenoviral constructs
(Ad-elafin, Ad-lacZ or vehicle alone)
Adenoviral constructs of known concentration were diluted in MEEM with or
without the addition of 4mM CaCl2 (to form CaPi precipitates), or in USG medium,
and incubated for 20 minutes at room temperature to allow formation of AdiCaPi
coprecipitates where applicable (Fasbender et al., 1998). Adenovirus was applied to
epithelial cells at an moi of 100 in a total volume of 250pl for 45 minutes at 37°C.
Cells were washed twice with PBS, and incubated for 18-20 hours at 37°C in the
absence ofmedia bathing the apical surface.
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2.2.5.5. Staining for P-galactosidase in primary murine tracheal epithelium
Epithelial cells, infected with Ad-lacZ as described in section 2.2.5.4., were
stained for P-galactosidase production according to the same technique used to stain
Ad-lacZ-infected RAW 264.7 murine macrophages in section 2.2.4.4. Similarly, cells
were left to air dry and then photographed following staining.
2.2.5.6. Assay to investigate the effects of elafin gene augmentation on the
antimicrobial activity of primary murine tracheal epithelium against
Pseudomonas aeruginosa and Staphylococcus aureus
Colonies of P. aeruginosa strains PAOl or J1385, or S. aureus strain C1705,
were inoculated into 10ml nutrient broth containing 5% yeast extract and incubated
overnight at 37°C in an orbital shaker at 200 rev/min. Bacterial suspensions were
centrifuged at 3000rpm for 15 minutes at room temperature, supernatant discarded
and the pellet resuspended in 10ml phosphate buffer. Suspensions were adjusted with
phosphate buffer to an absorbance of 1.00 read at 590nm, yielding an estimated
bacterial concentration of 1 x 109 cfu/ml.
Serial dilutions of this suspension were performed in phosphate buffer down
to 1 x 107 cfu/ml, and 20 nanolitres (nl) were added to cells using a Hamilton
precision syringe (Hamilton Company, Reno, NV, USA) to provide an initial
bacterial colony count of approximately 200. Concurrently, 20nl of bacterial
suspension was plated onto several agar plates, along with 100pl phosphate buffer, to
obtain more accurate values pertaining to the initial number of bacteria added to
cells. Bacteria were incubated with cells for 3 hours at 37°C.
Cell inserts were washed with both 105pl phosphate buffer and 105pi
phosphate buffer containing 0.5% Triton X-100 (to ensure removal of bacteria
attached to cell surface). These samples were pooled and centrifuged for 10 minutes
at 8000rpm; supernatants were removed for analysis by elafin ELISA, while bacterial
pellets were resuspended in phosphate buffer and plated onto PIA (P. aeruginosa) or
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Columbia agar (S. aureus), either neat or following serial dilution in phosphate
buffer. Plates were incubated for 16 hours at 37°C and colonies counted.
2.2.6. STATISTICAL ANALYSIS
Results are reported either (i) as pooled data from a series of n separate
experiments, each carried out in triplicate, and presented as mean ± S.E., or (ii) as
individual experiments, carried out in triplicate, and presented either as mean ± S.E.
or mean ± SD. Statistical significance was analysed by one-way analysis of variance
with comparisons between groups made using the Bonferroni Multiple Comparison
Test.
Statistical significance was assigned to data returning a P value of less than
0.05.
73
Chapter 3: Interactions of elafin with bacterial lipopolvsaccharide
CHAPTER 3
INTERACTIONS OF ELAFIN WITH BACTERIAL
LIPOPOLYSACCHARIDE
3.1. AIMS
The principal aim of the work described in this chapter was to determine
whether elafin is capable of direct interaction with the lipopolysaccharide component
of the outer membrane ofGram-negative bacteria. A secondary aim was to determine
the relative contributions of the distinct structural domains of elafin to LPS-binding.
Moreover, experiments were designed to investigate which region of the LPS
molecule elafin may bind to.
In the event that an interaction between these molecules was observed, a
further aim was to investigate how the binding of elafin to LPS would affect the
interaction of LPS with LPS-binding protein, and to assess the relative affinity of
these molecules for LPS.
The synthetic elafin molecules used in these experiments have been described
in Chapter 2 (section 2.1.2.). In brief, these peptides are full-length elafin
(approximately 9.9kDa), the NH2-terminal domain (approximately 5.2kDa) and the
COOH-terminal domain (approximately 4.8kDa).
3.2. RESULTS
3.2.1. Preliminary experiments to visualise LPS serotype ladders and establish
conditions for initial interaction assays
As discussed in Chapter 1, LPS consists of three major portions, of which
lipid A is considered the most important since this domain harbours the endotoxic
properties of the molecule. This domain is also known to be the most conserved
across Gram-negative bacterial species, and is recognised as an important binding
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site for anti-endotoxin molecules (Morrison and Jacobs, 1976; Gazzano-Santoro et
al., 1992; Appelmelk et al., 1994).
Four LPS serotypes of the Escherichia coli species were subjected to Bis-Tris
polyacrylamide gel electrophoresis (PAGE) analysis and visualised by silver staining
(Figure 1). E. coli 055:B5 LPS is a smooth-form LPS (indicated by the O prefix
before the serotype number); this can be visualised by the presence of a number of
bands detected above 6kDa in a characteristic 'ladder' pattern. K12, R2 and R3 are
rough-form serotypes and therefore contain no oligosaccharide repeats. The lipid A-
core portion of these rough serotypes is represented by a single band just below
6kDa. The position of the cathode and anode is indicated by encircled - or + signs
next to all gels in this chapter.
In order to asses interaction of elafin with LPS using PAGE techniques,
preliminary experiments were performed to assess the effects of SDS (sodium
dodecyl sulphate) on the migration of LPS; it should be noted that the electrophoresis
system used to separate LPS samples in Figure 1 contained SDS in electrode buffer,
and the similar compound LDS (lithium dodecyl sulphate) in sample buffer. SDS
(and indeed LDS) is an anionic detergent that is used in PAGE techniques to bind to
and denature molecules, conferring to them an overall negative charge proportional
to their size and, as such, can dissociate multimeric molecules (such as LPS) into
their subunits. Thus SDS-PAGE allows molecules to be resolved by molecular
weight, following migration to the anode. It was therefore hypothesised that SDS
may be a hindrance to any potential interaction between cationic elafin molecules
and anionic LPS molecules in subsequent experiments, hence every effort was made
to minimise the presence of SDS throughout experimental conditions.
Figure 2 demonstrates the importance of the inclusion of SDS in electrode
buffers to the separation of LPS into its component moieties. Firstly it must be noted
that gels themselves contained no SDS. Absence of SDS in sample buffer effected
only a minor disruption of LPS banding when SDS was added to electrode buffer
(Figure 2A); however, exclusion of SDS from electrode buffers allowed LPS to
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LPS serotype
055 K12 R2 R3 055 K12 R2 R3
Figure 1. LPS serotypes separated as characteristic 'ladder' pattern
LPS samples were diluted to the appropriate concentration in dELO and mixed with
reducing sample buffer to a total sample volume of 20pl. Electrophoresis was
performed at 200V for 35 minutes in SDS-free Bis-Tris-HCl buffered (pH 6.4)
polyacrylamide gels with a concentration gradient of 4-12%, using denaturing SDS
electrode buffer; sample buffer contained LDS (lithium dodecyl sulphate) (Invitrogen
NuPAGE Novex Bis-Tris electrophoresis system). Bands were visualised using the
Bio-Rad Silver Stain Kit. M= molecular weight markers.
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Figure 2. SDS in electrode buffer is critical for the resolution of LPS structure
by PAGE
LPS samples were diluted to the appropriate concentration in dELO and mixed with
sample buffer to a total volume of lOpl; each lane contains 25pg of LPS.
Electrophoresis was performed in SDS-free 14% gels at 60V-150V for 3 hours using
a pH 8.8 maxigel PAGE technique as detailed in 'Materials and Methods', and gels
were silver stained. Sample buffer either contained or lacked SDS as per labels (+ =
sample buffer containing SDS, - = sample buffer containing no SDS). Gel A was
performed using electrode buffer containing SDS; gel B was performed using
electrode buffer lacking SDS.
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migrate only as a 'streak', whilst the absence of SDS in sample buffer further hindered the
ability of the LPS molecules to migrate (Figure 2B).
3.2.2. Direct interactions of elafin with LPS
Although the inclusion of SDS in electrode buffer was shown to be essential
in order to dissociate LPS into its 'ladder' pattern by PAGE, in the complete absence
of SDS in any buffers LPS could still migrate weakly in an unresolved form, due to
anionic charges on the molecules (Figure 2B). Initial experiments were therefore
undertaken to investigate the interaction of elafin and elafin fragments with LPS
using this native pH 8.8 PAGE technique, entirely devoid of SDS. Similar native
PAGE techniques have been used by others to demonstrate binding of molecules
such as sCD14 and SLPI to LPS (Hailman et al., 1994; Ding et al., 1999). Since
previous work has described the LPS-binding properties of SLPI (Ding et al., 1999),
the other member of the antileukoprotease superfamily of proteinase inhibitors and a
molecule with which elafin shares approximately 40% sequence homology (Wiedow
et al., 1990; Sallenave and Ryle, 1991; Sallenave and Silva, 1993), it seemed
reasonable to use human SLPI as a control for binding to LPS. E.coli 015 LPS, as an
example of a typical smooth-form LPS serotype, was used for the purpose of these
investigations.
Full-length elafin was shown to inhibit the migration of LPS in this gel
system, an observation that is suggestive of a direct interaction between the
molecules (Figure 3). A similar observation was noted in the case of SLPI. For the
purpose of these investigations the molecular weights of elafin and SLPI, 9.9kDa and
11.7kDa respectively, were considered to be similar enough to compare binding
using 'exact' weights i.e. 250ng-5pg in this case. It must be noted that in these
conditions neither elafm nor SLPI alone entered the gel matrix, presumably due to
their net positive charge (lanes 2); Figure 4 demonstrates the same finding in the case
of both the NFL- and COOH-termini of elafin. In normal circumstances LPS
migrates to the anode, as shown in lane 1 of all gels in Figures 3 and 4. Incubation
with elafin or SLPI inhibited the migration of LPS, and this inhibition occurred at a
lower ratio of elafin:LPS than SLPLLPS. As the concentration of each proteinase
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LPS Elafin 250ng 500ng lp.g 2.5pg 5pg
20pg 5pg Elafin
Lane 1 2 3 4 5 6 7
20pg LPS +
LPS SLPI 250ng 500ng lug 2.5ug 5ug
20pg 5gtg SLPI
Lane 1
Figure 3. Elafin and SLPI inhibit migration of LPS in a pH 8.8 native gel system
Nondenaturing PAGE followed by silver staining. Samples of elafin or SLPI were
incubated with E.coli 015 LPS at 37°C overnight in PBS containing ImM EDTA,
and mixed with SDS- and mercaptoethanol-free sample buffer to a total volume of
25pl prior to electrophoresis. Electrophoresis was performed in SDS-free 15% gels at
70V-110V for 2-3 hours, using pH 8.8 minigels as detailed in 'Materials and
Methods'. Electrode buffer was SDS-free. Gels were silver stained.
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Figure 4. Elafin N-terminal and C-terminal domains inhibit migration of LPS in
a pH 8.8 native gel system
Nondenaturing PAGE followed by silver staining. Samples of NH2- or COOH-
terminal elafin domains were incubated with E. coli 015 LPS at 37°C overnight in
PBS containing ImM EDTA, and mixed with SDS- and mercaptoethanol-free
sample buffer to a total volume of 25pi prior to electrophoresis. Electrophoresis was
performed in SDS-free 15% gels at 70V-110V for 2-3 hours, using pH 8.8 minigels
as detailed in 'Materials and Methods'. Electrode buffer was SDS-free. Gels were
silver stained.
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inhibitor increased, an increasingly intense band was detected at the top of the gel
matrices (lanes 3-7); this may represent a complex of peptide and LPS which is
unable to enter the gel, perhaps due either to being too large to migrate or possessing
too positive an overall charge.
Interestingly, both terminal domains of the full-length elafin molecule
inhibited the migration of LPS (Figure 4), suggesting that both can bind to LPS.
It should be noted at this point that EDTA was included in reaction mixtures
during these preliminary experiments, as per the technique described by Hailman et
al. (1994) and Ding et al. (1999). EDTA is known to destabilise LPS (Yu and
Wright, 1996), possibly by chelating divalent cations associated with the inner core
region of the molecule (Rietschel et al., 1994). This chelation may therefore promote
elafin binding to LPS. However, later observations suggested that inclusion ofEDTA
was not essential for elafin-LPS interaction, and thus subsequent experiments were
performed in the absence ofEDTA to avoid artificial disaggregation of LPS.
It must also be emphasised that several problems arose in the execution of
these experiments. For example, difficulties were encountered with the
reproducibility of LPS migration, and in particular with the consistency of signal
obtained with silver staining. Therefore, a number of further experiments were
designed to clarify these findings.
A simple dot-blot technique was used in an attempt to demonstrate binding of
full-length elafin to LPS in a simplified system. Although Figure 5 shows the results
of a dot-blot investigating elafin interaction with only E. coli 06 LPS and P.
aeruginosa 02 LPS, a range of LPS serotypes were used during this study (not
shown). HNE was used as a positive control since elafin is known to bind to and
inhibit this enzyme.
A number of difficulties were encountered in demonstrating an interaction
using this method. Although it appeared at first glance that a dose response with
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Figure 5. Non-specific binding of antibodies hinders investigation of elafin-LPS
interaction by dot-blot
2|_ig of LPS or HNE were spotted onto nylon membrane and allowed to dry.
Increasing amounts of elafin were dotted onto these spots, dried and the membrane
blocked with PBS-Tween/5% skim milk for 1 hour at 4°C. Elafin was then detected
by immunoblot analysis as described in 'Materials and Methods'. 06 = E. coli 06
LPS, PA02 = P. aeruginosa 02 LPS. HNE was used as a positive control. Bottom
two rows: row 6, no LPS or elastase spotted prior to addition of elafin; row 7, elafin
spotted prior to blocking instead of LPS.
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increasing elafin concentration was suggestive of binding to the immobilised LPS
(rows 1-4), controls in the lower rows demonstrated problems of non-specific
binding. When no elafin was spotted onto LPS or elastase, a signal was still obtained
(row 5). Additionally, elafin spotted onto a blocked membrane in the absence of LPS
or elastase also bound and produced a signal (row 6). It therefore appeared that dots
may not necessarily be specific for elafin; indeed there appeared to be antibody
cross-reactivity with both LPS and elastase (row 5), and elafin appeared to be
binding directly to the blocking agent (row 6).
To assert beyond doubt that elafin and its constituent moieties interact
directly with LPS, an acidic (pH 4.5) native PAGE system was utilised (see Chapter
2 for more details) (Figures 6 and 7). The pH of these gels is considerably lower than
the p/ (isoelectric point or pH) of the peptides (the p7 of elafin is 9.7 (Wiedow et al.,
1990), whereas that of SLPI is 8.9 (Zitnik et al., 1997)), hence they are charged
positively in this buffer system and migrate to the cathode, as demonstrated by lanes
1 and 8 of each gel. LPS did not migrate in this system, as assessed by silver staining
(not shown).
Full-length elafin was shown to bind to LPS; this interaction was manifested
by the gradual disappearance of the characteristic elafin band in a dose-responsive
manner with increasing LPS concentration (Figure 6, lanes 1-7 of upper gel). Again,
SLPI acted as a positive control for this interaction and appeared to bind LPS with a
higher affinity than elafin, by virtue of the loss of the SLPI band at a lower LPS
concentration (Figure 6, lower gel). Both elafin NFL- and COOH-terminal domains
bound to LPS, although the affinity of the NFL- terminal domain for LPS appeared to
be much greater (Figure 7, lanes 1-7). It must be noted that, in terms of affinity of
full-length elafin for LPS versus that of its constituent domains, Figures 6 and 7
cannot be compared directly. 2.5pg of full-length elafin was subjected to PAGE,
contrasted with 5pg of its termini; this was due to differences in the absolute
amounts of peptides required for detection by silver staining. Since each of elafin's
terminal domains contribute approximately half of the entire molecule (i.e. the
molecular weight of full-length elafin is 9925 Da, the NFL-terminal domain 5172 Da,
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Lane 1 2 3 4 5 6 7 8
Figure 6. Direct binding of elafin to smooth-form LPS and comparison with the
effects of SLPI
Native pH 4.5 PAGE of peptides followed by coomassie staining. Peptides were
incubated alone or with E. co'li 055:B5 LPS for 30 mins at 37°C in 24pl total sample
volume; 6pl of sample buffer was mixed with samples prior to loading.
Electrophoresis was performed in 15% gels at 80V for 2-3 hours, and peptides were
detected by coomassie staining.
Elafin +12.5ug +25pg +50ug +100pg +200ug +400ug Elafin
2.5pg LPS 2.5pg
SLPI +12.5ug +25ug +50ug +100ug +200ug +400ug SLPI
2.5pg LPS 2.5pg
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Lane 12 3 4 5 6 7 8
Figure 7. Direct binding of N-terminal and C-terminal elafin domains to
smooth-form LPS
Native pH 4.5 PAGE of peptides followed by coomassie staining. Peptides were
incubated alone or with E. coli 055:B5 LPS for 30 mins at 37°C in 24pl total sample
volume; 6pl of sample buffer was mixed with samples prior to loading.
Electrophoresis was performed in 15% gels at 80V for 2-3 hours, and peptides were
detected by coomassie staining.
N- +12.5pg +25ug +50pg +100ug +200p.g +400pg N-
5pg LPS 5pg
C- +12.5pg +25pg +50pg +100ug +200ug +400ug C-
5pg LPS 5pg
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and the COOH-terminal domain 4776 Da), gels in Figure 7 represent around four
times the molar concentration of elafin's domains as compared with the full-length
molecule shown in Figure 6. This makes comparison of the whole molecule with its
terminal domains difficult; however, on consideration of these acidic PAGE gels
alone, it may tentatively be drawn that the affinities for LPS of the full-length
molecule and its NFL-terminal domain are similar, while that of the COOH-terminal
domain is weaker than either.
It must be noted at this point that, during the course of these investigations,
difficulties were encountered in finding a suitable negative control protein for studies
concerning binding to LPS (i.e. demonstration of a molecule unable to interact with
LPS). These problems will be discussed briefly in the 'Discussion' section at the end
of this chapter.
3.2.3. Investigation of a potential elafin binding domain within the LPS molecule
Well-characterised LPS-binding molecules such as LBP, bactericidal/
permeability-increasing protein (BPI) and polymyxin B are known to bind to LPS at
a site within the conserved lipid A domain (Morrison and Jacobs, 1976; Tobias et al.,
1989; Gazzano-Santoro et al., 1992). Initial assays to ascertain a potential elafin
binding domain within the LPS molecule investigated its binding to three rough-form
LPS serotypes, E. coli K12, R2 and R3 (discussed briefly in Chapter 1, section
1.3.2.2.); these rough-form serotypes consist solely of the lipid A-core moiety, as
demonstrated in Figure 1 by the presence of only the lowest molecular weight band
following PAGE (Goldman and Leive, 1987; Poxton, 1995), and therefore
interaction with elafin would suggest a binding site within this region.
Elafin was found to bind strongly to K12 (Figure 8, upper gel, lanes 2 and 3).
Binding to R2 and R3 was demonstrated by a dose-responsive weakening and
upwards shift of the elafin band (perhaps caused by a decrease in the overall net
positive charge of the elafin molecules following interaction with LPS), but did not
appear to be as strong as the interaction with K12 (lanes 4-7). SLPI appeared to have
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Elafin full-length
EL +30|ig +60(j.g +100fj.g +200p.g +100gg +200p.g EL
2.5gg K12 K12 R2 R2 R3 R3 2.5|ig
Lane 1 2 3
SLPI
SLPI +30|o.g +60(j.g +100|j.g +200gg +1 OOjag +200pg SLPI
2.5 j_ig K12 K12 R2 R2 R3 R3 2.5gig
Lane 1 2 3 4 5 6 7
Figure 8. Binding of elafin to rough-form LPS serotypes and comparison with
SLPI
Native pH 4.5 PAGE of peptides followed by coomassie staining. Peptides were
incubated alone or with rough-form E. coli LPS serotypes K12, R2 or R3 for 30 mins
at 37°C in 24p,l total sample volume; 6p.l of sample buffer was mixed with samples
prior to loading. Electrophoresis was performed in 15% gels at 80V for 2-3 hours,
and peptides were detected by coomassie staining.
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N- +60pg +200pg +200pg C- +60jj.g +200pg +200pg
5pg K12 R2 R3 5pg K12 R2 R3
I IO
Lane 1 2 3 4 5 6 7 8
Figure 9. Binding of N-terminal and C-terminal elafin domains to E.coli K12
rough-form LPS
Native pH 4.5 PAGE of peptides followed by coomassie staining. Peptides were
incubated alone or with rough-form E. coli LPS serotypes K12, R2 or R3 for 30 mins
at 37°C in 24pl total sample volume; 6pl of sample buffer was mixed with samples
prior to loading. Electrophoresis was performed in 15% gels at 80V for 2-3 hours,
and peptides were detected by coomassie staining.
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a higher affinity than elafin for rough-form LPS serotypes (Figure 8, lower gel),
concurring with the findings in section 4.2.1. using the smooth-form E. coli serotype
055:B5.
Figure 9 demonstrates that both NH2- and COOH-terminal elafin domains
bound to K12 LPS (lanes 2 and 6), but no strong indication was observed of
interaction with either R2 or R3 serotypes.
Laboratory stocks of the LPS serotypes were such that K12 could only be
used in smaller quantities than R2 and R3 (Figures 8 and 9). However, the molecular
weights of these rough-form serotypes are similar (approximately 2.5kDa (Srimal et
al., 1996; Vinogradov et al., 1999)) and it was apparent that binding of elafin
peptides to K12 occurred at a lower mass ratio than binding to either R2 or R3,
suggestive of a greater affinity for this serotype (Figures 8 and 9).
Interaction of elafin and its terminal domains with rough-form LPS serotypes
was strongly suggestive of binding to LPS via the lipid A-core portion. These
findings were corroborated by further PAGE investigations using polymyxin B (a
cationic cyclic polypeptide antibiotic isolated from Bacillus polymyxa, known to bind
to lipid A with high affinity and to neutralise many of the biological effects of LPS
(Morrison and Jacobs, 1976)) as a control peptide, as shown in Figures 10 and 11.
LPS was separated into its 'ladder' pattern using native PAGE conditions at pH 8.8
(Figures 10A and 11 A), but with SDS in electrode buffer, and silver stained. When
the proteins were separated alone, these low SDS conditions hindered the migration
of elafin to the anode (Figure 10A and B, lane 1) and completely inhibited migration
ofpolymyxin B (Figure 11 A and B, lane 1).
Incubation of elafin or polymyxin B with 055:B5 or R2 LPS serotypes
disrupted the LPS banding in a similar fashion, in particular by increasing the
intensity of the lowest molecular weight bands near the lipid A-core region (Figures
10A and 11A), but taken alone these findings are not easily interpretable. In order to
specifically detect peptide in the same gels, western blotting for elafin and
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EL 4|ig 055:B5 LPS 2pg R2 LPS
2|ig 'alone +2|ig +4|ig' 'alone +2 fig +4fig '
EL EL EL EL
Figure 10. Elafin binds to lipid A-core portion of LPS
PAGE (pH 8.8) using SDS in electrode buffer only, followed by silver staining (A)
or western blotting with anti-elafin polyclonal antibody (B). Elafin was incubated
alone or with LPS for 30 mins at 37°C in 20|il total sample volume; 5fil of sample
buffer was mixed with samples prior to loading. Electrophoresis was performed in
15% gels at 70V-110V for 2-3 hours.
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Polymxyin B
PB 4pg Q55:B5 LPS PB ^^pgR^PS^
2pg klone +2pg +4pg ' 2pg 'alone +2pg +4pg '
PB PB PB PB




PB 055 LPS 055 PB R2 LPS R2
2pg 4gtg + PB 2pg 2pg + PB
Lane 1
Figure 11. Binding of polymyxin B to lipid A-core portion of LPS
PAGE (pH 8.8) using SDS in electrode buffer only, followed by silver staining (A)
or western blotting with anti-polymyxin B monoclonal antibody (B). Polymyxin B
was incubated alone or with LPS for 30 mins at 37°C in 20pl total sample volume;
5pi of sample buffer was mixed with samples prior to loading. Electrophoresis was
performed in 15% gels at 70V-110V for 2-3 hours.
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polymyxin B was performed (Figures 10B and 11B). Western blotting for elafin
demonstrated that the weak elafin band obtained when peptide was run alone was
significantly augmented on incubation with LPS (Figure 10B); these strong bands
correlated with the position of the lowest LPS band, strongly suggesting that elafin
had bound to the lipid A-core moiety and migrated with LPS. Figure 1 IB
demonstrates a similar finding in the case of polymyxin B; the peptide alone did not
migrate at all, but strong bands were obtained on incubation with LPS and these
again correlated with the position of the lipid A-core domain.
To extend these findings, an investigation was undertaken to study how the
well-characterised LPS-binding molecules LBP and polymyxin B affected the
binding of elafin to LPS; as previously mentioned, LBP and polymyxin B are known
to bind LPS via the lipid A domain (Morrison and Jacobs, 1976; Tobias et al., 1989).
A 1.8kDa peptide comprising an LPS-binding portion of LBP, amino acids
86-96 of the full-length molecule, was used to study the effects of LBP on elafin-LPS
interaction (Figure 12). Lanes 3-5 represent molar ratios of LBP:elafin of 5:1, 10:1
and 15:1 respectively.
Binding of LBP peptide to LPS inhibited subsequent binding of elafin in a
dose-responsive fashion (visualised by migration of unbound elafin), suggestive of
competition for the same binding site.
Binding of both NFL- and COOH-terminal elafin domains to LPS was also
inhibited by pre-bound LBP peptide (Figure 13). Lanes 3-5 represent molar ratios of
LBP:elafin peptide of 1:1, 3:1 and 5:1 respectively. Higher intensity of signal in
lanes 3-5 indicates the presence of more free elafin peptides, which are prevented
from binding to LPS and consequently migrate through the gel.
Additionally, studies demonstrated that polymyxin B bound to LPS could
inhibit subsequent binding of either full-length elafin or its two terminal domains
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Figure 12. LBP peptide bound to LPS inhibits subsequent binding of full-length
elafin
Native pH 4.5 PAGE of elafin followed by coomassie staining. Elafin was incubated
alone (lane 1) or with E. coli 055:B5 LPS for 30 mins at 37°C (lane 2) in 24pl total
sample volume; alternatively LBP peptide (aa 86-96) was incubated with LPS for 30
mins at 37°C prior to addition of elafin, followed by further incubation for 30 mins at
37°C (lanes 3-5). 6pl of sample buffer was mixed with samples prior to loading.
Electrophoresis was performed in 15% gels at 80V for 2-3 hours, and elafin was
detected by coomassie staining.
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N-terminus of
elafin LBP peptide
N- N- + 11,8pg 5.4pg 9pg I
5pg 50pg LPS + LPS (before addition ofN-)
I I©




C- C- + I 1.8pg 5.4ja.g 9pg I
5pg 50pgLPS + LPS (before addition of C-)
1 I©
Lane 12345
Figure 13. LBP peptide bound to LPS inhibits subsequent binding of N-terminal
and C-terminal elafin domains
Native pH 4.5 PAGE of elafin peptides followed by coomassie staining. Elafin
peptides were incubated alone (lane 1) or with E. coli 055:B5 LPS for 30 mins at
37°C (lane 2) in 24pl total sample volume; alternatively LBP peptide (aa 86-96) was
incubated with LPS for 30 mins at 37°C prior to addition of elafin peptides, followed
by further incubation for 30 mins at 37°C (lanes 3-5). 6p,l of sample buffer was
mixed with samples prior to loading. Electrophoresis was performed in 15% gels at
80V for 2-3 hours, and peptides were detected by coomassie staining.
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Figure 14. Polymyxin B bound to LPS inhibits subsequent binding of elafin
peptides
Native pH 4.5 PAGE of elafin peptides followed by coomassie staining. Elafin
peptides were incubated alone (lane 1) or with E. coli 055 :B5 LPS for 30 mins at
37°C (lane 2) in 24pl total sample volume; alternatively polymyxin B was incubated
with LPS for 30 mins at 37°C prior to addition of elafin peptides, followed by further
incubation for 30 mins at 37°C (lane 3). 6pl of sample buffer was mixed with
samples prior to loading. Electrophoresis was performed in 15% gels at 80V for 2-3
hours, and peptides were detected by coomassie staining.
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(Figure 14). Polymyxin B was bound to LPS at a molar ratio of 5:1 to elafin or its
terminal domains.
These findings indicate that elafin, LBP and polymyxin B may compete for a
similar binding site within the LPS molecule.
3.2.4. Effects of elafin on the interaction of LPS with LBP
Having established that elafin binds directly to LPS and may compete with
LBP for a binding site within the LPS molecule, experiments were designed to
investigate whether elafin could preclude the binding of LPS to LBP. An ELISA
technique measuring the binding of biotinylated LPS to immobilised LBP was used
for these studies; this technique has previously been used to demonstrate that several
cationic antimicrobial peptides can inhibit the LPS-LBP interaction (Scott et al.,
2000b).
Binding of LPS to concentrations of LBP ranging from 0-50ng/ml produced a
linear standard curve (Figure 15). For the purpose of investigation of the effects of
elafin on this interaction, 25ng/ml LBP was used throughout.
Initial experiments investigated the effects of elafin peptide concentrations
ranging from 0.625- lOpM (Figure 16). SLPI was also used since, although it has
previously been shown by others to bind to LPS, its effects on the binding of LPS to
LBP have not been elucidated. Over these high concentrations, both the NH2- and
COOH-terminal elafin domains markedly inhibited the LPS-LBP interaction, though
the COOH-terminal domain was the more potent inhibitor. Inhibition by both NH2-
and COOH-terminal domains was maximal at 5pM, eliciting 51% and 73%
inhibition respectively. Interestingly, inhibition in both cases decreased at lOpM.
Inhibition of the LPS-LBP interaction by SLPI was dose-responsive to a maximal
76% inhibition at lOpM. Polymyxin B, incorporated as a positive control for
inhibition of LPS-LBP interaction, was the most potent inhibitor over these
concentrations to a maximal 89% at lOpM. Intriguingly, Figure 16 demonstrates that
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Figure 15. Standard curve of binding of LBP to LPS
Biotinylated E. coli 055:B5 LPS was added to wells containing increasing
concentrations of recombinant LBP bound to anti-LBP monoclonal antibody.
Binding of LPS to LBP was detected using HRP-conjugated streptavidin and
absorbance read at 490nm. Values represent mean ± S.E. of n=3 experiments, each
performed in duplicate.
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Figure 16. Effects of 0.625-10|oM elafin peptides on the binding of LPS to LBP
Biotinylated E. coli 055:B5 LPS or biotinylated LPS pre-incubated with peptide for
30mins at 37°C was added to wells containing 25ng/ml recombinant LBP,
immobilised using anti-LBP monoclonal antibody. Binding of LPS to LBP was
detected using HRP-conjugated streptavidin and absorbance read at 490nm. ELISA
technique is depicted diagrammatically beneath graph. For a more detailed
description of this technique see Chapter 2, section 2.2.1.7. Values represent mean ±
S.E. of n=3 experiments, each performed in duplicate. Where no error bars are
shown, they were smaller than the symbols.
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full-length elafin inhibited the LPS-LBP interaction only at the lowest
concentrations, and in fact markedly enhanced the level of LPS detectable in wells
by up to 82% at 10pM elafin. This finding will be discussed in the 'Discussion'
section at the end of this chapter.
On the basis of these findings, and considering that all peptides inhibited the
LPS-LBP interaction to some extent at lower concentrations as demonstrated by
Figure 16, the concentration of test peptides was reduced to the range 9.75nM-
156nM (Figure 17). This concentration range also relates more closely to the ratios
of elafin:LPS investigated previously using PAGE techniques (Figures 3, 4 , 6 and
7). For instance, in this ELISA system, a constant 270nM LPS was added to test
wells following incubation with the varying concentrations of full-length elafin, such
that the molar ratios of full-length elafm:LPS in Figure 17 range from 1:28 to 1:1.7.
Conversion of the fixed concentration of LPS separated by basic (pH 8.8) PAGE in
Figures 3 and 4 to a molarity (20pg/20pl sample volume « 48.8pM), and conversion
of the range of full-length elafin concentrations incubated with LPS (250ng to
5pg/20pl sample volume » 1.25pM to 25pM), indicates that the molar ratios of
elafin:LPS tested by basic PAGE ranged from 1:39 to 1:2. Similarly, conversion of
the constant full-length elafin concentration resolved by acidic PAGE in Figure 6 to a
molarity (2.5pg/24pl sample volume « 10.4pM), and conversion of the range of LPS
concentrations incubated with elafin (12.5pg to 400pg/24pl sample volume «
25.4pM to 813pM), demonstrates that the molar ratios of elafin:LPS investigated by
acidic PAGE ranged from 1:78 to 1:2.4. Thus, the molar ratios of elafin:LPS tested
by PAGE (Figures 3, 4, 6 and 7) and ELISA (Figure 17) are largely comparable.
In the concentration range 9.75nM-156nM, all forms of elafin inhibited the
LPS-LBP interaction (Figure 17). The patterns of inhibition of NFL- and COOH-
terminal domains were very similar across the concentration range, although the
COOH-terminal domain was the more effective inhibitor below 39nM; maximal
inhibition by both termini was around 47% at 78nM. At low concentrations,
inhibition effected by full-length elafin was comparable with that of the NFL-
terminal domain but was weaker than either of its constituent termini at intermediate
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concentrations; maximal inhibition by full-length elafin was obtained at 156nM.
Inhibition of LPS-LBP binding by all three elafin peptides was more or less identical
at 156nM (around 45%).
SLPI also inhibited the LPS-LBP interaction maximally at 156nM. The dose-
response curves for SLPI and full-length elafin were similar, however elafin's NH2-
and COOH-terminal domains appeared to be more powerful inhibitors than SLPI
over these concentrations.
As was also the case at higher concentrations shown in Figure 16, polymyxin
B was the most powerful inhibitor overall. Greatest inhibition of LPS-LBP binding
by polymyxin B was 62% at 156nM.
Separate experiments were designed to investigate the relative affinities of
elafin and LBP for binding to LPS. Using an ELISA technique measuring elafin
bound to immobilised LPS, LBP was shown to have a stronger affinity for LPS than
that of elafin for LPS (Figure 18). Elafin pre-bound to LPS was displaced on addition
of LBP, while simultaneous addition of elafin and LBP to LPS resulted in a 90%
reduction in elafin-LPS binding (as compared with binding in the absence of LBP).
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Figure 17. Elafin peptides in the concentration range 9.75-156nM inhibit the
binding of LPS to LBP
Biotinylated E. coli 055:B5 LPS or biotinylated LPS pre-incubated with peptide for
30mins at 37°C was added to wells containing 25ng/ml recombinant LBP,
immobilised using anti-LBP monoclonal antibody. Binding of LPS to LBP was
detected using HRP-conjugated streptavidin and absorbance read at 490nm. ELISA
technique is depicted diagrammatically beneath graph. For a more detailed
description of this technique see Chapter 2, section 2.2.1.7. Values represent mean ±
S.E. of n=3 experiments, each performed in duplicate.
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Figure 18. Elafin binding to LPS is out-competed by LBP
Elafin (156nM) was added to wells containing E. coli 055:B5 LPS immobilised
using polymyxin B. Alternatively, 25ng/ml LBP was added to wells containing elafin
pre-incubated with LPS, or elafin and LBP were added to wells simultaneously.
Binding of elafin to LPS was detected using anti-elafin polyclonal antibody followed
by an HRP-conjugated secondary antibody; absorbance was read at 490nm. Major
ELISA components are depicted diagrammatically beneath graph. For a more
detailed description of this technique see Chapter 2, section 2.2.1.8. Values represent
mean ± S.E. of n=4 experiments, each performed in duplicate. *** = significant
difference, PO.OOl, compared with 'elafin alone'. ### = significant difference,
PO.OOl, compared with 'elafin then LBP'.
102
Chapter 3: Interactions of elafin with bacterial lipopolvsaccharide
3.3. DISCUSSION
The principal novel observation arising from the work in this chapter is that
elafin is capable of direct interaction with Gram-negative bacterial LPS.
Furthermore, this binding appears to take place within the conserved lipid A domain
of the LPS molecule. As a direct consequence of its interaction with LPS, elafin is
capable of inhibiting subsequent binding of LPS to the lipid transfer protein LBP, a
central step in LPS-mediated cellular activation (Tobias and Ulevitch, 1986;
Schumann et al., 1990).
It seems important to point out at this point that this study did not set out to
investigate the kinetics of elafin's interactions with LPS. The foremost objective of
the work in this chapter was to determine whether or not elafin could directly bind to
LPS, and secondarily to identify to which region of the LPS molecule elafin may
bind. By answering these initial questions, it was hoped that we could go on to reveal
potential roles for elafin in modulating LPS-mediated inflammation. The author is
aware that the use of techniques such as saturation radioligand binding assays would
perhaps allow us to characterise the interactions of elafin with LPS more specifically,
but for the purposes of our investigation such studies were considered to be
unnecessary.
Before going on to consider the findings of this chapter in more depth, the
following section provides a brief discussion concerning the use of peptide controls
for these studies.
3.3.1. Technical considerations - control proteins
As mentioned within the results section of this chapter, difficulties were
encountered in finding a suitable negative control for these studies. Polymyxin B and
SLPI were used as positive controls throughout the course of this investigation, since
these molecules had previously been shown to possess LPS-binding properties.
However, identifying a 'passive' protein which did not bind to LPS proved difficult.
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The 14kDa cationic protein cytochrome c (an essential component of the
mitochondrial respiratory chain; for a brief review see Green et al., 1998) was chosen
due to its cationicity and similar molecular weight to elafin. However, cytochrome c
bound to LPS directly and could also inhibit the interaction of LPS with LBP (data
not shown). Similarly, the cationic antimicrobial peptide protamine (Johansen et al.,
1997) was found to bind to LPS (not shown). Interestingly, since the completion of
the studies described herein, a study has been documented describing the LPS-
binding activity of protamine and its pro-inflammatory effects in LPS-activated
whole blood (Bosshart et al., 2002).
Finally, bovine serum albumin (BSA) was shown to be capable of binding to
LPS, and could effectively inhibit the LPS-LBP interaction (data not shown). Recent
work has demonstrated that human serum albumin can bind to rough-form LPS and
lipid A (Jurgens et al., 2002). Moreover, another study published since cessation of
this investigation has implicated a role for albumin in interactions of endotoxin with
LBP and soluble CD14 (Gioannini et al., 2002), suggesting that albumin may not be
an innocent bystander in LPS-mediated cellular activation.
Thus, it appears that a plethora ofmolecules can bind to LPS and modulate its
effects to some degree. It is interesting to note that the majority of published works
investigating the effects of cationic antimicrobial peptides on LPS activity do not
include a negative control, and it may therefore be the case that others have
encountered similar difficulties. For the purpose of these studies, we have considered
the terminal domains of elafin as 'internal' controls for the binding of the full-length
molecule to LPS, and in this regard several observations have provided evidence for
specificity in LPS-binding activity. The findings of this investigation are discussed in
the following section.
3.3.2. Interactions of elafin with LPS
Prior to commencing investigation of the LPS-binding properties of elafin, it
was deemed necessary to gain an understanding of the characteristics of LPS within
the PAGE conditions used for subsequent studies. Figures 1 and 2A demonstrate the
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inherent complexity and variation of LPS structure amongst serotypes, particularly
with regard to composition of the diverse O-specific polysaccharide side-chain and
consequent molecular weight. The classical 'ladder' pattern observed in these figures
can be attributed to assembly of a range of O-polysaccharide lengths by a particular
bacterial strain due to incomplete chain synthesis (Erridge et al., 2002). As discussed
in detail in Chapter 1, the general LPS structure consists of three distinct regions: (i)
the highly hydrophobic lipid A domain responsible for the endotoxic properties of
the molecule, (ii) the core oligosaccharide consisting of inner and outer core
portions, and (iii) the serotype-specific O-polysaccharide side-chain (Rietschel et al.,
1992). Appendix I at the end of this chapter provides a schematic diagram of this
general LPS structure, as shown previously in Chapter 1. The heterogeneity of LPS
within the Enterobacteriaceae family is demonstrated by PAGE in Figure 1. E. coli
K12, R2 and R3 are rough-form LPS serotypes and as such contain only lipid A-core
oligosaccharide (represented by the lowest band in each lane), whereas the smooth-
form E. coli serotype 055 :B5 also consists of a number of O-polysaccharide repeats;
each subsequently larger band in the 055:B5 lanes corresponds to lipid A-core
oligosaccharide bound to an extra O-antigen unit (Goldman and Leive, 1987).
Well-characterised LPS-binding molecules such as LBP, BPI and polymyxin
B are known to bind to the conserved lipid A portion of LPS (Morrison and Jacobs,
1976; Tobias et al., 1989; Gazzano-Santoro et al., 1992), however the precise
binding sites of these molecules within the lipid A structure are unclear. For
example, a study carried out by Morrison and Jacobs (1976) concluded that
polymyxin B binds to lipid A-Kdo, as they demonstrated interaction with LPS
derived from Salmonella minnesota Re595, a mutant strain unable to synthesise
heptose. However, most recent studies concur that the minimal LPS structure to
which LBP, BPI and polymyxin B bind is the acylated glucosamine disaccharide unit
of lipid A (Gazzano-Santoro et al., 1992; Theofan et al., 1994; Srimal et al., 1996;
Kellogg et al., 1999; Kellogg et al., 2001). Furthermore, it has been demonstrated
that BPI and LBP compete for binding to identical or overlapping determinants
within the LPS molecule; these studies also suggested that the affinity of BPI for
LPS is 20-100-fold greater than that of LBP (Gazzano-Santoro et al., 1994; Wilde et
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al., 1994). The binding site for polymyxin B also appears to overlap with those of
LBP and BPI, since binding of BPI to LPS is inhibited by polymyxin B (Schafer et
al., 1984).
The ability to bind to the conserved lipid A portion of LPS is therefore
considered a requisite of anti-endotoxin agents, and it is this characteristic which
enables LPS-binding molecules to interact with a broad range of heterogeneous
serotypes.
However, in advance of exploring the possibility of elafin interaction with
smaller structural determinants of the LPS holo-molecule, binding to smooth-form
serotypes was investigated. E. coli LPS was chosen for these studies for a number of
reasons. Firstly, as a major gut commensal, E. coli LPS is recognised as a prominent
causative agent of septic shock following translocation from the gastrointestinal tract
(Bochud et al., 2001; Erridge et al, 2002). Secondly, the lipid A of E. coli LPS is
considered to represent the optimal structure for induction of the immune response
i.e. endotoxicity; this structure consists of hexa-acylated (chain length C12-C14)
lipid A containing a bis-phosphorylated P(l-6)-linked D-glucosamine disaccharide
unit (Rietschel et al., 1993; Rietschel et al., 1994). Thirdly, LPS of E. coli has been
extensively studied in terms of both structure and activity, and considerable expertise
in the field of pathogenicity of the Enterobacteriaceae exists locally within
Edinburgh University (Poxton , 1995; Currie et al., 2001).
Full-length elafin bound directly to smooth-form LPS and this interaction was
demonstrated using two different PAGE-based techniques (Figures 3 and 6). These
native PAGE assays were utilised to minimise inclusion of SDS in the systems, since
as an anionically-charged detergent SDS was deemed a potential impediment to
interaction of cationic peptides and anionic LPS molecules. The interaction of elafin
with LPS was detected either by inhibition of LPS migration in pH 8.8 native PAGE
gels (Figure 3), or by inhibition of elafin migration in pH 4.5 native PAGE gels
(Figure 6), and in both systems the interaction was dose-dependent. Interaction of
SLPI with LPS was also investigated (Figures 3 and 6), and in this regard SLPI was
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used as a positive control since direct binding of SLPI to LPS has previously been
demonstrated by Ding et al. (1999); Ding et al. used a silver-stained PAGE technique
similar to that employed in Figure 3, and this study corroborates their findings.
Although Figure 3 initially suggested that elafin's interaction with LPS is of a
greater affinity than that of SLPI with LPS, Figure 6 strongly suggests that SLPI
interacts with LPS more strongly than elafin; the intense SLPI band observed in the
absence of LPS (lanes 1 and 8) was inhibited at a much lower dose of LPS than was
the case with elafin. Although several factors could account for this disparity of
affinity for LPS, net charge of the proteinase inhibitors may play a role in these
findings. The overall net charge of the full-length elafin molecule is +7, whilst that of
SLPI is +12 (these charges were determined using the amino acid sequences given by
Sallenave and Silva (1993) and Thompson and Ohlsson (1986) respectively).
However, if indeed charge were the sole determinant of affinity for binding to
anionic targets in the LPS structure, SLPI's affinity for LPS would be expected to be
almost twice that of elafin. Figure 6 suggests that this is not the case, since at least
200pg of LPS was required to elicit a similar inhibition of elafin migration to that
obtained with 12.5pg LPS in the case of SLPI; this observation implies that SLPI
affinity for LPS is more than double that of elafin. Thus, although the cationicity of
elafin and SLPI may be an important determinant of binding to LPS, other properties
of the molecules may be required for interaction.
Interestingly, both NH2- and COOH-terminal domains of elafin were
demonstrated to bind to smooth-form LPS (Figures 4 and 7). The ISTL-terminal
domain was found to bind to LPS more strongly than the COOH-terminal domain.
Previous work has shown that the anti-proteinase activity of elafin resides
exclusively within the COOH-terminal domain, whilst both domains harbour
inherent anti-microbial activity (Simpson et al., 1999). The study by Simpson et al.
(1999) demonstrated that the majority of elafin's antimicrobial activity against
Gram-negative P. aeruginosa is located within the NH2-terminal domain; this portion
of elafm has a net charge of +5, while that of the COOH-terminus is +2. Although
charge was shown not to be the sole determinant of antimicrobial activity in the
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Simpson et al. study (indeed, COOH-terminal elafin displayed more potent activity
than the NFL-terminus against the Gram-positive pathogen S. aureus), our initial
hypothesis prior to this study was that the NH2-terminal domain would be the major
site of LPS-binding, due to its greater cationicity and antimicrobial activity against
Gram-negative organisms. Whilst it appears that the NH2-terminal domain does
indeed harbour the majority of elafin's LPS-binding activity, the COOH-terminus
also appears to play a role in the activity of the full-length molecule.
These findings were further extended by investigation of binding of elafin to
smaller fragments of the LPS molecule. Full-length elafin interacted directly with
rough-form K12, R2 and R3 E. coli LPS serotypes lacking the O-specific side-chain
(Figure 8). These serotypes represent three of the five core oligosaccharide types in
E. coli (the other two being R1 and R4) and are constructed of lipid A bound to core
oligosaccharide (Amor et al., 2000). These regions are far more conserved than the
hypervariable O-polysaccharide antigens, of which there are more than 170 in E.
coli, and this lack of diversity in lipid A-core oligosaccharide can be attributed to the
constraints imposed by their essential role in outer membrane stability (Heinrichs et
al., 1998). Binding of elafin to these core types strongly suggests that interaction of
elafin with smooth-form LPS results from interaction with components within the
lipid A-core region, structurally conserved between species and serotypes.
Interestingly, elafin appeared to bind to K12 more strongly than either R2 or R3.
This finding can perhaps be explained by analysis of the outer core structure of the
core types (as detailed by Nnalue et al. (1999), Vinogradov et al. (1999) and Amor et
al. (2000)). Appendix II following this chapter provides the structures of the K12, R2
and R3 outer core oligosaccharides, in addition to the chemical structure of E. coli
lipid A (these structures were previously shown in Chapter 1, along with the
structures of R1 and R4). All three of these outer core oligosaccharides consist of
three hexose sugars attached to two side chain residues. In the cases of R2 and K12,
the hexose sugars are all glucose residues, while the second glucose is replaced by
galactose in R3. The side-chain residues of the core types are as follows: galactose
and A-acetyl glucosamine in R2; V-acetyl glucosamine and glucose in R3; and
galactose and heptose in K12. K12 therefore contains a fourth heptose residue (in
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addition to the triplet of heptoses found in the inner core of all 5 E. coli core
oligosaccharide types), and this heptose is partially substituted by a P-linked jV-acetyl
glucosamine. It may potentially be this side-chain which results in higher affinity
binding of elafin to K12 core oligosaccharide, by providing an additional sugar
residue for elafin interaction; this residue may also be substituted with charged
groups, such as phosphate, with which elafin may interact electrostatically (Erridge
et al., 2002).
Although these findings already strongly indicated that elafin binds directly
to a site within the lipid A-core portion, PAGE techniques designed to separate LPS
into its 'ladder' pattern confirmed, using polymyxin B as a positive control, that
elafin indeed binds to and migrates with the lowest molecular weight moiety of both
smooth-form and rough-form serotypes (Figures 10 and 11).
Both the NH2- and COOH-terminal elafin domains bound to K12 LPS, but
interaction with either R2 or R3 could not be demonstrated (Figure 9). On
comparison of Figures 8 and 9, it must be noted that the molar concentration of
terminal domains used was four times that of full-length elafin; thus the ratio of
peptide:LPS was greater in Figure 9, suggesting perhaps the dose of R2 and R3
serotypes may not have been sufficient to inhibit peptide migration. In any case, the
previous observations concerning structural diversity of the core oligosaccharide
types may also account for the greater affinity of elafin's terminal domains for K12.
SLPI also bound rough-form LPS and, as was found to be the case with
smooth-form serotypes, this interaction was of a greater higher affinity than that of
elafin and LPS (Figure 8). These findings suggest that elafin and SLPI bind LPS
within a similar portion of the LPS molecule.
The discovery that elafin, and its constituent terminal domains, could be
precluded from binding to LPS by peptides known to bind LPS within the lipid A
domain provided strong evidence that elafin binds directly to the highly conserved
LPS backbone of acylated glucosamine disaccharide (Figures 12-14); this suggests
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that, although affinity for different core types may vary due to the nature of hexose
residues and side-chains, binding to LPS occurs regardless of core oligosaccharide.
The LBP peptide portion used to inhibit binding of elafin peptides to LPS in
Figures 12 and 13 constitutes amino acids 86-99 of the molecule, and binds directly
to lipid A. This portion of the LBP molecule is highly cationic (net charge +6) due
to the presence of three arginine residues and three lysine residues, and the basic
residues in this region have been demonstrated previously to play an important role
in the interactions of LBP with LPS (Lamping et al., 1996). The NFL-terminal
domain (amino acids 1-197) is known to possess the LPS-binding properties of the
holo-molecule, while the COOH-terminal domain (amino acids 198-456) is
important for transfer of LPS to CD 14 (Han et al., 1994; Thoefan et al., 1994; Taylor
et al., 1995; Abrahamson et al., 1997). The abundance of glutamate and aspartate
residues throughout the molecule reduces its overall charge to +4, and this net
positive charge resides entirely within the NH2-terminal domain since the charge on
the COOH-terminal domain is neutral (determined by analysis of the complete amino
acid sequence ofLBP detailed by Wilde et al. (1994)).
While it is widely accepted that the binding domain for LBP within the LPS
molecule lies within lipid A, the structural features of lipid A which are important for
binding by LBP have not been well studied. However, a study by Gazzano-Santoro et
al. (1995) characterised the lipid A elements which are important for binding of
rBPl23, a recombinant fragment of the homologous protein BPI, corresponding to the
NH2-terminal domain of the molecule (amino acids 199-456). BPI is a potently
Gram-negative bactericidal protein stored in azurophilic granules of
polymorphonuclear leukocytes which, in contrast to LBP, neutralises the biological
activities of LPS (Elsbach, 1998). The study by Gazzano-Santoro et al. (1995) found
that binding of rBPl23 to lipid A was dependent upon two negatively charged
moieties, usually but not necessarily phosphate, attached to the 1 and 4' hydroxyl
groups of the glucosamine disaccharide unit, and also upon the presence of fatty acid
chains attached to the disaccharide (Gazzano-Santoro et al., 1995). Since LBP and
BPI share approximately 45% sequence homology at the amino acid level, and the
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predominant divergences within their sequences are located in the COOH-terminal
domains (Gray et al., 1989; Beamer et al., 1998), it is perhaps reasonable to surmise
that the same structural determinants of lipid A may be important for binding of
LBP.
The inhibition of binding of full-length elafin (Figure 12) and both NH2- and
COOH-terminal elafin domains (Figure 13) to LPS pre-bound to LBP peptide
suggests that these structural determinants within lipid A (described above) may also
play a part in the interaction of elafin with lipid A. Indeed, the observation that the
cyclic cationic decapaptide antibiotic polymyxin B also prevents interaction of elafin
peptides with LPS adds further support to this theory (Figure 14). The binding of
polymyxin B to lipid A has been extensively investigated, and both electrostatic
interactions with phosphoryl groups and hydrophobic interactions involving acyl
chains of lipid A have been shown to be important (Rustici et al., 1993; Srimal et al.,
1996; Thomas et al., 1998; Yin et al., 2003).
It therefore appears that elafin binds LPS within a portion of lipid A
commonly targeted by LPS agonists and antagonists alike. It seemed logical to
extend these findings to an investigation of the effects of elafin on the interaction of
LPS with LBP, since this step is central to the initiation of cellular responses to LPS
(as discussed in Chapter 1). A recent study by Scott et al. (2000b) described the
ability of a number of structurally diverse cationic antimicrobial peptides, including
HBD-2, HNP-1 and polymyxin B, to block the binding of LPS to LBP. A similar
assay was used here to reveal that full-length elafin and both its NH2- and COOH-
terminal domains can also inhibit the interaction of LPS with LBP (Figures 16 and
17). The implications of this phenomenon for the LPS-induced stimulation of
macrophages were further investigated in Chapter 4. Additionally, SLPI was
investigated in these assays and was also shown to have an inhibitory effect on the
LPS-LBP interaction. Polymyxin B, used here as a positive control, was investigated
in the study carried out by Scott et al. (2000b) and has been revealed in both studies
to be a highly potent inhibitor of the interaction.
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Intriguingly, while concentrations of full-length elafin at the low end of the
test range effectively inhibited LPS-LBP interaction, higher concentrations (above
1.25pM) inhibited to a lesser degree and in fact appeared to enhance the binding of
LPS to immobilised LBP in a dose-responsive manner (Figure 16). Investigation of
this anomaly suggested that elafin mediated binding of LPS to several components of
the assay, including blocking agent, plastic in the wells and even LBP itself (data not
shown). It is important to note that no non-specific effects were observed other than
in the presence of elafm. Two possible explanations may account for this effect of
elafin at high concentrations. Firstly, it is feasible that elafin molecules may be more
disposed to forming polymers at higher concentrations and this aggregation could
facilitate generation of larger elafin-LPS aggregates, resulting in increased signal.
Secondly, aggregates of LPS may be more effectively disassembled at higher elafm
concentrations, liberating more individual LPS polymers which subsequently bind to
LBP. Similar findings were obtained by Kellogg et al. (2001) using a monoclonal
antibody (1B6) to lipid A; Kellogg's study found that 1B6 inhibition of LPS activity
in the Limulus amoebocyte lysate (LAL) assay was decreased at higher antibody
concentrations, and in this case it was the presence of more free LPS monomers
which enhanced activity.
Nevertheless, in the range 0-160nM, full-length elafin effectively inhibited
the LPS-LBP interaction (Figure 17). Inhibition was maximal at 160nM
(approximately 45% inhibition) and generally dose-dependent below this
concentration. In fact the activities of full-length elafin, SLPI, NFL-terminus and
COOH-terminus were all very similar at 156nM, whilst over the entire concentration
range (0-1 OpM, Figures 16 and 17) the COOH-terminus was the more active of
elafin's terminal domains. It is also interesting to note that the activity of the full-
length molecule in inhibiting LPS-LBP binding was never as great as that of the
COOH-terminal domain at any concentration, and only at lower concentrations (0-
19.5nM) and intermediate concentrations (625nM-1250nM) was the full-length
molecule more active than the NH2-terminus. Despite the fact that NH2-terminal
elafin was demonstrated in Figure 7 to possess a stronger affinity for LPS than the
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COOH-terminal domain, it appears that this does not correlate directly with the
ability to inhibit the interaction of LPS with LBP (Figures 16 and 17).
These findings are strongly suggestive that charge plays a minor role in the
inhibition of LPS-LBP interaction by the elafin peptides. Indeed, if charge were the
major determinant of elafin's ability to prevent LBP binding to LPS, the full-length
molecule would elicit the most potent inhibition, and the effects of the NH2-terminal
domain would be expected to be intermediate between that of the COOH-terminus
and full-length elafin. In fact, polymyxin B was demonstrated to be the most
effective test peptide and yet the net charge of this molecule is +5 (Schroder et al.,
1992), equivalent to that of elafin's NH2-terminus and lower than that of lull-length
elafin. This observation, coupled with the finding that the most potent inhibition by
elafin peptides was consistently educed by the moiety with the lowest cationic
charge, indicates that other properties of these peptides, such as hydrophobicity, play
a part in this activity.
Certainly, a number of studies have described the importance of both
hydrophobicity and cationicity as determinants of affinity of endotoxin-binding
molecules (Weiss et al., 1983; Kellogg et al., 1999; Yin et al., 2003). In this regard,
it may tentatively be suggested that hydrophobic residues within the COOH-terminal
domain could contribute to these findings, whilst these effects may be partially
masked in the full-length molecule. Although both NH2- and COOH-terminal
domains contain a number of hydrophobic residues (for example, 11 of the NH2-
domain's 50 residues are valine), the COOH-terminus contains three profoundly
hydrophobic regions. These are: Ile-Ile-Leu-Ile (amino acids 56-59), Cys-Ala-Met-
Leu (amino acids 61-64) and Met-Ala-Cys-Phe-Val (amino acids 89-93). The
hydrophobicity of these regions of the molecule was confirmed using the online
Swiss Institute of Bioinformatics ProtScale hydrophobicity scale programme (Kyte
and Doolittle, 1982) (data not shown). The crystal and solution structure of the
recombinant elafin molecule has revealed that the polypeptide chain folding takes a
flat spiral shape composed of a flexible external region (NH2-terminal), and a central
twisted (3-hairpin accompanied by two external segments linked by the proteinase
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binding loop (COOH-terminal) (Tsunemi et al., 1996; Francart et al., 1997). Three of
the four disulphide bridges connect the external segments to the central [3-sheet,
while the fourth disulphide bridge links the binding loop to the central (3-turn
(Tsunemi et al., 1996). Analysis of the elafin structure, as described by these studies,
reveals that the first two of the aforementioned hydrophobic regions of the COOH-
terminus are exposed on the external surface of the molecule, while the third is
buried within the internal core. Thus these exposed hydrophobic regions (one of
which contains the Ala-Met scissile bond) may potentially play a key role in the
LPS-binding activity of both full-length elafin and its COOH-terminal domain.
Expansion of the ELISA technique used to obtain the results presented in
Figures 15-17 allowed a more detailed analysis of the relative affinities of elafin and
LBP for LPS (Figure 18). This modified ELISA measured direct binding of elafin to
LPS immobilised to polystyrene microtitre plates in complex with polymyxin B. LPS
alone bound poorly to assay wells, thus the technique of pre-complexing LPS to
polymyxin B in order to enhance adhesion was adapted from a study carried out by
Scott and Barclay (1987). Although polymyxin B was expected to occupy binding
sites on LPS required for elafin binding (Figure 14), significant binding of elafin to
LPS could still be detected under the employed conditions. The concentration of
polymyxin B was deemed sufficient to stabilise LPS molecules but insufficient to
occupy the entire binding domain. No non-specific effects such as binding of
antibodies to BSA blocking protein, as documented by Chart et al. (1998), were
shown to contribute to signal.
Pre-incubation of elafin with LPS prior to addition to immobilised LBP
appeared to be a critical step in the inhibition of LPS-LBP binding; this conclusion
could be drawn from the observations that (i) LBP was capable of displacing 60% of
elafin previously bound to immobilised LPS, and (ii) LBP could effectively out-
compete elafin for binding to free sites within LPS when both proteins were exposed
to LPS simultaneously (Figure 18). These findings further suggest that affinity of the
protein-LPS interactions must rely on physicochemical factors exclusive of those
involved in electrostatic interactions, given that elafin is more cationic than LBP.
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It is apparent, therefore, that the affinity of LBP for LPS is stronger than that
of elafin. The implications of this finding for the effects of elafin on the pro¬
inflammatory activity of LPS will be discussed further in the following chapter.
It seems appropriate at this point to consider whether elafin shares any
structural homology with the three LPS-binding molecules LBP, BPI and polymyxin
B discussed within the previous pages. Appendix III (at the end of this chapter)
details an amino acid sequence alignment of the mature peptides of elafin, LBP and
BPI; the signal peptide sequences have been excluded for the purposes of this
alignment. Additionally the structure of polymyxin B is given. Firstly, it is clear that
the sequences of LBP and BPI are highly homologous, sharing 45% identity in 456
residues (Gray et al., 1989). There is very little homology in general between the
sequences of LBP/BPI and that of elafin, although some similar residues do exist
between the sequences and these areas are shaded. In particular a number of valine,
proline, glycine and lysine residues are shared (the vast majority of which are located
in the exposed external region of the elafin molecule (Tsunemi et al., 1996)), for
example a Val-Pro region (amino acids 5-6 of elafin) which is manifest in all three
sequences. Likewise, elafin and polymyxin B share little in terms of sequence. The
most important features of polymyxin B are the five positively charged a-y-
diaminobutyric acid (DAB) residues which are considered to be important for
electrostatic interactions with anionic phosphate charges of lipid A, and the
hydrophobic 6-methylheptanoyl/octanoyl and d-Phe-Leu regions required for
interaction with fatty acid chains (Srimal et al., 1996; Tsubery et al., 2002).
Thus the interactions of elafin and LPS appear to take place as a result of both
hydrophobic and electrostatic interactions, and in this regard it is the amphipathic
nature of the elafin molecule that appears to be the key determinant of its endotoxin-
binding activity.
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3.4. SUMMARY
The results presented in this chapter indicate that elafin possesses LPS-
binding activity, and that the binding site for elafin is located within the highly
conserved lipid A portion of the LPS molecule. Moreover, binding of elafin to the
lipid A domain can prevent subsequent interaction of LPS with the acute-phase
glycoprotein LBP, an important process in the genesis of the inflammatory response
to endotoxin. The affinity of LBP for LPS was shown, however, to be greater than
that of elafin.
These findings suggest that elafin may potentially play a role in innate
immunity as a modulator of host responses to LPS. The effects of elafin on LPS-
mediated inflammation were further investigated in Chapter 4.
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APPENDIX I
General structure of LPS from Gram-negative enterobacteria
In the depicted general scheme of smooth-form LPS architecture, the terminal O-
specific chain (O-polysaccharide) may be formed by up to 50 repeating units. In the
core region, an inner and outer core can be distinguished on account of the different
sugars present in these domains. The lipid A domain represents the primary
immunostimulatory centre of LPS, determining endotoxicity in mammalian species.
Long-chain fatty acids (acyl chains) are shown attached to the disaccharide of lipid
A. Each individual hexagon represents a monosaccharide subunit. Abbreviations:
Hep, D-glycero-D-wcwrco-heptose; Kdo, 2-keto-3-deoxyoctulosonic acid; GlcN,
glucosamine; P, phosphate; NH3+, ethanolamine. Adapted from Haeffner-Cavaillon
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APPENDIX II
Structures of the K12, R2 and R3 outer core oligosaccharides from the LPS of
E. coli (A), and the chemical structure of E. coli lipid A (B)
A. While there are over 160 identified E. coli O-serotypes, only 5 unique core
structures have been determined. Although all 5 share a structural theme, with a tri-
hexose carbohydrate backbone and two side chain residues, the order of hexoses in
the backbone and the nature, position and linkage of the side chain residues can all
vary. This diagram provides the structure of K12, R2 and R3. HepII is the last
residue of the inner core oligosaccharide. * indicates the point of attachment of O-
antigen, but this has only been determined experimentally for R2 (diagram adapted
from Amor et al., 2000). B. The structural format of E. coli lipid A is widely
considered to be close to that optimally recognised by human cellular LPS receptors
(bisphosphorylated diglucosamine backbone substituted with 6 acyl chains) (diagram
adapted from Erridge et al., 2002). Abbreviations: Glc, glucose; Hep, D-glycero-D-
manno-heptose; Gal, galactose, GlcNAc, JV-acetyl glucosamine; Pi, phosphate.
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E. coli K12
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APPENDIX III
Amino acid sequence alignments of elafin, LBP and BPI and structural diagram
of polymyxin B
The amino acid sequences for elafin (Sallenave and Silva, 1993), LBP and BPI
(Wilde et al., 1994) were aligned using the online Baylor College of Medicine
ClustalW 1.8 Multiple Sequence Alignment programme. Highly homologous regions
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CHAPTER 4
THE EFFECTS OF ELAFIN PEPTIDES ON THE
INFLAMMATORY RESPONSE OF MACROPHAGES
AND CLARA CELLS TO LPS IN VITRO
4.1. AIMS
The primary aim of this chapter was to determine how the interactions of
elafin with LPS, described in Chapter 3, would affect the pro-inflammatory
properties of LPS in vitro. In the event of an effect on LPS activity being
demonstrated, secondary aims were to determine which terminal domain of the elafin
molecule, if either, is more active in its effects on LPS function, and to investigate
whether elafin peptides themselves initiate an inflammatory response from cells in
vitro.
Two cell types were chosen for use in this study: the murine macrophage cell
line RAW 264.7, which has been extensively used by others in models of LPS-
induced inflammation (for example studies performed by Gough et al. (1996),
Ndengele et al. (2000) and Kiemer et al. (2002)); and a cell line of murine
bronchiolar epithelial (Clara) cell lineage, designated DJS2-2 (Magdaleno et al.,
1997; Park et al., 2000; Ramsay et al., 2003). These cell lines represent two
important cellular targets for LPS in the in vivo environment; indeed the response of
the macrophage to LPS in particular can be considered as a critical event in the onset
and progression of inflammation. Both serum-containing and serum-free conditions
were investigated in order to model potential effects of elafin in varying in vivo
compartments, for example serum-rich circulation or serum-deficient sites in the
airways.
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4.2. RESULTS
4.2.1. Experiments to characterise LPS response and serum requirements of RAW
264.7 murine macrophages
Several preliminary experiments were undertaken to establish a set of
conditions for subsequent investigation of the effects of elafin on LPS-mediated
cytokine release. These studies were carried out using the RAW 264.7 macrophage
cell line, the more LPS-responsive of the two cell types. It was deemed desirable to
minimise the concentration of LPS used in assays in order to avoid overwhelming the
test 'system'. Additionally we wished to identify a concentration of LPS that would
activate cells sufficiently in both serum-rich and serum-free conditions.
LPS-induced TNF-a secretion by RAW 264.7 macrophages was greatly
enhanced in the presence of 10% foetal calf serum (Figure 1). For example, 0.5ng/ml
LPS induced a mean TNF-a response of approximately 6500 pg/ml in 10% serum,
compared with only 76 pg/ml in serum-free conditions; and while as little as 5 ng/ml
LPS elicited secretion of 88000 pg/ml TNF-a in serum-rich conditions, the lowest
LPS concentration capable of inducing significant release of cytokine in serum-free
medium was 50 ng/ml (4700 pg/ml TNF-a secreted) (Figure 1). Baseline TNF-a
levels were similar, although TNF-a present in serum may also have contributed
slightly (17-27 pg/ml TNF-a was measured in serum-free medium compared with
59-75 pg/ml in serum-rich medium). On average, approximately lOOx more LPS was
required in serum-free medium to elicit a comparable response to that observed in
serum-rich medium. However, most significant for these investigations was the
observation that 50ng/ml LPS induced a substantial TNF-a response in both serum-
free and serum-rich conditions (Figure 1). This concentration of LPS was thus used
for all subsequent studies.
Considering the finding in Chapter 3 that LBP (the serum glycoprotein that
plays an important role in LPS signalling by catalysing transfer of LPS monomers to
CD14 (Hailman el al., 1994)) has a higher LPS-binding affinity than elafin, efforts
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were made to diminish the presence of this acute phase reactant in test assays. An
experiment aimed at investigating the effects of LBP on LPS activity suggested that
the majority of the LPS-induced activation of RAW 264.7 macrophages in serum-
rich media was mediated by LBP (Figure 2). LBP is present at approximately 5-
15pg/ml in human serum (Calvano et al., 1994; Gallay et al., 1994; Froon et al.,
1995). Using the figure of 5pg/ml as a reference, 25ng/ml natural human LBP added
to serum-free medium reproduced the effects of the equivalent 0.5% serum on LPS
stimulation of cells (Figure 2).
Since LBP was considered a potential hindrance to interaction of elafin with
LPS, but was central to an enhanced cellular response to LPS, the effects of lower
serum concentrations were investigated. A considerable serum effect was observed
as low as 0.2% serum, and the pro-inflammatory effects of serum appeared to
saturate at around 6% (Figure 3). Hence, we chose to minimise the presence of LBP
in culture conditions by including 0.2% serum, approximately equivalent to 10 ng/ml
(160pM) LBP.
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No LPS 0.5ng/ml 5ng/ml 50ng/ml 500ng/ml 5ug/ml
LPS concentration
Figure 1. LPS stimulation of RAW 264.7 murine macrophages in serum-free
and serum-rich conditions
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight, washed twice with PBS and 500pl fresh medium added prior to addition
of LPS. Stimulation with increasing concentrations of E. coli 055:B5 LPS was
carried out for 4 hours at 37°C in either serum-free DMEM or DMEM containing
10% foetal calf serum (FCS). Media were removed and analysed by TNF-a ELISA.
Data represent mean ± S.E. of n=3 experiments, each performed in triplicate.
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LPS alone LPS + LBP LPS + 0.5%
serum
Figure 2. Natural human LBP reproduces the effects of serum on LPS-mediated
stimulation ofRAW 264.7 murine macrophages
RAW 264.7 murine macrophages were seeded overnight at 5 x 105 cells/well of a 48-
well plate and washed twice with PBS. 500pl fresh DMEM was added, containing:
no FCS (Bars 1, 2 and 3); 0.5% FCS (Bar 4); or 25ng/ml natural human LBP
(approximately equivalent to the concentration present in 0.5% serum) (Bars 1 and
3). 50ng/ml E. coli 055:B5 LPS was incubated with cells for 4 hours at 37°C. Media
were removed and analysed by TNF-a ELISA. Data are derived from a single
experiment, carried out in triplicate. Values represent mean ± SD.
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Figure 3. TNF-a response of RAW 264.7 murine macrophages to 50ng/ml LPS
is enhanced by FCS concentrations as low as 0.2%.
RAW 264.7 murine macrophages were seeded overnight at 5 x 105 cells/ well of a
48-well plate, washed twice with PBS and 500pl of fresh DMEM containing varying
concentrations of FCS added prior to LPS stimulation. 50ng/ml E. coli 055:B5 LPS
was incubated with cells for 4 hours at 37°C, and media analysed by TNF ELISA.
Data represent the mean ± S.E. of n=3 experiments, each performed in triplicate.
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4.2.2. The effects of elafin peptides on LPS-mediated TNF-a secretion by RAW
264.7 murine macrophages
4.2.2.1. LPS stimulation ofmacrophages in medium containing serum
Prior to investigating the effects of elafin on the TNF-a response of
macrophages to LPS, it was important to determine whether elafin itself induced the
cellular release of TNF-a. This investigation was also of consequence since it is
known that similar defensin and antimicrobial peptide molecules can be cytotoxic to
mammalian cells, albeit at high concentrations in the pM range (compared to the nM
concentrations of elafin used here) (Lehrer et al., 1993; Risso et al., 1998). No
significant TNF-a secretion was induced by elafin peptides (full-length molecule,
NFL-terminal domain or COOH-terminal domain) (Figure 4). Additionally,
incubation of elafin peptides with murine macrophages was not associated with
morphological damage to the cellular monolayer, as evidenced by light microscopy,
and trypan blue exclusion indicated that elafin peptides induced no apparent damage
to cells (data not shown).
Stimulation of RAW 264.7 macrophages with LPS in medium containing
0.2% serum induced a typical TNF-a release of between 20000-30000pg/ml (20-
30ng/ml) over the 4-hour incubation time, compared with a TNF-a secretion of
approximately 70-150pg/ml by unstimulated cells. Addition of full-length elafin to
cell culture medium at the same time as LPS had no significant effects on the LPS-
induced release of TNF-a (Figure 5A). However, incubating LPS with full-length
elafin for 30 minutes at 37°C prior to addition to cells reduced the secretion of TNF-
a, and inhibition of LPS-induced TNF-a release was significant at lOnM and lOOnM
full-length elafin (Figure 5B). The maximum inhibition observed was around 40% at
1 OOnM elafin.
Similar assays were undertaken in order to investigate the contribution of
NH2- and COOH-terminal elafin domains to the anti-inflammatory activity of the
full-length molecule. The NH2-terminal domain had no significant effect on LPS-
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mediated TNF-a release from macrophages, even when incubated with LPS prior to
addition to cells (Figure 6). A trend towards decreased TNF-a response to LPS that
had been pre-incubated with NFL-terminus was observed, but the down-regulation of
cellular response was not significant (Figure 6B). However, the COOH-terminal
domain significantly inhibited TNF-a secretion but, as was the case with the full-
length molecule, this inhibition was observed only when LPS had been incubated
with COOH-terminus prior to addition to test wells and not on simultaneous addition
of LPS and peptide (Figure 7). Inhibition of TNF-a was maximal at lOOnM COOH-
terminus and the degree of inhibition, approximately 34% at this concentration of
peptide, was very similar to that effected by the full-length molecule (40% as per
Figure 5B). These observations suggest that the majority of elafin's LPS-inhibitory
activity in serum-containing milieu is contributed by its COOH-terminal domain.
During the course of these investigations, difficulties were again encountered
in finding a suitable negative control peptide for the LPS-induced activation of cells,
as discussed in Chapter 3. In early investigations using macrophages as a model for
LPS-mediated inflammation, polymyxin B was used as a positive control for
inhibition of TNF-a secretion and this peptide elicited reproducible, significant
down-regulation of TNF-a (not shown). However, identifying a 'passive' peptide
which had no effects on LPS activation proved difficult. Cytochrome c, which we
had previously shown could bind to LPS and inhibit LPS-LBP interaction, also
effectively down-regulated LPS-mediated TNF-a secretion by macrophages (data
not shown). Similarly, protamine was found to inhibit TNF-a secretion (not shown).
BSA, which could bind LPS and inhibit interaction of LPS with LBP during the
investigations described in Chapter 3, was shown to have a slight anti-inflammatory
effect on LPS-mediated stimulation over the test concentrations used here. The
terminal domains of elafin have thus been used in these studies as 'internal' controls.
It could also be suggested that control peptides are perhaps not as important in assays
in which elafin is added simultaneously with LPS in serum, since in this case a range
of protein molecules are present in the test system.
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Concentration of peptide
Figure 4. Elafin peptides have no significant effect on secretion of TNF-a by
RAW 264.7 murine macrophages (medium containing serum)
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight, washed twice with PBS and 500pl DMEM containing 0.2% FCS added.
Full-length elafin (FL EL), NH2-terminal elafin domain (N-) or COOH-terminal
elafin (C-) were incubated with cells for 4 hours, and media were analysed by TNF-a
ELISA. Values represent mean ± S.E. of n=4 experiments, each performed in
triplicate.
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Figure 5. Full-length elafin down-regulates LPS-mediated TNF-a secretion by
RAW 264.7 murine macrophages, in medium containing serum
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight, washed twice with PBS and 500pl DMEM containing 0.2% FCS added.
50ng/ml E. coli 055:B5 LPS was incubated with cells for 4 hours either alone or in
the presence of increasing concentrations of elafin; media were analysed by TNF-a
ELISA. GRAPF1 A: Elafin and LPS added to cells simultaneously. GRAPFI B: Elafin
pre-incubated with LPS for 30 mins at 37°C prior to addition to cells. Values
represent mean ± S.E. of n=5 (A) or n=6 (B) experiments, each performed in
triplicate. ** = significant difference, P<0.01, compared with 'LPS alone'. *** =
significant difference, PO.OOl, compared with 'LPS alone'.
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Figure 6. N-terminal elafin domain has no significant effect on LPS-mediated
TNF-a secretion by RAW 264.7 murine macrophages, in medium containing
serum
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight, washed twice with PBS and 500pl DMEM containing 0.2% FCS added.
50ng/ml E. coli 055:B5 LPS was incubated with cells for 4 hours either alone or in
the presence of increasing concentrations of NH2-terminus; media were analysed by
TNF-a ELISA. GRAPH A: NHrterminus and LPS added to cells simultaneously.
GRAPH B: NH2-terminus pre-incubated with LPS for 30 mins at 37°C prior to
addition to cells. Values represent mean ± S.E. of n=3 (A) or n=4 (B) experiments,
each performed in triplicate.
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Figure 7. C-terminal elafin domain down-regulates LPS-mediated TNF-a
secretion by RAW 264.7 murine macrophages, in medium containing serum
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight, washed twice with PBS and 500pl DMEM containing 0.2% FCS added.
50ng/ml E. coli 055:B5 LPS was incubated with cells for 4 hours either alone or in
the presence of increasing concentrations of COOH-terminus; media were analysed
by TNF-a ELISA. GRAPH A - COOH-terminus and LPS added to cells
simultaneously. GRAPH B - COOH-terminus pre-incubated with LPS for 30 mins at
37°C prior to addition to cells. Values represent mean ± S.E. of n=3 experiments,
each performed in triplicate. * = significant difference, P<0.05, compared with 'LPS
alone'. ** = significant difference, P<0.01, compared with 'LPS alone'.
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4.2.2.2. LPS stimulation ofmacrophages in serum-free medium
Prior to commencing investigation of the effects of elafin on LPS stimulation
of macrophages in serum-free milieu, it was again deemed necessary to study the
effects of elafin peptides alone; this is especially relevant in the case of serum-free
conditions since serum has been shown to protect cells from the cytotoxic effects of
defensins (Lehrer et al., 1993). Elafin peptides themselves elicited no significant
release of TNF-a by murine macrophages, as compared with cells incubated in the
absence of peptides (Figure 8). As was previously demonstrated in medium
containing serum, elafin peptides also caused no discernible damage to the cell
monolayer when incubated with cells in serum-free medium, as assessed by light
microscopy and trypan blue exclusion (not shown).
Although the magnitude of macrophage response to LPS in serum-free
medium was much lower than that elicited in medium containing serum, secretion of
TNF-a was still considerable. Typical values obtained on analysis of media from
LPS-stimulated cells were between 3500-5500 pg/ml TNF-a, as compared with
TNF-a levels of around 8-60 pg/ml when cells were incubated for 4 hours in the
absence of LPS.
Interestingly, the effects of elafin on LPS-mediated stimulation of
macrophages in serum-free conditions were in stark contrast to those previously
observed in serum-containing conditions. Although full-length elafin had no effect
on LPS-induced TNF release when LPS and elafin were added simultaneously, pre-
incubating elafin with LPS significantly enhanced the pro-inflammatory activity of
LPS (Figure 9). The effects of elafin were again maximal in the range lOnM-lOOnM,
and these concentrations enhanced the TNF-a response of macrophages by up to
300%.
Both the NH2- and the COOH-terminal domains of the full-length molecule
were shown to contribute to this pro-inflammatory activity (Figures 10 and 11).
Unlike full-length elafin, neither terminus induced any significant effects at lOnM,
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but both domains significantly enhanced LPS-induced TNF-a secretion at lOOnM.
As was observed in the previous section using serum-containing milieu, the COOH-
terminus exerted a greater activity than the NH2-terminus. Indeed, while both the
full-length molecule and the NH2-terminal domain enhanced TNF-a secretion by up
to approximately 300% (Figures 9 and 10), the COOH-terminal domain up-regulated
TNF-a secretion by 600% at lOOnM; this suggests that elafin's terminal domains do
not function synergistically, and that the observed pro-inflammatory activity of the
full-length molecule may be regulated by an interaction between its constituent
domains.
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Figure 8. Elafin peptides have no significant effect on secretion of TNF-a by
RAW 264.7 murine macrophages (serum-free medium)
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight, washed twice with PBS and 500pl serum-free DMEM added. Full-length
elafrn (FL EL), NFE-terminal elafin domain (N-) or COOPI-terminal elafin (C-) were
incubated with cells for 4 hours, and media were analysed by TNF-a ELISA. Values
represent mean ± S.E. of n=4 experiments, each performed in triplicate.
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Figure 9. Full-length elafin enhances LPS-mediated TNF-a secretion by RAW
264.7 murine macrophages, in serum-free medium
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight, washed twice with PBS and 500pl serum-free DMEM added. 50ng/ml E.
coli 055:B5 LPS was incubated with cells for 4 hours either alone or in the presence
of increasing concentrations of elafin; media were analysed by TNF-a ELISA.
GRAPH A: Elafin and LPS added to cells simultaneously. GRAPH B: Elafin pre-
incubated with LPS for 30 mins at 37°C prior to addition to cells. Values represent
mean ± S.E. of n=5 (A) or n =4 (B) experiments, each performed in triplicate. *** =
significant difference, P<0.001, compared with 'LPS alone'.
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Figure 10. N-terminal elafin domain enhances LPS-mediated TNF-a secretion
by RAW 264.7 murine macrophages, in serum-free medium
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight, washed twice with PBS and 500pl serum-free DMEM added. 50ng/ml E.
coli 055:B5 LPS was incubated with cells for 4 hours either alone or in the presence
of increasing concentrations of NLL-terminus; media were analysed by TNF-a
ELISA. GRAPH A: NH2-terminus and LPS added to cells simultaneously. GRAPH
B: NH2-terminus pre-incubated with LPS for 30 mins at 37°C prior to addition to
cells. Values represent mean ± S.E. of n=4 experiments, each performed in triplicate,
significant difference, P0.001, compared with 'LPS alone'.***
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Figure 11. C-terminal elafin domain enhances LPS-mediated TNF-a secretion
by RAW 264.7 murine macrophages, in serum-free medium
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight, washed twice with PBS and 500pl serum-free DMEM added. 50ng/ml E.
coli 055:B5 LPS was incubated with cells for 4 hours either alone or in the presence
of increasing concentrations of COOH-terminus; media were analysed by TNF-a
ELISA. GRAPE! A - COOH-terminus and LPS added to cells simultaneously.
GRAPH B - COOH-terminus pre-incubated with LPS for 30 mins at 37°C prior to
addition to cells. Values represent mean ± S.E. of n=4 (A) or n=3 (B) experiments,
each performed in triplicate. *** = significant difference, P0.001, compared with
'LPS alone'.
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4.2.3. The effects of elafin peptides on LPS-mediated MIP-2 secretion by murine
bronchiolar epithelial cells (Clara cells)
4.2.3.1. LPS stimulation of Clara cells in medium containing serum
Although Clara cells are unlikely to be bathed in serum-containing milieu in
airways of healthy individuals in vivo, respiratory inflammation or injury can lead to
increased epithelial permeability and 'leakage' of serum into the lung (Arsalane et
al., 2000; Broeckaert et al., 2000). With this in mind, the effects of elafin on the LPS
stimulation of Clara cells were investigated in both serum-free and serum-containing
conditions. Moreover, the C-X-C chemokine MIP-2 (a homologue of human IL-8)
was chosen as a marker of LPS-induccd Clara cell activation since, in contrast to
macrophages, epithelial cells produce very little TNF-a (Mannel and Echtenacher,
2000).
Baseline levels ofMIP-2 produced by Clara cells were low (approximately 8-
12 pg/ml) and elafin peptides (full-length, NLL-terminus and COOH-terminus) had
no significant effect on MIP-2 secretion (Figure 12). Moreover, incubation of elafin
peptides was not associated with any morphological perturbation of the Clara cell
monolayer or cellular injury, as evidenced by light microscopy and trypan blue
exclusion (not shown).
Stimulation of Clara cells with LPS typically resulted in a secretion of
between 175-275 pg/ml MIP-2. Addition of full-length elafin to cells at the same
time as LPS had no effect on the MIP-2 secretion by Clara cells, however pre-
incubating elafin with LPS before adding to culture media caused a significant
enhancement in the cellular response (Figure 13). The effects of elafin were maximal
at lOnM-lOOnM, and at these concentrations MIP-2 secretion was around 200% of
that observed in response to LPS alone.
NFL-terminal and COOH-terminal elafin domains also had no effect on
cellular response to LPS when LPS and peptides were added concurrently (Figures
14A and 15A respectively). However, following pre-incubation with LPS both
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domains enhanced MIP-2 secretion to a significant degree at lOOnM peptide (Figures
14B and 15B). The COOH-terminal domain was shown to be the more active domain
since it up-regulated LPS-induced MIP-2 release by 240%, compared with a 140%
increase in the case of the NH2-terminal domain.
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Concentration of peptide
Figure 12. Elafin peptides have no significant effect on secretion of MIP-2 by
murine Clara cells (medium containing serum)
Clara cells were seeded at 3 x 105 cells/well of a 48-well plate overnight, washed
twice with PBS and 500pl DMEM containing 0.2% FCS added. Full-length elafin
(FL EL), NH2-terminal elafin domain (N-) or COOH-terminal elafin (C-) were
incubated with cells for 4 hours, and media were analysed by MIP-2 ELISA. Values
represent mean ± S.E. of n=3 experiments, each performed in triplicate.
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Figure 13. Full-length elafin enhances LPS-mediated MIP-2 secretion by murine
Clara cells, in medium containing serum
Clara cells were seeded at 3 x 105 cells/well of a 48-well plate overnight, washed
twice with PBS and 500pl DMEM containing 0.2% FCS added. 50ng/ml E. coli
055:B5 LPS was incubated with cells for 4 hours either alone or in the presence of
increasing concentrations of elafin; media were analysed by MIP-2 ELISA. GRAPH
A: Elafin and LPS added to cells simultaneously. GRAPH B: Elafin pre-incubated
with LPS for 30 mins at 37°C prior to addition to cells. Values represent mean ± S.E.
of n=4 (A) or n=3 (B) experiments, each performed in triplicate. ** = significant
difference, P<0.01, compared with 'LPS alone'. *** = significant difference,
P0.001, compared with 'LPS alone'.
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Figure 14. N-terminal elafin domain enhances LPS-mediated MIP-2 secretion
by murine Clara cells, in medium containing serum
Clara cells were seeded at 3 x 105 cells/well of a 48-well plate overnight, washed
twice with PBS and 500pl DMEM containing 0.2% FCS added. 50ng/ml E. coli
055:B5 LPS was incubated with cells for 4 hours either alone or in the presence of
increasing concentrations of NH2-terminus; media were analysed by MIP-2 ELISA.
GRAPH A: NH2-terminus and LPS added to cells simultaneously. GRAPH B: NH2-
terminus pre-incubated with LPS for 30 mins at 37°C prior to addition to cells.
Values represent mean ± S.E. of n=4 experiments, each performed in triplicate. * =
significant difference, P<0.05, compared with 'LPS alone'.
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Figure 15. C-terminal elafin domain enhances LPS-mediated MIP-2 secretion
by murine Clara cells, in medium containing serum
Clara cells were seeded at 3 x 105 cells/well of a 48-well plate overnight, washed
twice with PBS and 500pl DMEM containing 0.2% FCS added. 50ng/ml E. coli
055:B5 LPS was incubated with cells for 4 hours either alone or in the presence of
increasing concentrations of COOH-terminus; media were analysed by MIP-2
ELISA. GRAPH A - COOH-terminus and LPS added to cells simultaneously.
GRAPH B - COOH-terminus pre-incubated with LPS for 30 mins at 37°C prior to
addition to cells. Values represent mean ± S.E. of n=4 experiments, each performed
in triplicate. *** = significant difference, PO.OOl, compared with 'LPS alone'.
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4.2.3.2. LPS stimulation of Clara cells in serum-free medium
As in previous sections in this chapter the effects of elafin peptides on cells
were firstly assessed, independently of LPS-stimulation assays. Full-length elafin and
its terminal domains did not themselves induce significant MIP-2 secretion by Clara
cells (Figure 16) and did not cause damage to the cell monolayer (not shown).
In serum-free medium, a larger concentration of LPS was required to elicit a
response from Clara cells than in serum-containing conditions (lpg/ml LPS as
compared to 50ng/ml LPS in the previous section). Clara cells typically responded to
stimulation with lpg/ml LPS in serum-free medium with secretion of MIP-2 levels
between 80-250 pg/ml.
In these conditions, full-length elafin had no effect on the LPS-mediated
release of MIP-2, when added either simultaneously with LPS or following pre¬
incubation with LPS (Figure 17). There was a trend towards an enhancement of
cellular chemokine secretion in response to LPS that had been pre-incubated with
elafin, but this trend was found to be non-significant (Figure 17B).
Similar findings were obtained on investigation of the effects of the NH2-
terminal domain on LPS-mediated MIP-2 release (Figure 18); cells appeared to be
more responsive to LPS that had been pre-incubated with NFL-terminus, but this did
not reach statistical significance (Figure 18B).
The COOH-terminal domain, on the other hand, up-regulated LPS-mediated
MIP-2 release at all concentrations tested and this effect was observed even when
peptides were added to cell culture medium at the same time as LPS (Figure 19). The
maximal enhancement of LPS stimulation was 215%, on incubation of LPS with
InM COOH-terminus prior to addition to cells (Figure 19B). These results are again
suggestive of a prominent role for the COOH-terminal domain in the LPS-binding
activities of the elafin molecule, although this effect may be masked or modulated to
some extent in the full-length peptide.
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Figure 16. Elafin peptides have no significant effect on secretion of MIP-2 by
murine Clara cells (serum-free medium)
Clara cells were seeded at 3 x 105 cells/well of a 48-well plate overnight, washed
twice with PBS and 500pl serum-free DMEM added. Full-length elafin (FL EL),
NFL-terminal elafin domain (N-) or COOFl-terminal elafin (C-) were incubated with
cells for 4 hours, and media were analysed by MIP-2 ELISA. Values represent mean
± S.E. of n=5 experiments, each performed in triplicate.
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Figure 17. Full-length elafin has no significant effect on LPS-mediated MIP-2
secretion by murine Clara cells, in serum-free medium
Clara cells were seeded at 3 x 105 cells/well of a 48-well plate overnight, washed
twice with PBS and 500pl serum-free DMEM added, lpg/ml E. coli 055:B5 LPS
was incubated with cells for 4 hours either alone or in the presence of increasing
concentrations of elafin; media were analysed by MIP-2 ELISA. GRAPH A: Elafin
and LPS added to cells simultaneously. GRAPH B: Elafin pre-incubated with LPS for
30 mins at 37°C prior to addition to cells. Values represent mean ± S.E. of n=4 (A) or
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Figure 18. N-terminal elafin domain has no significant effect on LPS-mediated
MIP-2 secretion by murine Clara cells, in serum-free medium
Clara cells were seeded at 3 x 105 cells/well of a 48-well plate overnight, washed
twice with PBS and 500pl serum-free DMEM added, lpg/ml E. coli 055:B5 LPS
was incubated with cells for 4 hours either alone or in the presence of increasing
concentrations ofNH2-terminus; media were analysed by MIP-2 ELISA. GRAPH A:
NH2-terminus and LPS added to cells simultaneously. GRAPH B: NH2-terminus pre-
incubated with LPS for 30 mins at 37°C prior to addition to cells. Values represent
mean ± S.E. of n=5 experiments, each performed in triplicate.

































Figure 19. C-terminal elafin domain enhances LPS-mediated MIP-2 secretion
by murine Clara cells, in serum-free medium
Clara cells were seeded at 3 x 105 cells/well of a 48-well plate overnight, washed
twice with PBS and 500pl serum-free DMEM added, lpg/ml E. coli 055:B5 LPS
was incubated with cells for 4 hours either alone or in the presence of increasing
concentrations of COOH-terminus; media were analysed by MIP-2 ELISA. GRAPE!
A - COOH-terminus and LPS added to cells simultaneously. GRAPH B - COOH-
terminus pre-incubated with LPS for 30 mins at 37°C prior to addition to cells.
Values represent mean ± S.E. of n=4 experiments, each performed in triplicate. * =
significant difference, P<0.05, compared with 'LPS alone'. ** = significant
difference, P<0.01, compared with 'LPS alone'. *** = significant difference,
PO.OOl, compared with 'LPS alone'.
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4.3. DISCUSSION
The principal novel observation arising from the data in this chapter is that
elafin is capable of directly modifying the inflammatory response of macrophages
and epithelial cells to LPS. These findings suggest that the interactions of elafin with
LPS, previously described in Chapter 3, may confer to elafin a physiological role in
modulation of LPS-induced inflammation.
In initially selecting a cell type for use in these investigations, the
macrophage was considered to be the ideal choice and for our studies we elected to
use the RAW 264.7 murine macrophage cell line. This macrophage cell line has been
used in a considerable number of studies as a model for macrophage activity; these
studies include investigation of LPS-induced TNF-a secretion (Zhang et ah, 1999;
Scott et al., 2000b; Jarvis et al., 2002), LPS-induced IL-1(3 secretion (Ndengele et
al., 2000), LPS-induced IL-6 secretion (Scott et al., 1999b), LPS-induced nitric oxide
(NO) production (Kiemer et al., 2002; Tsao et al., 2002), LPS-mediated gene
expression using gene array technology (Scott et al., 2000a), binding and
internalisation of LPS (Ding et al., 1999; Kutuzova et al., 2001), lipoteichoic acid
(LTA)-induced TNF-a and IL-6 production (Scott et al., 1999a), LTA-induced NO
production (Kuo et al., 2003) and direct killing of Candida albicans (Marcil et al.,
2002).
The role and importance of the macrophage in the inflammatory response has
been discussed in depth in Chapter 1. As a major instigator of LPS-mediated effects
in vivo, the macrophage can be considered a desirable target for modulating LPS-
induced inflammation. Macrophages react to the presence of LPS in a hyper-
responsive fashion and secrete a plethora of factors, including the classic pro¬
inflammatory cytokines IL-1, IL-6 and TNF-a (Dinarello, 1997); for the purpose of
this investigation we used TNF-a as an inflammatory marker, since this cytokine
generates many of the immunopathological features of LPS-induced shock (Beutler
and Cerami, 1986). It is apparent that subverting the release of high concentrations of
TNF-a into the circulation would be a valuable strategy in preventing LPS-mediated
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tissue damage and sepsis. It was with this supposition in mind that these
investigations were initiated.
However, since much of our interest lies in strategies to modulate
inflammation in the lung, experiments were designed to model two different in vivo
compartments: serum-containing conditions were investigated in order to model an
environment such as the bloodstream, while serum-free conditions were used to
model serum-deficient sites such as the airways.
In this regard, we also elected to model the responses of epithelial cells of the
airways which, along with macrophages, may be the first line of defence against
bacterial pathogens. Clara cells are nonciliated secretory cells which line the
bronchiolar epithelium and play an important role in the repair of damaged airways
(Boers et al., 1999). These cells are known to comprise from 50% to 90% of cells
lining the murine airways (Strayer et al., 1998), and as such were considered an
excellent model for epithelial cell activity. Much of the interest of studies into Clara
cell biology to date has concerned their role in secretion of the anti-inflammatory
protein Clara cell secretory protein, CC16 (also known as CC10 or CCSP). This
molecule is a major component of the surface lining fluid of the lung and has been
shown to play a role in modulating intrapulmonary inflammation, potentially by
inhibiting the activity of phospholipase A2 (Facchiano et al., 1991; Johnston et al.,
1997; Hayashida et al., 2000). Additionally, Clara cells respond to inflammatory
stimuli such as TNF-a by releasing multiple inflammatory cytokines and
chemokines, such as IFN-y and MCP-1 (Park et al., 2000). For our studies we chose
to use MIP-2 as a marker of LPS-induced Clara cell activation since, unlike
macrophages, epithelial cells are not major producers of TNF-a (Mannel and
Echtenacher, 2000). MIP-2 is a C-X-C chemokine which, similar to its human
homologue IL-8, is a potent mediator of neutrophil migration (Tekamp-Olson et al.,
1990).
While the results in this chapter were presented by taking each cell type in
turn, discussion of these data will be approached by firstly examining the contrasting
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observations in the presence or absence of serum, followed by a general discussion
ofpotential mechanisms and implications for elafin functions in vivo.
4.3.1. Effects of elafin on LPS-mediated cellular activation in the presence of serum
Having established in Chapter 3 that binding of elafin could prevent
interaction of LPS with LPS-binding protein, it seemed logical to extend these
findings to an investigation of the effects of elafin on LPS-induced inflammation.
Serum proteins such as LBP and sCD14 are known to play important roles in LPS-
mediated cellular activation (Wright et al., 1990; Hailman et al., 1994; Tobias et al.,
1995; Hailman et al., 1996). Therefore, prior to investigating the effects of elafin on
LPS stimulation in serum-containing or serum-free conditions, it was deemed
necessary to gain an understanding of the effects of serum in our system.
In these studies, macrophages responded to stimulation with LPS in a dose-
dependent and serum-dependent manner (Figures 1-3). These observations, although
important for establishing conditions for subsequent studies, are by no means novel
(similar findings using the RAW 264.7 cell line have been reported by Lichtman et
al., 1998)); however it was of interest to note that the majority of the activity of
serum in augmenting LPS activity appeared to be attributable to LBP (Figure 2). A
study carried out by Wurfel et al. (1997) demonstrated that the blood of LBP
knockout mice was profoundly hyporesponsive to LPS ex vivo, and that the LPS-
induced response of leukocytes obtained from normal littermates was greatly
suppressed when stimulation was performed in sera from LBP knockout mice. In
spite of this, LBP knockout mice exhibited only slight hyporesponsiveness to LPS in
vivo, suggesting that other molecules or mechanisms can mediate LPS-
responsiveness in the host (Wurfel et al., 1997). Our findings corroborate those of
Wurfel et al. (1997) in suggesting the importance of serum LBP as a key mediator of
LPS-induced cellular responses in vitro.
This rationale was of great significance for our investigations, since it was
deemed desirable to minimise the presence of LBP in cellular assays, as a
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consequence of the observation in Chapter 3 that LBP may outcompete elafin for
binding to LPS. We wished to study the effects of elafin on LPS-mediated cellular
stimulation using a test system in which elafin would not be overwhelmed, and
therefore we chose to minimise the concentration of serum. Indeed, pilot experiments
using 10% foetal calf serum serum in cell culture media suggested that elafin had
little effect on LPS-mediated TNF-a secretion by macrophages (data not shown), and
we hypothesised that this phenomenon was due to high LBP concentration. Thus, we
elected to investigate the effects of elafin on LPS-mediated cellular stimulation in
media containing 0.2% serum.
An essential pre-requisite to analysing elafin's effects was to determine
whether elafin or its terminal domains themselves represent an inflammatory insult to
cells. This was shown not to be the case using both cell types, in serum-containing or
serum-free conditions (Figures 4, 8, 12 and 16). Recent studies have documented
direct induction of inflammatory mediator release by cationic antimicrobial peptides;
for example, a half-sized peptide of human SLPI containing the COOH-terminal
domain induced TNF-a secretion by murine peritoneal macrophages (Sano et al.,
2003), while the human cathelicidin LL-37 directly induced production of the C-C
chemokine MCP-1 by RAW 264.7 murine macrophages and the C-X-C chemokine
IL-8 by A549 human epithelial cells (Scott et al., 2002). However, it must be noted
that these findings were obtained using peptides in the pM range, as compared with
our studies which investigated the effects of elafin up to a maximum concentration of
lOOnM.
Most notably, we demonstrate here that elafin is capable of modulating LPS-
mediated activation of both macrophages and Clara cells in serum-containing milieu.
Strikingly, the effects of elafin were found to be divergent depending on the cell
type, in that elafin dampened macrophage responses while enhancing those of Clara
cells. Additionally, it was evident that pre-incubation of elafin with LPS prior to
addition to cells was critical for facilitation of these effects.
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In serum-containing milieu full-length elafin inhibited TNF-a secretion by
macrophages by up to 40% (Figure 5B), whereas the same concentrations of elafin
could enhance release of MIP-2 by Clara cells by more than 200% (Figure 13B)
(both figures relative to the cellular response to LPS alone). Interestingly, the
majority of the effects of the full-length elafin molecule appeared to be contributed
by the COOH-terminal domain, since this was shown to be the more active domain
using both cell types. In macrophage experiments, activity of full-length elafin was
comparable with the COOH-terminus (Figure 5B and Figure 7B) while the NFL-
terminus did not significantly down-regulate TNF-a release (Figure 6B). These
results support the findings in Chapter 3 which suggested that, although the NH2-
terminus appeared to bind LPS more strongly than the COOH-terminus, the COOH-
terminus was the more effective portion in inhibiting LPS interaction with LBP
(demonstrated by Figures 16 and 17 in Chapter 3); indeed, these Chapter 3 figures
also demonstrated that the COOH-terminus may be more active than the full-length
molecule. Similarly, while both elafin terminal domains up-regulated LPS-mediated
MIP-2 secretion by Clara cells, the COOH-terminus was shown to be the more active
domain (Figures 14 and 15). These findings suggest that the effects of the COOH-
terminal domain may be modulated by the NH2-terminus to a certain extent in the
full-length elafin molecule; certainly, the termini do not appear to act synergistically
in full-length elafin.
4.3.2. Effects of elafin on LPS-mediated cellular activation in the absence of serum
In stark contrast to the findings with macrophages in serum-containing media,
pre-incubation of elafin peptides with LPS led to a greatly enhanced TNF-a response
following macrophage stimulation in serum-free conditions. Full-length elafm
augmented TNF-a secretion by as much as 300% (Figure 9B). The COOH-terminus
was again found to be the more active domain, and in fact it was demonstrated to
enhance LPS-induced TNF-a secretion even more effectively than full-length elafin
(Figure 9B and Figure 1 IB).
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These observations were corroborated by the studies carried out using Clara
cells in serum-free conditions. Neither full-length elafin nor the NH2-terminal
domain significantly affected MIP-2 release (Figures 17 and 18), while the COOH-
terminal domain greatly enhanced LPS-mediated activation, even in the absence of
the pre-incubation step (Figure 19).
Taking into account the above findings which suggest that the elafin COOH-
terminal domain is more active than the full-length molecule in enhancing cellular
responses to LPS in the absence of serum, it is tempting to speculate that the elafin
molecule may undergo proteolytic cleavage in tissues low in serum products (such as
the airways) in order to release the more active domain. Of interest in this regard,
elafm has also been isolated as a 6kDa (57 amino acid) peptide in psoriatic epidermis
and bronchial secretions (Wiedow et al., 1990; Sallenave and Silva, 1993); this form
of elafin contains the entire COOH-terminal domain of the 9.9kDa elafin molecule
(along with twelve NFL-terminal residues), and may represent a proteolytic fragment
with physiological activity.
Thus, in terms of the responsiveness of both macrophages and Clara cells to
LPS in serum-free milieu, elafin's effects appear to be pro-inflammatory.
4.3.3. Potential mechanisms and functions for elafin in vivo
Hence it seems that exogenous elafin may play contrasting roles in
modulation of LPS-mediated macrophage and epithelial cell activation, and these
effects are further dependent on the presence or absence of serum during stimulation.
In sites rich in serum and serum products, such as the circulation, elafin may
be beneficial in restricting overt secretion by macrophages of TNF-a and,
potentially, other pro-inflammatory products. It is also a possibility that elafin may
regulate secretion of anti-inflammatory cytokines, although time restraints prevented
such studies within this investigation; such findings have previously been
documented by Sano et al. (2000), who demonstrated that the homologous proteinase
inhibitor SLPI could up-regulate production of IL-10 and transforming growth
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factor-beta (TGF-P) by LPS-stimulated macrophages. Interestingly, researchers have
failed to demonstrate any role for extracellular SLPI in down-regulating LPS-
mediated TNF-a secretion by macrophages (Zhang et al., 1997; Sano et al., 2003).
This observation could be explained by comparing the results obtained by these two
groups with findings presented here. We demonstrated in Chapter 3 that SLPI can
prevent the interaction of LPS with LBP, which is suggestive of a possible anti¬
inflammatory role for SLPI in LPS-induced macrophage activation. However, as
with elafin these assays involved a pre-incubation step of peptide with LPS and this
may also be important for SLPI; it is possible that SLPI may be out-competed for
LPS-binding by LBP in serum. The study by Sano et al. (2003) used tissue culture
conditions containing 10% serum (no mention was made of serum content in the
paper by Zhang et al. (1997)), which as we found may be too rich in LBP to observe
an effect (data not shown here). Moreover, both previous studies used high
concentrations of LPS in the pg/ml range, compared with 50ng/ml used here, and
thus the effects of SLPI may have been overwhelmed. Although the E. coli LPS
serotype used in the Sano study was different to that used here, 10p,g/ml of LPS may
have presented too great an inflammatory insult. Finally, and perhaps critically,
neither study involved a pre-incubation period of LPS with SLPI prior to addition to
cells, a pre-requisite which we found to be essential in order to observe the effects of
elafin.
A great many studies have suggested roles for cationic antimicrobial peptides
in dampening macrophage responses to LPS, such as those describing activity of
peptides derived from silk moth cecropin and bee melittin (Gough et al., 1996; Scott
et al., 1999b), Limulus anti-LPS factor (LALF) and BPI (Dankesreiter et al., 2000),
polymyxin B (Coyne et al., 1993), cathelicidins CAP18 and CAP11 (Nagaoka et al.,
2001), peptides derived from human lactoferrin (Zhang et al., 1999) and the human
defensins HNP-1 and HBD-2 (Scott et al., 2000b).
Fewer studies have described a function for antimicrobial peptides in
enhancing the release of pro-inflammatory mediators, however some findings merit
discussion here. The study by Sano et al. (2003) demonstrated that a half-portion of
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SLPI, representing the COOH-terminal domain of the holo-molecule, significantly
up-regulated TNF-a secretion by LPS-stimulated macrophages. Although this study
was performed in serum-containing conditions, their results may be suggestive of a
similar activity for SLPI to that described here for elafin. Another study described by
Bosshart et al. (2002) demonstrated that a number of arginine-rich cationic
polypeptides such as hCAP37 and protamine can amplify LPS-induced IL-8
production by monocytes in human whole blood, and hypothesised that these
peptides may directly facilitate transfer of LPS to CD14.
In our studies, elafin was shown to exert anti-inflammatory activity only
when macrophages were stimulated with LPS in serum-containing conditions, and
only when added to cells already in complex with LPS. It therefore appears that the
interaction of elafin with LPS may prevent serum factors, such as LBP, from binding
LPS and transferring it to CD14, thus dampening cellular responses. The same does
not apply to activation of Clara cells, since even in serum-containing media elafin
enhanced their response to LPS. Moreover, in the absence of serum elafin also acts to
enhance LPS-mediated macrophage activation.
To aid understanding of potential mechanisms underlying these findings, it is
necessary to examine differences in requirements for LPS activation in these two cell
types. Epithelial cells are relatively hyporesponsive to stimulation with LPS, and this
can perhaps be explained by findings concerning their expression of important
molecules of the 'LPS receptor complex' (described in Chapter 1). While
macrophages express surface TLR4 and mCD14, expression of these molecules by
airway epithelial cells are more debatable. Whereas some studies have reported that
TLR4 is not expressed on the surface of airway epithelial cells (Tsutsumi-Ishii and
Nagaoka, 2003; Guillot et al., 2004), a recent study has demonstrated membrane
localisation of a low level of TLR4 in A549 (alveolar) epithelial cells, which was
upregulated following viral stimulation (Monick et al., 2003). The study by Guillot et
al. (2004) also demonstrated that TLR4 resides intracellularly in human alveolar and
bronchial epithelial cells, providing a rationale for prevention of chronic pulmonary
inflammatory disease induced by continuous microbial exposure. Lack of surface
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localisation in airway epithelial cells is not as a result of the absence of the accessory
protein MD-2, since expression of this molecule has been demonstrated in human
alveolar and tracheobronchial epithelial cells (Monick et al., 2003; Guillot et al.,
2004).
While LPS-mediated activation of macrophages is known to occur via
interactions with mCD14, knowledge surrounding a role for the membrane-bound
form of CD14 in activation of epithelial cells is less well understood. A number of
studies have suggested that pulmonary epithelial cells are mCD14-negative (Pugin et
al., 1993; Hedlund et al., 2001), while others have demonstrated surface expression
of CD14 (Becker et al., 2000; Tsutsumi-Ishii and Nagaoka, 2003). However, the
level of surface CD14 expression in these cells was very low compared with that of
myeloid cells (Becker et al., 2000). Recently it has been demonstrated that, while a
tracheobronchial epithelial cell line expressed a low level of surface CD 14, primary
bronchial epithelial cells did not express surface CD14 (Guillot et al., 2004). The
latter finding is in agreement with a study by Striz et al. (1998) in which human
bronchial epithelial cells were shown to be mCD14-negative; this study further
suggested the importance of sCD14 in activation of these cells (Striz et al., 1998). It
therefore appears that the soluble form of CD14 may indeed be a key mediator of
epithelial cell activation by LPS in the absence of mCD14, as suggested by various
studies (Pugin et al., 1993; Backhed et al., 2002; Schulz et al., 2002). Furthermore,
sCD14 may also at least enhance the LPS-mediated activation of mCD14-bearing
myeloid cells (Hailman et al., 1996).
sCD14 is present in serum at concentrations of around 3-4pg/ml in healthy
individuals, while this figure rises moderately but significantly in sepsis patients
(Grunwald et al., 1992; Landmann et al., 1995). The 'catalytic' lipid transfer protein
LBP, which transfers LPS monomers to CD14, is present in normal human serum at
levels of approximately 5-15pg/ml (Calvano et al., 1994; Gallay et al., 1994; Froon
et al., 1995). However, during sepsis, acute phase serum levels of LBP can reach
peak levels of up to 200pg/ml (Froon et al., 1995). LBP and sCD14 are also present
in lung fluids, although at much lower concentrations in the ng/ml range (Dubin et
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al., 1996; Martin et al., 1997). sCD14 may be released into the airways by alveolar
macrophages (Hasday et al., 1997), while recent findings have demonstrated that
alveolar epithelial cells can produce and secrete LBP (Dentener et al., 2000). It is
also possible that airway epithelial cells may release sCD14, since intestinal
epithelial cell lines have recently been shown to do so (Funda et al., 2001).
It is apparent that excluding serum from culture media during LPS
stimulation has a profound effect on the ability of LPS to induce inflammation, due
primarily to the absence of both LBP and sCD14. Serum itself has also been shown
to activate cells directly and induce their proliferation by activating signalling
pathways. For example, serum has been shown to activate MAP kinases and can lead
to phosphorylation ofRaf and ERK2 (Cabedo et al., 1996), and can also induce NF-
kB activation via augmentation of the IkB kinases IKKa and IKKp (Sasu and
Beasley, 2000).
The observation in Chapter 3 that elafin can inhibit interaction of LPS with
LBP (following direct binding to LPS) provides a straightforward rationale to help
explain the inhibition of LPS-mediated macrophage activation in serum-containing
milieu. It is equally possible that elafin could prevent interaction of LPS with other
molecules of the LPS-receptor complex, such as CD14 or TLR4-MD2, either by
binding to LPS or to these other key molecules. Elafm-mediated preclusion of any of
these interactions could potentially dampen cellular activation. Appendix IV at the
end of this chapter provides a diagrammatic representation of these proposed
mechanisms, and also of those discussed below concerning macrophage and Clara
cell activation in different serum conditions. The anti-inflammatory effects of elafin
may also be mediated by an intracellular mechanism via abrogation of the signalling
pathway downstream of TLR4. Morover, elafin could potentially interfere with
intracellular LPS recognition by the NOD protein family, described in detail in
Chapter 1 and recently reviewed by Inohara and Nunez (2003). In this regard, elafin
may be internalised either alone (excess unbound elafin may be present in reaction
mixtures added to the cells) or in complex with LPS, and inhibit a critical step prior
to gene transcription. As yet an elafin receptor has not been identified, however
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previous work has demonstrated that SLPI binds with high affinity to a receptor on
the surface of monocytes and is internalised by these cells (McNeely et al., 1997);
this internalisation has been suggested by others as a critical step in the anti¬
inflammatory activity of exogenous SLPI (Mulligan et al., 2000; Taggart et al.,
2002). It is additionally feasible that elafm-LPS complexes may be internalised
following interaction with CD14 (Gegner et al., 1995; Thieblemont and Wright,
1999; Vasselon et al., 1999). It should be noted that potential roles for intracellular
elafin in interfering with the LPS signalling pathway downstream of the receptor
complex are discussed in depth in Chapter 5, and as such will not be subjected to
great scrutiny here.
Although elafin-mediated inhibition of LPS interaction with molecules such
as LBP may dampen macrophage activation in serum, the same was shown not to be
true of Clara cell activation. Clara cell activation was enhanced by elafin in the
presence of serum. As discussed above, it is likely that Clara cells are dependent on
sCD14 to enhance their responsiveness to LPS due to absent or low level expression
of mCD14. Moreover, Clara cell activation may rely upon sCD14-mediated LPS
uptake and delivery to intracellular TLR4, as described in Chapter 1 (Thieblemont
and Wright, 1999). It is possible that, in the case of Clara cells, elafin prevents
binding of LPS by LBP as suggested previously, but that elafin functions to replace
LBP in transfer of LPS from micelles to monomers. The elafin-LPS complex may
potentially be recognised effectively by sCD14 (more-so than by membrane-bound
CD 14) and lead to augmented cellular activation. Equally, uptake and internalisation
of elafin-LPS complexes or stimulation of a hitherto unidentified elafin receptor,
proposed above as a mechanism of anti-inflammatory activity, could also potentially
lead to enhancement of LPS-mediated activation.
Thus it may be hypothesised that, in defined circumstances, elafin may act as
a 'carrier' molecule for LPS. In this model, elafin may function to replace serum
factors to transfer LPS to the LPS recognition machinery.
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In serum-free conditions elafin significantly up-regulated the LPS-mediated
inflammatory response of macrophages; it is therefore suggested that elafin can play
a catalytic role, similar to that of LBP, in transporting LPS monomers to the
macrophage surface and, in particular, to mCD14. It is also feasible that elafm-LPS
complexes may interact with TLR4-MD-2, or could be endocytosed as described
above. In the presence of serum, however, elafin's net activity may be anti¬
inflammatory due to inhibition of the rapid LBP-mediated transfer of LPS to CD14.
Clara cell stimulation was enhanced slightly (but non-significantly) by full-
length elafin and the NLL-terminal domain in the absence of serum, while the
COOH-terminal domain caused a significant increase in LPS-induced MIP-2
secretion. Similarly, this effect may be facilitated by elafm-mediated transfer of LPS
to (potentially) mCD14 on the surface of Clara cells, by interaction of elafin-LPS
with TLR4-MD-2, or by internalisation of LPS and recognition by intracellular
TLR4 or NOD receptors. While in all other cases described thus far elafin only had
effects following pre-incubation with LPS, in serum-free medium the COOH-
terminus enhanced MIP-2 release even when added at the same time as LPS. The
lack of requirement for prior interaction of COOH-terminus with LPS in this case is
intriguing, and may be explained by the absence of sCD14 and LBP that would
otherwise compete with the elafin peptide for binding to LPS in serum. Thus the
COOH-terminus, which as discussed previously may exert even more potent activity
than either full-length elafin or the ML-terminus, is unhindered in its interaction
with LPS; as Clara cells may express only low levels (or have no expression at all) of
surface CD 14 and TLR4-MD-2, LPS activation of these cells is less efficient than
macrophages, and thus the elafin peptide may have time to bind LPS prior to
signalling.
To further delineate the findings of this chapter, the hypotheses proposed
above could potentially be investigated using adenoviral overexpression techniques
(such as those utilised in chapters 5 and 6 of this thesis) with which our laboratory
has extensive experience. For example, selective augmentation of molecules of the
LPS receptor complex in cells lacking these components and therefore unresponsive
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to LPS, such as human embryonic kidney (HEK) 293T cells (see Medvedev and
Vogel, 2003), could aid understanding of how elafin could act as an LPS 'carrier'
protein in serum-free conditions. Adenovirus-mediated overexpression of TLR4-
MD-2 in these cells may provide an answer as to whether elafin can deliver LPS
directly to this complex in the absence of LBP or CD 14. Moreover, overexpression
ofmCD14 could potentially reveal a role for elafin in mediating LPS transfer to this
molecule, prior to recognition by TLR4-MD-2. Similar studies could be also used to
augment NOD proteins such as NODI in HEK 293T cells (shown previously by
Inohara et al. (2001) to confer LPS-responsiveness) in order to investigate whether
elafin-LPS complexes can be internalised and delivered to these intracellular
receptors. Such overexpression studies could equally be performed in the cell types
used in this study, however initially it would perhaps be more informative to make
use of a naive cell type with an LPS-unresponsive phenotype.
With regards to macrophage activation in serum-containing milieu, selective
monoclonal antibody-mediated blocking of LBP would perhaps help to address the
question of whether this is the key molecule in conversion of elafin from an anti¬
inflammatory agent to a pro-inflammatory one: in the presence of LBP in serum,
elafin may prevent LBP-LPS interaction and provide an anti-inflammatory
phenotype, whereas in the absence of LBP's catalytic activity elafin may be free to
bind LPS and itself act as a carrier molecule. Analogous studies to block sCD14
could be performed in the case of Clara cells to test the previous hypothesis that
elafin can enhance LPS-mediated activation by transferring LPS to sCD14 in serum.
Regardless, initial findings presented here suggest that elafin may play a role
in down-regulating potentially deleterious systemic responses to endotoxin, mediated
by TNF-a release by activated macrophages; conversely, elafin may enhance local
immune responses to LPS or to bacterial pathogens in serum-deficient sites by
augmenting the inflammatory response.
Elafin may thus play a pro-inflammatory role in the control of local responses
to Gram-negative bacterial infection in the airways. These findings may be
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particularly relevant in the human lung since elafin secretion may be associated with
alveolar epithelium, Clara cells, or tracheal epithelium (Sallenave et al., 1993; Nara
et al., 1994), and is augmented by pro-inflammatory mediators such as IL-1, TNF,
HNE and LPS (Sallenave et al., 1994; Reid et al., 1999).
It may be of benefit to the host to enhance migration of neutrophils and other
myeloid cells into the lung epithelium in order to combat bacterial invasion and aid
in the clearance of pathogens. However, an over-zealous immune response may lead
to interstitial tissue damage; in this regard, elafin may play an important role in
enhancing inflammatory responses locally while preventing the potentially
detrimental effects of exogenous proteases. Interestingly, another potentially pro¬
inflammatory role for elafin may be suggested by studies which have demonstrated
that proteinase-3 (PR-3) and HNE can degrade CD14 on the surface of monocytes,
leading to dampening of TNF-a production (Le-Barillec et al., 1999; Yard et al.,
2002). In inflamed tissues characterised by infiltration of monocytes/macrophages
and neutrophils, elafin may inhibit this proteinase-mediated CD 14 degradation and
thus perpetuate the inflammatory response. A similar role could be proposed for
SLPI, which also inhibits the activity of another CD14-degrading proteinase,
cathepsin G (Le-Barillec et al., 2000).
The concentrations of elafin investigated here could well be relevant to the in
vivo situation. For example, elafin levels in the serum of healthy humans have been
measured at around 8-15ng/ml (approximately InM), while patients with psoriasis
may have serum elafin levels as high as 300ng/ml (approximately 30nM) (Alkemade
et al., 1995); the majority of elafin's effects observed here were induced at around
10-lOOnM. While elafin levels have not been measured in serum during human
sepsis, levels of SLPI have been shown to rise from approximately 43ng/ml (3.7nM)
to 150ng/ml (12.8nM) in septic surgical patients (Grobmyer et al., 2000). Moreover,
plasma concentrations of SLPI have been documented to reach 176ng/ml (15nM) in
patients with pneumonia (Duits et al., 2003b).
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With regards to elafin levels in the airways, these may also be within or
exceeding the range tested in the studies described here. In bronchoalveolar lavage
(BAL) fluid from normal subjects, elafin has been detected at concentrations around
3nM (Tremblay et al., 1996); this figure was found to be elevated to around 120nM
in BAL fluid from patients with active farmer's lung, a common form of
hypersensitivity pneumonitis (induced by inhalation of organic dust from hay) which
is characterised by influx of alveolar neutrophils and macrophages (Tremblay et al.,
1996). Similarly, levels of elafin in BAL fluid were shown to rise from less than 5nM
in healthy individuals to as much as 325nM in patients with established acute
respiratory distress syndrome (ARDS) (Sallenave et al., 1999a). The level of elafin in
epithelial lining fluid has not been determined, but is likely to be several orders of
magnitude greater than that measured in BAL fluid.
The findings of this chapter additionally corroborate recent studies regarding
activity of elafin in murine models. Simpson et al. (2001a) demonstrated that
adenovirus-mediated overexpression of elafin in murine airways augmented TNF-a
and MIP-2 levels in BAL fluid following LPS administration, and these increases
were associated with enhanced LPS-induced airway neutrophilia (Simpson et al.,
2001a). In good agreement with the concentrations of elafin tested here, Simpson et
al. (2001a) measured adenovirus-derived (since no murine elafin homologue exists)
elafin levels in BAL fluid of up to around 140ng/ml (14nM). Furthermore, work
carried out using transgenic mice expressing human elafin has demonstrated that
these mice exhibit lower serum-to-BALF ratios of pro-inflammatory cytokines
(TNF-a, MIP-2 and MCP-1) than wild-type mice, following LPS administration to
the lungs; these cytokine levels were correlated with elafin concentrations (pg/ml
range) in BAL fluid, and were also associated with an increase in neutrophil and
macrophage influx (Sallenave et al., 2003). Conversely, in response to systemic LPS,
mice expressing elafin had lower levels of serum TNF-a than wild-type mice, while
peritoneal macrophages from elafin mice were hypo-responsive to LPS (Sallenave et
al., 2003). The data described in this chapter may help to further clarify these in vivo
observations.
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4.4. SUMMARY
The results presented in this chapter demonstrate that the LPS-binding
properties of elafin, described in Chapter 3, confer to the elafin molecule the ability
to modulate the pro-inflammatory activity of LPS in vitro. Serum conditions were
shown to be an important determinant of the effects of elafin and these findings may
be of relevance to potential roles for elafin in vivo.
Elafin may play a role in innate immunity by modulating host responses to
Gram-negative bacterial LPS: elafin could function to enhance immune responses in
sites of local inflammation, such as the airways, but to down-regulate potentially
deleterious responses to LPS in the circulation.
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APPENDIX IV
Schematic diagram of potential mechanisms of the effects of elafin on LPS-
mediated activation ofmacrophages and Clara cells
Potential mechanisms to explain the elafin-mediated effects in this chapter are
depicted diagrammatically. Elafin is represented by a red diamond to indicate
possible interactions with the receptor complex. Question marks denote points of
particular uncertainty. 'X' across an arrow denotes inhibition of a step in the
pathway; '+++' indicates augmentation.
For description of the potential mechanisms represented in these diagrams, please
refer to section 4.3.3. under 'Discussion' in Chapter 4.
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CHAPTER 5
THE EFFECT OF ELAFIN GENE AUGMENTATION ON
THE INFLAMMATORY RESPONSE OF
MACROPHAGES TO LPS IN VITRO
5.1. AIMS
The principal aim of the work described in this chapter was to study the
effects of elafin gene augmentation on the inflammatory response of murine
macrophages to LPS, using an adenovirus-based strategy. This gene transfer
approach uses a replication-deficient adenovirus vector (Ad), encoding human elafin
cDNA under the control of the powerful murine cytomegalovirus (MCMV)
promoter, to facilitate cellular overexpression of elafin (Sallenave et al., 1998).
Simpson et al. (2001b) have previously used this technique to demonstrate that
adenoviral augmentation of elafin protects human alveolar epithelial (A549) cells
against the injurious effects of both HNE and whole activated neutrophils in vitro,
and murine lungs against acute inflammatory injury mediated by P. aeruginosa in
vivo. Moreover, adenoviral overexpression of elafin has been shown to enhance
human neutrophil migration in vitro, and to augment LPS-mediated neutrophil
migration into murine airways in vivo (Simpson et al., 2001a).
The experiments described herein were undertaken to investigate whether
similar genetic augmentation of elafin could modulate the vigorous macrophage
response to LPS in vitro. Chapter 4 demonstrated that exogenous elafin peptides can
directly modulate the LPS-mediated inflammatory response of macrophages, and that
this activity can be pro- or anti-inflammatory depending on the absence or presence
of serum, respectively. While the use of synthetic peptides facilitated investigation of
elafin's extracellular effects on LPS activation, it was envisaged that genetic
overexpression could potentially delineate any intracellular effects of elafin. It must
be noted that, due to time constraints, the following experiments were carried out
using only cell culture conditions incorporating serum. Thus, the experiments
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described in this chapter set out to model the effects of Ad-elafin on macrophage
responses to LPS in serum-containing sites, such as the circulation.
5.2. RESULTS
5.2.1. Experiments to establish conditions for optimal Ad-elafin infection of RAW
264.7 murine macrophages
Prior to commencing investigation of the effects of elafin overexpression on
LPS-mediated activation ofmacrophages, it was deemed necessary to establish a set
of optimal conditions for adenoviral infection of these cells. It is known that
infection of macrophages with adenovirus vectors is feasible using a high
multiplicity of infection (moi), but is relatively inefficient due to a low level of
cellular expression of the Coxsackie/adenovirus receptor (CAR) (Kaner et al., 1999;
Worgall et al., 1999). For example, Kaner et al. (1999) demonstrated that alveolar
macrophages expressed Ad vector transgenes 100 to 1000-fold less efficiently than
A549 cells. However, adenoviral gene transfer to cells lacking the receptor activity to
bind adenovirus fibre protein has been shown to be enhanced by generation of
calcium phosphate (CaP04 or CaPi) precipitates in the infection milieu (Fasbender et
al., 1998); such precipitates have also been used previously to aid transfection of
plasmid DNA into cultured cell lines (Chen and Okayama, 1988). Using this
technique, Ad:CaPi co-precipitates can markedly augment transgene expression by
increasing fibre-independent binding of virus to cells (Fasbender et al., 1998).
On consideration of these findings, it seemed prudent to initially investigate
the efficiency of adenoviral infection of RAW 264.7 murine macrophages, and the
effects of incorporating CaPi precipitates into viral infection media. For this purpose,
comparisons were made between efficiency of gene transfer when infection was
performed either in the DMEM used to maintain cells on a day-to-day basis, or in
media prepared to contain CaPi precipitates. In the latter case, calcium chloride
(CaCL) was added to a Minimum Essential Eagle's Medium (MEEM) formulation
containing 1.8mM Ca2+ and 0.86mM Pi, thus forming an infection medium
containing microscopically apparent CaPi precipitates.
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Figure 1 demonstrates that infection of RAW 264.7 cells with the Ad-lacZ
reporter construct could be achieved when infection was performed in DMEM, with
infection efficiency around 30% at moi 100 (Panel B). Incubating Ad-lacZ with cells
in MEEM without addition of Ca , and therefore without CaPi co-precipitates,
resulted in infection efficiency around 50% (Panel D). However, incorporation of
4mM Ca2+ into MEEM resulted in formation of CaPi precipitates in the viral
infection media, with a concomitant increase in infection efficiency to approximately
100% (Panel F); in this case, precipitates were formed with a final concentration of
5.8mM Ca2+ and 0.86mM Pi. Incubation of macrophages with CaPi precipitates did
not appear to effect any morphological damage to the cells, and this observation was
supported by performing cell counts and trypan blue exclusion (data not shown).
In order to investigate efficiency of infection of cells with Ad-elafin, cells
were infected with the viral construct in a range of infection media and at varying
moi, and cell supernatants and lysates were analysed by elafin ELISA (Figures 2 and
3). As suggested by Figure 1, elafin production was greatly enhanced by
incorporation of CaPi precipitates into infection media, and more specifically this
9-4-
efficiency could be augmented by increasing the concentration of Ca added to
MEEM to form precipitates (Figure 2). Relatively little elafin was produced by Ad-
• • 7 l
elafin-infected cells in DMEM or MEEM without addition of Ca , and elafin
9+ •
production was optimal when 4mM Ca was added. Both secreted and intracellular
elafin levels were measured; the observation that similar dose responses were
obtained with secreted and intracellular elafin supports findings using trypan blue
exclusion (not shown) that cells were intact following incubation with Ad:Pi, and
suggests that extracellular elafin levels were not associated with cell lysis (Figure 2).
Figure 2 demonstrates data pertaining to an Ad-elafin moi of 100, but the level of
elafin production could also be affected by altering the moi while using a constant
9+
final concentration of 5.8mM Ca /0.86mM Pi in infection media (Figure 3).
Notably, uninfected cells produced no detectable elafin since no murine homologue
of elafin has been identified to date, and the anti-elafin antibody did not cross-react
with any cell-derived protein. Similar dose-response relationships were again
obtained for extra- and intracellular elafin levels (Figure 3).
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Figure 1. Calcium phosphate (CaPi) precipitates enhance the efficiency of
adenoviral infection ofRAW 264.7 murine macrophages
RAW 264.7 murine macrophages (5 x 105/well of a 48-well plate) were treated with vehicle
alone or Ad-lacZ at moi 100, and incubated in DMEM containing 0.2% serum for 18-20
hours at 37°C. Cells were then subjected to X-gal staining as described in 'Materials and
Methods'. Blue colouration indicates expression of the P-galactosidase gene.
DMEM=Dulbecco's Modified Eagle's Medium; MEEM = Minimum Essential Eagle's
Medium.
PANEL A - no viral infection of cells, incubated in DMEM
PANEL B - cells infected with Ad-lacZ (moi 100) in DMEM
PANEL C - no viral infection of cells, incubated in MEEM
PANEL D - cells infected with Ad-lacZ (moi 100) in MEEM
PANEL E - no viral infection of cells, incubated in MEEM plus 4mM Ca2~
PANEL F - cells infected with Ad-lacZ (moi 100) in MEEM plus 4mM Ca2
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Figure 2. Increasing the concentration of Ca2+ in infection medium augments
elafin production by Ad-elafin-infected RAW 264.7 macrophages
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight. Cells were then infected with Ad-elafin (moi 100) for 45 minutes at 37°C
• "7 I
in 250pl DMEM or in 250pl MEEM with varying concentrations of Ca added.
Cells were washed twice with PBS, 500pl DMEM containing 0.2% FCS added and
cells incubated for 23 hours. Media were analysed by elafin ELISA to measure levels
of secreted elafin (A). Alternatively, cells were lysed to obtain total protein and
lysates analysed by ELISA for intracellular elafin (B). Values represent mean ± S.E.
of n=3 experiments, each performed in triplicate.
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Figure 3. Increasing the multiplicity of infection (moi) of Ad-elafin augments
elafin production by RAW 264.7 macrophages
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight. Cells were then infected with Ad-elafin at increasing moi for 45 minutes
at 37°C, in 250pl MEEM containing 5.8mM Ca2+/0.86mM Pi. Cells were washed
twice with PBS, 500p.l DMEM containing 0.2% FCS added and cells incubated for
23 hours. Media were analysed by elafin ELISA to measure levels of secreted elafin
(A). Alternatively, cells were lysed to obtain total protein and lysates analysed by
ELISA for intracellular elafin (B). Values represent mean ± S.E. of n=3 experiments,
each performed in triplicate.
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Within the range of mois tested, elafin production was maximal at moi 100;
moreover, cell viability was unaffected at this moi. On consideration of the results
shown in Figures 2 and 3, all subsequent viral infections were performed using an
moi of 100, and with infection media comprising MEEM with 4mM Ca2+ added
(giving a final concentration of 5.8mM Ca /0.86mM Pi to form precipitates).
Additionally, it was deemed necessary to investigate the effects of CaPi
precipitates on the TNF-a response of cells since, although this treatment did not
appear to directly affect cell viability, it was important that cells would retain their
LPS-responsive activity for subsequent assays. CaPi precipitates were demonstrated
to be a considerable inflammatory stimulus to macrophages; over a 23-hour period,
cells which had been incubated for 45 minutes with CaPi secreted a significantly
greater concentration of TNF-a than cells which had been incubated for 45 minutes
with DMEM (Figure 4). It should be noted that 45 minutes represents the incubation
period used for adenoviral infections, and cells would normally be stimulated with
LPS 23 hours post-infection. However, despite these observations, incubation of cells
with CaPi had no significant effects on their subsequent inflammatory response to
LPS stimulation, as compared with cells incubated with DMEM (Figure 5). It was
therefore concluded that the use of CaPi precipitates to enhance elafin gene
augmentation was a practicable strategy for our investigations.
5.2.2. The effect of LPS on elafin production by Ad-elafin-infected RAW 264.7
murine macrophages
Previous work has demonstrated that LPS can upregulate elafin production by
Ad-elafin-infected human A549 cells and human monocyte-derived macrophages in
vitro, and also elafin secretion in murine airways treated with Ad-elafin (Simpson et
al., 2001a). This effect has been attributed to the presence of LPS-responsive
elements within the MCMV promoter (Loser et al., 1998; Simpson et al., 2001a).
Assays were performed to investigate whether LPS has similar effects on elafin
production by Ad-elafin-infected murine macrophages in this system.
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Figure 4. Calcium phosphate (CaPi) induces a more pronounced inflammatory
response from RAW 264.7 macrophages than DMEM
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight, then incubated for 45 minutes at 37°C with either 250pl DMEM, or 250pl
MEEM containing 5.8mM Ca2+/0.86mM Pi. Cells were washed twice with PBS and
500pl DMEM containing 0.2% FCS added. Cells were incubated at 37°C for lhour
or 23 hours, and media analysed by TNF-a ELISA. Values represent mean ± S.E. of
n=3 experiments, each performed in triplicate. *** = significant difference, P0.001,
compared with cells incubated for 23 hours following treatment with DMEM.
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Figure 5. Incubation of RAW 264.7 macrophages with calcium phosphate
(CaPi) has little effect on their inflammatory response to LPS
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight, then incubated for 45 minutes at 37°C with either 250p,l DMEM, or 250pil
MEEM containing 5.8mM Ca2+/0.86mM Pi. Cells were washed twice with PBS and
500pl DMEM containing 0.2% FCS added. Following 23 hours incubation, cells
were stimulated with 50ng/ml E. coli 055:B5 LPS for 4 hours at 37°C; media were
analysed by TNF-a ELISA. Values represent mean ± S.E. of n=3 experiments, each
performed in triplicate.
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Figure 6. LPS upregulates elafin production by Ad-elafin-infected RAW 264.7
macrophages
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight. Cells were then infected with Ad-elafin (moi 100) for 45 minutes at 37°C,
in 250pl MEEM containing 5.8mM Ca2+/0.86mM Pi. Cells were washed twice with
PBS and 500pl DMEM containing 0.2% FCS added. Following 23 hours incubation,
cells were stimulated with increasing concentrations of E. coli 055:B5 LPS for 4
hours at 37°C. Media were analysed by elafin ELISA to measure levels of secreted
elafin (A). Alternatively, cells were lysed to obtain total protein and lysates analysed
by ELISA for intracellular elafin (B). Values represent mean ± S.E. of n=3
experiments, each performed in triplicate. ** = significant difference, P<0.01,
compared with baseline (0 LPS). *** = significant difference, PO.OOl, compared
with baseline (0 LPS).
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Figure 6 demonstrates that 4-hour incubation of LPS with Ad-elafin-infected cells
caused a dose-responsive increase in elafin production, both extracellularly and
intracellularly. This effect was very significant at higher concentrations of LPS,
although as low as 5ng/ml LPS induced a significant increase in the concentration of
elafin secreted. While levels of secreted elafin could be significantly augmented by
lower LPS concentrations than intracellular (Figure 6A), intracellular elafin was
more sensitive to up-regulation in terms of 'fold-increase' (for example, an
approximately four-fold increase at 5pg/ml LPS) (Figure 6B).
5.2.3. Inflammatory response ofRAW 264.7 murine macrophages to infection with
adenovirus constructs
Prior to investigating the effects of elafin overexpression on the TNF-a
response of macrophages to LPS, it was necessary to consider the inflammatory
response of cells to infection with adenovirus constructs in the absence of additional
stimulation. For the purpose of the experiments described in the following section,
several adenovirus vectors were used to provide informative controls. In addition to
Ad-elafin, infections were carried out using the following vectors: Ad-ItcB, encoding
the gene for an NF-kB super-repressor mutant of the cytoplasmic protein IkBcx,
known to play an essential role in the regulation of NF-kB activation (which
subsequently regulates TNF-a production (Shakhov et al., 1990)) (Baldwin, 1996;
Jobin et al., 1998); Ad-dl70/3, an empty adenovirus vector which does not encode a
transgene; Ad-m-eotaxin, encoding the cDNA for the murine CC chemokine eotaxin,
an 8.4kDa secreted protein which acts as a chemoattractant for inflammatory
leukocytes, particularly eosinophils (Rothenberg et al., 1995; Corrigan, 1999); and
finally Ad-mSLPI, which encodes the cDNA for murine SLPI, the other member of
the antileukoprotease superfamily of proteinase inhibitors. The Ad-mSLPI construct
was regarded as a potential control vector for the following LPS stimulation assays,
since several previous investigations have suggested that SLPI can exert anti¬
inflammatory effects intracellularly (Zhu et al., 1999; Mulligan et al., 2000; Taggart
et al., 2002). These studies will be discussed in more depth in the 'Discussion'
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Figure 7. Infection of RAW 264.7 macrophages with adenoviral constructs
induces a significant inflammatory response, compared with uninfected cells
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight, then infected with Adenovirus constructs (moi 100) for 45 minutes at
37°C in 250pl MEEM containing 5.8mM Ca2+/0.86mM Pi. Cells were washed twice
with PBS, 500pl DMEM containing 0.2% FCS added and cells incubated for 23
hours at 37°C. Media were then analysed by TNF-a ELISA. Key to virus-infected
cells: UN==uninfected, EL=Ad-elafin, IkB=Ad-IicB, dl70/3=Ad-dl70/3, EOT=Ad-m-
eotaxin, SLPI=Ad-mSLPI. Values represent mean ± S.E. of n=3 experiments, each
performed in triplicate. *** = significant difference, PO.OOl, compared with
uninfected cells.
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section of this chapter. However, it should be noted that effects of SLPI using this
system have not previously been documented.
Adenoviral infection ofRAW 264.7 macrophages with all constructs induced
a significant inflammatory response, in comparison to uninfected cells (Figure 7).
TNF-a release was measured after incubation of macrophages with viral constructs
at moi 100 or with vehicle alone, followed by incubation for 23 hours; this
incubation represents the same period for which cells would be left to express
transgene before being stimulated with LPS in the experiments to follow. However,
while viral infection with Ad constructs elicited an inflammatory response per se, the
levels of response induced by the different vectors were similar and, indeed, non¬
significant when compared together statistically. In general, viral infection induced
around a 2.5-fold increase in TNF-a secretion (Figure 7).
5.2.4. The effect of elafin gene augmentation on the inflammatory response of
RAW 264.7 murine macrophages to LPS
The effects of Ad-elafin infection on the LPS-mediated TNF-a response of
RAW 264.7 cells were investigated in a series of linked experiments (Figures 8 and
9). Firstly, cells were virally infected, incubated for 23 hours to allow expression of
transgene and then stimulated with 50ng/ml LPS in their conditioned media (Figure
8A). The TNF-a responses of Ad-dl70/3- (empty vector) and Ad-m-eotaxin-infected
cells were similar to that observed with uninfected cells. Ad-m-eotaxin was chosen
as a control since the product of this transgene is a secreted protein of similar
molecular weight to elafin (8.4 kDa and 9.9 kDa respectively), and this chemokine
was detectable by ELISA (data not shown); it was shown, however, to have no effect
on LPS activation of these cells. In contrast, Ad-elafin-, Ad-IxB- and Ad-mSLPI-
infected cells were significantly hyporesponsive to LPS stimulation in the presence
of their conditioned media (Figure 8A). Interestingly, these cells exhibited an even
more profound degree of LPS-hyporesponsiveness when conditioned media were
replaced with fresh media just prior to addition of LPS (Figure 8B). This suggests
that products secreted by cells during the 23-hour incubation, such as sCD14 or LBP
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perhaps, may accelerate the response to LPS and mask to a certain extent the effects
of the viral transgenes. The average percentage decrease in TNF-a secretion by Ad-
elafin-, Ad-IicB- or Ad-mSLPI-infected cells, as compared with uninfected cells, is
provided above each bar. As shown by both Figures 8A and 8B, the most potent
inhibitor of TNF-a secretion was the NF-kB super-repressor Ad-ItcB, while the anti¬
inflammatory effects of Ad-elafin and Ad-mSLPI were comparable and highly
significant.
In order to investigate whether secreted (transgene-derived) products of
adenovirally-infected cells could suppress the response of uninfected cells to LPS,
conditioned media were removed from Ad-infected wells and added to washed
'naive' cells prior to addition of LPS (Figure 9). For these assays, conditioned media
were removed from Ad-treated cells either 4 hours or 23 hours post-infection; media
derived from 4-hour incubations permitted us to investigate whether the effects
observed in Figure 8B could be attributed to the effects of peptides secreted during
LPS stimulation. Conditioned media from Ad-elafin-infected cells had no effect on
the LPS-mediated TNF-a response of uninfected cells, whether taken from cells 23
hours (Figure 9A) or 4 hours (Figure 9B) post-infection. These results strongly
suggest that secreted elafin did not contribute to the LPS-hyporesponsive phenotype
of Ad-elafin-infected cells, observed in Figure 8, and that elafin retained
intracellularly may play a role in this effect. Additionally, conditioned media from
Ad-ItcB- and Ad-mSLPI-infected cells failed to confer LPS-hyporesponsiveness to
uninfected cells (Figure 9); while the product of the Ad-IxB transgene is retained
intracellularly, Ad-mSLPI-infected cells produce a secreted protein, which was found
to have no effect on LPS activation. Similarly, and as expected, conditioned media
derived from the negative control vectors Ad-dl70/3 and Ad-m-eotaxin had no effect
on TNF-a secretion.
Figure 10 demonstrates the elafin levels produced by Ad-elafin-infected cells
during the course of these experiments, measured both extracellularly (Figure 10A)
and intracellularly (Figure 10B). During 23-hour incubation post-infection and
subsequent 4-hour incubation with LPS, Ad-elafin-infected cells secreted around
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100ng/ml elafin (Figure 10A, bar 1); around 90% of this was removed by washing
elafin-conditioned media from cells prior to LPS stimulation (Figure 10A, bar 2).
Therefore, approximately lOOng/ml (lOnM) elafin was present in the media bathing
Ad-elafin-infected cells during LPS stimulation in the experiments described by
Figure 8A, and this was reduced to around lOng/ml (InM) in the experiments
described by Figure 8B. These findings taken alone could suggest that extracellular
elafin was responsible for dampening macrophage responses to LPS in these assays,
and that the effects of elafin are more pronounced at lower concentrations. However,
as shown in Figure 9, analogous elafin-conditioned media from Ad-elafin-infected
cells failed to confer LPS-hyporesponsiveness to uninfected cells. Bars 3 and 4 of
Figure 10A indicate that elafin levels in media transferred to uninfected cells were
either approximately 70ng/ml (7nM) or 6ng/ml (0.6nM). The discrepancies between
bars 1 and 3, and bars 2 and 4 respectively, are likely due to LPS upregulation of the
transgene in Ad-elafin cells during the 4-hour LPS incubation period; this
upregulation cannot occur in the uninfected cells (bars 3 and 4).
In terms of intracellular elafin, the technique used to measure these levels
may have taken into account elafin on the cell surface, or else some cells were
removed by washing, since intracellular elafin was lower after washing the cells
(Figure 10B, comparing bars 1 and 2). Moreover, elafin was detected in the lysates of
uninfected cells to which had been added Ad-elafin-conditioned media (Figure 10B,
bars 3 and 4). It is unclear if this represents elafin which was attached to the cell
surface on lysis, or if the cells internalised elafin from the surrounding milieu. As
mentioned previously, no murine homologue of elafin has been identified to date,
and no murine protein has been observed to cross-react with the anti-elafin antibody
used in these experiments.
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Figure 8. Ad-elafin-infected RAW 264.7 macrophages are hyporesponsive to LPS, and
this effect is more pronounced when conditioned medium is replaced with fresh
medium prior to stimulation
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight, then infected with Ad constructs (moi 100) for 45 minutes at 37°C in 250pl
MEEM containing 5.8mM Ca2+/0.86mM Pi. Cells were washed twice with PBS, 500pl
DMEM containing 0.2% FCS added and cells incubated for 23 hours at 37°C. 50ng/ml E.
coli 055:B5 LPS was then incubated with cells for 4 hours in their conditioned media (A), or
alternatively conditioned media were replaced with fresh DMEM/0.2% FCS prior to addition
of LPS (B). Media were analysed by TNF-a ELISA. Key to virus-infected cells:
UN=uninfected, EL=Ad-elafin, IkB=Ad-lKB, dl70/3=Ad-dl70/3, EOT=Ad-m-eotaxin,
SLPI=Ad-mSLPI. Values represent mean ± S.E. of n=3 experiments, each performed in
triplicate. *** = significant difference, P<0.001, compared with uninfected cells. ### =
significant difference, P<0.001, compared with Ad-dl70/3-infected cells. + = significant
difference, P<0.05, compared with Ad-EOT-infected cells. ++ = significant difference,
P<0.01, compared with Ad-EOT-infected cells. +++ = significant difference, P<0.001,
compared with Ad-EOT-infected cells. Figures above bars represent average % decrease in
TNF-a secretion, as compared with uninfected cells.
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Figure 9. Conditioned medium from Ad-elafin-infected RAW 264.7
macrophages does not confer LPS-hyporesponsiveness to uninfected cells
RAW 264.7 macrophages were plated out and infected with Adenovirus constructs
(moi 100) as per Figure 8. Conditioned media were removed from cells 23 hours and
4 hours post-infection, and these media were added to 5 x 105 washed, uninfected
cells/well of a 48-well plate. 50ng/ml E. coli 055:B5 LPS was then incubated with
cells for 4 hours in these conditioned media, and media were analysed by TNF-a
ELISA. (A) 23-hour conditioned media added to uninfected cells prior to LPS
stimulation. (B) 4-hour conditioned media added to uninfected cells prior to LPS
stimulation. Key to conditioned media added to uninfected cells: UN=uninfected,
EL=Ad-elafin, IkB=Ad-IicB, dl70/3=Ad-dl70/3, EOT=Ad-m-eotaxin, SLPI=Ad-
mSLPI. Values represent mean ± S.E. of n=3 experiments, each performed in
triplicate.
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Figure 10. Elafin levels produced by RAW 264.7 macrophages during LPS
stimulation assays
RAW 264.7 murine macrophages were seeded at 5 x 105 cells/well of a 48-well plate
overnight. Cells were then infected with Ad-elafin (moi 100) for 45 minutes at 37°C, in
250p,l MEEM containing 5.8mM Ca2+/0.86mM Pi. Cells were washed twice with PBS,
500p.l DMEM containing 0.2% FCS added and cells incubated at 37°C for 23 hours or 4
hours (producing 'elafin-conditioned media'). Cells were then incubated for 4 hours with
50ng/ml E. coli 055:B5 LPS, either in their 23-hour elafin-conditioned media (bar 1) or
following washing with PBS and addition of fresh medium (bar 2). Alternatively, elafin-
conditioned media were removed from Ad-infected wells and added to uninfected, washed
cells prior to LPS stimulation (bars 3 and 4).
Media were analysed by elafin ELISA to measure levels of secreted elafin (A). Alternatively,
cells were lysed to obtain total protein and lysates analysed by ELISA for intracellular elafin
(B). UN=uninfected cells, EL=Ad-elafin-infected cells. Values represent mean ± S.E. of n=3
experiments, each performed in triplicate.
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5.3. DISCUSSION
The principal novel observation arising from this work is that infection of
murine macrophages with an adenovirus vector encoding elafin suppresses their
vigorous pro-inflammatory response to bacterial LPS (Figure 8). Moreover, two
prominent findings suggest that this anti-inflammatory activity is independent of the
effects of extracellular elafin. Firstly, Ad-elafin-infected cells retained their LPS-
hyporesponsive phenotype even after elafm-conditioned media were removed prior
to stimulation, and indeed suppression of responses was more pronounced under
these conditions (Figure 8B). Secondly, conditioned media from Ad-elafin-infected
cells failed to dampen the inflammatory response of uninfected macrophages to LPS
(Figure 9).
Discussion of these data will focus on the efficiency of adenovirus-mediated
gene transfer to murine macrophages, the effects of LPS on elafin production by
these cells, and on the effects of elafin gene augmentation on their inflammatory
response to LPS.
5.3.1. Adenoviral infection of the murine macrophage cell line RAW 264.7
Much of the data described in the first part of this chapter concerns the
establishment of a set of optimal conditions for adenoviral infection of the RAW
264.7 macrophage cell line, and consequently expression of the elafin transgene.
Murine cells were studied in view of the facts that no murine homologue of elafin
has been identified to date, and that our laboratory has observed no cross-reaction of
the anti-human elafin antibody with any mouse product; thus we could study the
effects of introducing an entirely foreign gene (human elafin) into murine cells. We
chose to use macrophages as a target for adenoviral gene transfer in the context of an
in vitro model of LPS-induced inflammation, since this cell type is pivotal as the
major producer of the prototypic inflammatory cytokine TNF-a, which mediates
many of the immunopathological features of septic shock (Beutler et al., 1985;
Dinarello, 1997; Cohen, 2002). Macrophages are known to be one of a number of
cell types, including B and T lymphocytes, dendritic cells and fibroblasts, that are not
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easily infected by adenovirus vectors due to a low level of expression of the
adenovirus receptor CAR (Hidaka et al., 1999; Kaner et al., 1999; Schmidt el al.,
2000; Stockwin et al., 2002). Several studies have demonstrated that such low levels
of adenoviral infection efficiency can be surmounted by overexpression of CAR in
the target cell (Hidaka et al., 1999; Schmidt et al., 2000; Nalbantoglu et al., 2001;
Walters et al., 2001; Stockwin et al., 2002).
For the purpose of our studies, we chose to investigate the value of using
CaPi precipitates to enhance non-specific binding of adenovirus to macrophages, and
consequently to improve gene transfer of elafin to these cells. This technique has
previously been used to augment adenoviral gene transfer to airway epithelia both in
vitro and in vivo (Fasbender et al., 1998; Walters et al., 2001).
In this study, infection ofmacrophages with adenovirus was also shown to be
markedly enhanced by introducing virus to cells in the presence of CaPi co-
precipitates. Indeed, this approach facilitated an infection efficiency around 100% at
a viral moi of 100, as visualised using the Ad-lacZ reporter construct (Figure 1).
Moreover, increasing the efficiency of viral uptake also meant that a considerable
level of elafin overexpression could be achieved in these macrophages (Figures 2 and
3). The findings of this investigation are very similar to those of Fasbender et al.
(1998) with regards to the observation that optimal transgene expression was
9+ •
obtained on addition of 4mM Ca to form CaPi precipitates (Figure 2). These
findings suggest that perhaps the stoichiometry of Ca2+ to Pi may be optimal for
precipitate formation at this concentration. While the macrophages appeared to be
directly activated by CaPi precipitates, likely due to phagocytosis of the particles
thus inducing release of TNF-a (Figure 4), this inflammatory response did not lead
to any dampening of the cells' subsequent pro-inflammatory response to LPS (Figure
5).
An important point to note is that the levels of elafin measured from Ad-
elafin-infected cells could be extremely variable from assay to assay. In general,
however, macrophages infected with Ad-elafm at moi 100 secreted between 100-
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300ng/ml elafin (around 10nM-30nM) and retained around 2-40ng/ml (0.2nM-4nM)
intracellularly (Figures 2, 3, 6 and 10). The levels of elafin secreted by Ad-elafin-
infected macrophages were therefore within a similar range to those levels of
synthetic elafin peptide (lOnM-lOOnM) found to be effective in down-regulating the
effects of LPS in serum-containing medium in Chapter 4. The lack of an observed
effect of secreted elafm in this chapter, and the potential importance of measurable
levels of elafin retained intracellularly by Ad-elafm-infected cells, will be discussed
in section 5.3.3.
To date, two other studies have measured elafin levels produced by Ad-
elafin-infected macrophages. Simpson et al. (2001a) infected human monocyte-
derived macrophages with Ad-elafin at moi 50 without CaPi precipitates, and
reported maximum secreted elafin levels of 11.6ng/ml (of which up to around
1.5ng/ml may be attributable to endogenous human elafin). The same study also
reported adenoviral infection efficiency of macrophages of approximately 16%, in
agreement with similarly low rates of infection reported by others (Haddada et al.,
1993; Schneider et al., 1997; Worgall et al., 1999). Recent work carried out in our
laboratory, concurrently with studies described here, demonstrated that pre-
complexing Ad-elafin with the cationic liposome lipofectamine could also enhance
adenoviral gene delivery to human (monocyte-derived) macrophages (Henriksen et
al., 2004); the study by Henriksen et al. (2004) reported levels of elafin secretion
similar to those described here, using Ad-elafin at moi 100. These techniques thus
represent a vast improvement on previous protocols for adenovirus-mediated gene
transfer to macrophages.
5.3.2. The effect of LPS on elafin production by Ad-elafin-infected murine
macrophages
Prior to investigating the effects of elafm overexpression on the response of
macrophages to LPS, it seemed important firstly to establish how LPS stimulation
would affect the elafin transgene in adenovirally-infected cells.
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On consideration of the work of Simpson et al. (2001a), which reported that
LPS can upregulate the elafin transgene in vitro (in A549 cells and human
macrophages) and in vivo (murine lungs), it also seemed valuable to examine the
effects of LPS on elafin production by Ad-elafin-infected murine macrophages in
this system. This earlier work had been prompted by the knowledge that LPS could
stimulate the MCMV promoter, due to the presence of LPS-responsive elements
(Loser et al., 1998); the MCMV promoter is incorporated upstream of the elafin
transgene in the Ad-elafin construct (Sallenave et al., 1998). Simpson et al. (2001a)
demonstrated that 24-hour incubation of A549 cells with supraphysiological
concentrations of LPS from l-100pg/ml significantly augmented elafin secretion,
most notably by 2.5-fold at lOOpg/ml; although elafin secretion by macrophages was
also upregulated by LPS in their study, values did not reach significance.
In this investigation, upregulation of the elafin transgene was demonstrated
over a 4-hour incubation period, at much lower concentrations of LPS (Figure 6).
Secretion of elafin was significantly augmented by as little as 5ng/ml LPS, while
significant increases in intracellular elafin were observed on addition of 500ng/ml
LPS or more (Figure 6); these findings suggest that elafin may be produced by cells
predominantly as a secretory protein, and that elafin secretion following promoter
activation is sensitive to low levels of LPS. In the peripheral blood of healthy
humans, only small serum concentrations of around 3-10 pg/ml LPS are detectable
(Casey et al., 1993; Opal et al., 1999). However, elevated systemic LPS levels with
concentrations exceeding 500pg/ml are characteristic in patients with severe sepsis
(Opal et al., 1999). As shown in Figure 6, 0.5ng/ml (500pg/ml) LPS also elicited an
increase in elafin secretion, although this was not statistically significant. It is
therefore feasible that elafin production by Ad-elafin-infected macrophages may be
upregulatable by patho-physiologically relevant concentrations of LPS, and in this
regard could provide a negative feedback mechanism in inflammatory conditions
such as sepsis.
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5.3.3. The effect of elafin gene augmentation on the inflammatory response of
RAW 264.7 murine macrophages to LPS
Before studying the effects of elafin overexpression on the LPS-mediated
activation of macrophages, the response of these cells to adenoviral infection in the
absence of further stimulation was investigated. Adenoviral infection of
macrophages with all constructs induced a highly significant release of TNF-a
(Figure 7). However, an important finding for our studies was that the differences
between the response to each construct were non-significant, and so subsequent
findings could be analysed in the absence of concerns surrounding baseline responses
to adenoviral infection. The observation that adenoviral infection of macrophages
was associated with significant TNF-a secretion came as little surprise, since
macrophages are known to internalise adenovirus and initiate an inflammatory
immune response (Kuzmin et al., 1997; Worgall et al., 1997). In spite of
internalisation and clearance of adenovirus by macrophages in vivo, it is important to
note that macrophage expression of adenoviral transgene is in fact feasible in vivo
over a period of several days (Danel et al., 1998; Worgall et al., 1999).
The most edifying findings of this chapter were obtained from data shown in
Figures 8 and 9. Ad-elafin-infected macrophages were significantly hypo-responsive
to LPS, as compared with uninfected cells or with cells that had been infected with
the control constructs Ad-dl70/3 (empty vector) or Ad-m-eotaxin.
As mentioned in the 'Results' section, the eotaxin construct was chosen for
these studies as it encodes a secreted protein of very similar molecular weight to
elafin, but which would perhaps not be expected to play a modulatory role in the
LPS-induced activation of macrophages. The findings of this study indeed suggest
that it does not interfere with the TNF-a response of macrophages to LPS (Figures 8
and 9). The same observation was made with cells infected with Ad-dl70/3, therefore
it is apparent that adenoviral infection of macrophages per se does not provoke a
general metabolic inhibition leading to suppression ofTNF-a secretion.
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Two further adenoviral constructs were employed as potential controls, and
these were selected since it was anticipated that they would act as positive controls
for inhibition of an inflammatory response. The Ad-lKB construct encodes a super-
repressor of transcription factor NF-kB activity, a mutated IicBa resistant to
phosphorylation and degradation; this vector has previously been shown to strongly
inhibit NF-kB activity in human intestinal epithelial cells, resulting in down-
regulation of multiple proinflammatory molecules (Jobin et al., 1999). With
particular relevance to the work described here, it is known that LPS-induced TNF-a
production by macrophages is regulated by NF-kB (Shakhov et al., 1990). In
accordance, infection of the RAW 264.7 macrophage cell line with Ad-lKB
significantly suppressed the TNF-a response of these cells to LPS stimulation
(Figure 8). As expected, no similar effects were observed on transfer of Ad-hcB-
conditioned media to uninfected cells since the anti-inflammatory activity of IkB
results exclusively from its inhibition of NF-kB in the cytoplasm (Baeuerle and
Baltimore, 1988) (Figure 9).
The second 'positive' control construct used in these assays was an
adenovirus vector encoding murine SLPI (Ad-mSLPI). While SLPI overexpression
has previously been shown to inhibit the TNF-a response of macrophages to LPS
(Jin et al., 1997; Zhu et al., 1999), the system used to augment SLPI here is novel,
and therefore the findings of this study also add to the knowledge surrounding
functions of this molecule. The secretory nature of SLPI would suggest that it may
act as an extracellular mediator to modulate macrophage activation by LPS.
However, as discussed in Chapter 4, separate studies have failed to demonstrate any
role for extracellular SLPI in down-regulating LPS-mediated TNF-a secretion by
macrophages (Zhang et al., 1997; Sano et al., 2003); another group demonstrated
that recombinant SLPI also failed to attenuate macrophage nitrite production in
response to LPS (Zhu et al., 1999). One possible explanation for these findings could
relate to the importance of pre-incubating peptide with LPS prior to cellular
stimulation (suggesting unfavourable LPS-binding kinetics), since this step was
found to be critical in the modulation of LPS activity by elafin in Chapter 4. In this
regard, it is interesting to note that conditioned media from neither Ad-elafin- nor
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Ad-mSLPI-infected cells could dampen the TNF-a response of uninfected
macrophages to LPS (Figure 9). Figure 10 provides data pertaining to measured
elafin levels produced by Ad-elafin-infected cells, and it is notable that secreted
elafin concentrations were around lOOng/ml (approximately lOnM). Pre-incubation
of lOnM elafin peptide with LPS prior to macrophage stimulation was shown to
significantly down-regulate TNF-a release in analogous culture conditions in
Chapter 4 (Figure 5B). Given that incubation of peptide inhibitor with LPS prior to
stimulation appears to be a key determinant of this effect, it may have also been
informative to pre-incubate conditioned media with LPS before addition to cells; the
execution of such experiments was unfortunately prohibited by time constraints.
Nonetheless, as alluded to in the 'Results' section, a number of previous
studies have shown that SLPI is capable of exerting anti-inflammatory effects
intracellularly (Zhu et al., 1999; Mulligan et al., 2000; Taggart et al., 2002).
Accordingly, Ad-mSLPI-infected macrophages were found to be significantly hypo-
responsive to LPS in this study, and the magnitude of inhibition of TNF-a release
closely paralleled that induced by Ad-elafin infection (Figure 8). In the case of cells
overexpressing elafin or SLPI (or indeed IkB), the inhibition of TNF-a release was
more profound when conditioned media were removed and replaced with fresh
media prior to LPS stimulation; this could be due to the removal from the milieu of
cell-derived LPS-catalysing molecules such as LBP, and provides further evidence to
suggest that extracellular elafin and SLPI play no part in suppression of the TNF-a
response in these assays.
Appendix V at the end of this chapter provides a diagrammatic representation
of the proposed LPS signalling pathway, as previously discussed in Chapter 1. The
pathway leading to activation of transcription factor NF-kB may represent the most
likely candidate for inhibition by elafin (particularly on consideration of studies
performed using SLPI, discussed below), and is a critical pathway for LPS-mediated
TNF-a production (Shakhov et al., 1990; Baeuerle and Henkel, 1994; Eigler et al.,
1997; Mannel and Echtenacher, 2000). However, other intracellular pathways
downstream of TRAF6, involving mitogen-activated protein kinases (MAPKs) such
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as Jun N-terminal kinase (JNK), p38 and extracellular signal-related kinase (ERK),
and the transcription factor activated protein 1 (AP-1), may also be involved in the
TNF-a response to LPS (Cao et al., 2002; Kiemer et al., 2002; Comalada et al.,
2003; Marshall, 2003). Potentially, elafin could also interfere with phosphorylation
of any of these MAPKs, causing inhibition of downstream signalling and thus
inhibition of AP-1 activation. The diagram in Appendix V also includes potential
points of elafin interaction with the pathway (including those proposed in Chapter 4),
some ofwhich are still to be discussed here.
In evaluating the anti-inflammatory effects of Ad-elafin demonstrated in
Figure 8 of this chapter, it is perhaps most instructive, given the similarity between
these two molecules, to firstly consider the findings obtained by others with SLPI.
Earlier work carried out by Jin et al. (1997) demonstrated that macrophages
derived from a mouse line naturally resistant to LPS (C3H/HeJ) constitutively
overexpress SLPI, in contrast with macrophages that display sensitivity to LPS, such
as those derived from the C3H/HeN mouse line. This evidence for an important role
for SLPI in conferring LPS-unresponsiveness in C3H/HeJ mice has been eclipsed by
the discovery in this strain of a point mutation in the intracellular region of the Tlr4
gene, causing abrogation of downstream signalling and therefore LPS-
hyporesponsiveness (Poltorak et al., 1998; Qureshi et al., 1999); this discovery was
confirmed in Tlr4 knockout mice (Hoshino et al., 1999). TLR4, the product of this
gene, is now recognised as the signal-transducing receptor for LPS in mammalian
species (reviewed by Kopp and Medzhitov, 2003; Takeda et al., 2003). Interestingly,
in the Jin et al. (1997) study, LPS hyporesponsiveness could be restored by
interferon-y (IFN-y), and a recent study has demonstrated that IFN-y enhances
surface expression of TLR4 in human monocytes and macrophages (Bosisio et al.,
2002).
A recent study by Sano el al. (2003) sought to further investigate the
hypothesis of Jin et al. (1997) concerning a role for SLPI in the LPS-
hyporesponsiveness of macrophages from C3H/HeJ mice, and concluded that SLPI
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overexpression was not a factor. However, this study only investigated the effects of
extracellular SLPI on LPS-induced TNF-a secretion, and therefore this conclusion
cannot be drawn from their findings. Indeed, these observations (along with those
made here) serve to strengthen the evidence for an intracellular role for SLPI, since
the experiments carried out by Jin et al. (1997) also involved transfer of the SLPI
gene to macrophages; transfection of macrophages with SLPI suppressed the LPS-
induced activation of NF-kB and production of nitric oxide and TNF-a (Jin et al.,
1997). Interestingly, Jin et al. (1998) have also shown that transfection of
macrophages with SLPI can inhibit nitric oxide production in response to gram-
positive lipoteichoic acid.
Furthermore, an investigation carried out by Lentsch et al. (1999a)
demonstrated, in an IgG immune complex rat model of lung injury (which induces a
pathophysiology similar to sepsis), that exogenous SLPI reduced lung inflammation
by reducing activation of NF-kB; inhibition of NF-kB activity by SLPI was
associated with elevated levels of lung IkBP (Lentsch et al., 1999a). The anti¬
inflammatory effect of SLPI in this case was shown to be targeted at cell types other
than macrophages, for example by decreasing neutrophil influx through blockade of
expression of the adhesion molecule ICAM-1 by endothelial cells (Lentsch et al.,
1999a). More recently, work carried out using SLPI-deficient (SLPI"'") mice, which
show a higher mortality rate from endotoxin shock than wild-type mice, has
demonstrated that macrophages derived from SLPI"7" strains have increased NF-kB
DNA binding activity and suppressed IkBP expression during LPS stimulation
(Nakamura et al., 2003).
Several investigators have specifically suggested that SLPI may play a
prominent intracellular role in dampening macrophage responsiveness to LPS, and
that this may involve inhibition of the signal transduction pathway leading to NF-kB
activation (see Appendix V). An important finding was that transfection of
macrophages with a non-secretory (cytosolic) form of SLPI blocked their LPS-
mediated release of TNF and nitrite (Zhu et al., 1999). Moreover, a more recent
study has demonstrated that SLPI can prevent LPS-induced NF-kB activation by
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preventing degradation of the regulatory proteins interleukin-1 receptor-associated
kinase (IRAK), IkBcx (without affecting phosphorylation or ubiquitination) and IkBP
(Taggart et al., 2002). This inhibition was shown to be dependent upon the
antiproteinase activity of SLPI since an oxidised form of the molecule could not
elicit these effects. The importance of antiproteinase activity is in agreement with the
work of Mulligan et al. (2000), who have shown that SLPI mutants with reduced
protease-inhibitory capacity (due to substitutions at Leu7 , known to be critical for
binding of SLPI to serine proteases (Eisenberg et al., 1990)) are less able to inhibit
NF-kB activation than wild-type SLPI, in IgG immune complex-induced alveolitis in
rats. This study found that the suppressive effects of SLPI were most closely linked
to its trypsin-inhibitory activity (Mulligan et al., 2000). The two latter groups have
both hypothesised that SLPI's anti-inflammatory effects may thus be mediated by
inhibition of intracellular proteases of the proteasome pathway, and subsequent
inhibition of release and nuclear translocation ofNF-kB.
The studies of Taggart et al. (2002) and Mulligan et al. (2000) both involved
use of extracellular SLPI peptides, and these groups suggested that cellular
internalisation of SLPI was a critical pre-requisite for its anti-inflammatory activity.
Previous work has demonstrated that SLPI binds with high affinity to a receptor on
the surface of monocytes and is internalised by these cells (McNeely et al., 1997).
The small size of molecules such as elafin and SLPI (9.9 kDa and 11.7 kDa
respectively) may aid their access to the intracellular environment, since no evidence
has been reported of internalisation of the larger (52 kDa) serine protease inhibitor
ai-PI. It would be interesting to perform experiments involving pre-incubation of
elafin peptides with macrophages prior to LPS stimulation, since this may provide a
more informative answer to the questions of whether elafin uptake takes place and to
what degree, and whether this uptake has an effect on LPS signalling and
macrophage activation. Although a low level of elafin was detected in the lysates of
non-virally-infected cells that had been incubated with elafin-conditioned media
(Figure 10B, bars 3 and 4), these levels did not correlate with the differing
concentrations of elafin measured in media 23 hours or 4 hours post-infection
(Figure 10A, bars 3 and 4); moreover, it is unclear whether elafin measured in lysates
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had been taken up by cells, or was representative of elafin bound to the cell surface
on lysis.
Chapter 4 demonstrated that exogenous elafin peptides could act to either up-
regulate or down-regulate LPS-mediated TNF-a secretion, depending on the serum
content of the surrounding milieu. In serum-containing conditions parallel with those
investigated in this chapter, elafin exerted anti-inflammatory effects that required
complexing of elafin with LPS prior to stimulation. While it is possible that these
effects could, at least partly, be attributed to internalisation of elafin from medium
and subsequent elafin activity intracellularly, the observation that extracellular
elafin-LPS binding was critical suggests that this may not be the case. On the other
hand, if a hitherto unidentified elafin receptor exists on the surface of myeloid cells,
then it could be speculatively suggested that elafin-LPS complexes may be targeted
to a pathway leading to dampening of inflammatory responses. It seems more likely
that the anti-inflammatory effects of extracellular elafin observed in Chapter 4 result
from direct binding of the peptide to LPS, and interference of the subsequent LPS
interaction with molecules of the receptor complex, such as LBP, CD 14 and the
TLR4-MD-2 complex.
In any case, our study demonstrates that Ad-elafin infection of macrophages
renders them hypo-responsive to LPS, and that this activity does not relate directly to
elafin secreted by these cells. Thus, it is suggested that elafin overexpression may
also modulate macrophages responses to LPS from within the cell. Similar to the
findings obtained by others with SLPI (and corroborated here), elafin gene transfer to
macrophages appears to interfere with the LPS signalling pathway regulating TNF-a
release, and this inhibition is most likely to occur ultimately through inhibition of
NF-kB activation (Shakhov et al., 1990).
Indeed, a study by Henriksen et al. (2004) from our group, published during
the writing of this chapter, has shown that adenovirus-mediated overexpression of
elafin (and SLPI) can reduce TNF-a secretion by monocyte-derived macrophages in
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response to LPS; moreover, these effects were associated with decreased activation
ofNF-kB, and concomitant inhibition of IkBci degradation (Henriksen et al., 2004).
It is therefore eminently possible that elafin elicits anti-inflammatory effects
in macrophages intracellularly by inhibiting degradation of IkB via the proteasome
pathway. The aforementioned studies with SLPI have suggested the importance of its
antiproteinase activity for exertion of anti-inflammatory activity, and the same may
hold true for elafin. Inhibitors of the proteasome pathway have previously been
shown to attenuate activation ofNF-kB (Griscavage et al., 1996; Haas et al., 1998).
With regards to the effects of proteinase inhibitors, the proteasome pathway is
certainly known to possess trypsin and chymotrypsin-like activities, although the
precise nature of the proteases involved in this process are not well characterised
(Rivett, 1989; Hilt and Wolf, 1996). Although trypsin and chymotrypsin are not
among the serine proteases which elafin specifically targets, it is possible that the
action of other serine proteases, for example those with elastase-like activity, may be
inhibited by elafin. In this way, elafin could potentially prevent proteasome-mediated
degradation of IkB and thus inhibit the activation of NF-kB; proteolysis of IkB is
known to be essential for induction of NF-kB, since phosphorylation and
ubiquitination are insufficient to inactivate IkB, but are a necessary pre-requisite for
targeting by the proteasome (Henkel et al., 1993; Alkalay et al., 1995; Lin et al.,
1995). It would thus be interesting to design similar experiments to those carried out
using SLPI in the aforementioned studies, whereby elafin's antiproteinase activity
could be obliterated or compromised.
Although the proteasome may be regarded as a major potential target of
elafin in dampening macrophage responsiveness to LPS, it is also possible that these
effects are mediated at another point in the intracellular pathway. Elafin may
potentially bind and inactivate a component of the pathway upstream of the IkB/NF-
kB complex, and this activity may not necessarily be dependent on protease
inhibition. For example, the food derivative curcumin has been shown to block NF-
kB activation by interfering with events upstream of IKK (Jobin et al., 1999). It is
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feasible that elafin could interfere with signal-transmitting adapter proteins such as
MyD88, TIRAP or TRAF6, perhaps even by binding to them directly.
Furthermore, intracellular LPS receptors of the NOD protein family
(described in depth in Chapter 1) may potentially be a target for elafin, assuming that
internalised LPS may also be recognised by these proteins independently of TLR4.
NOD2, for example, has been specifically demonstrated in macrophages (Pauleau
and Murray, 2003). However, the role played by NOD receptors in recognition of
LPS is controversial; for instance, macrophages with a complete disruption of TLR4
are non-responsive to LPS (Hoshino et al., 1999), suggesting that if NOD proteins
are indeed unique receptors for LPS, their activity must be downstream of TLR4.
Potentially, macrophages may also recognise internalised LPS via TLR4 in
the cytosol, as demonstrated recently in intestinal and pulmonary epithelial cells
(Hornef et ah, 2002; Hornef et al., 2003; Guillot et al., 2004). Intracellular TLR4-
mediated recognition of LPS has not yet been demonstrated in macrophages, but
could represent an additional target for inhibition by elafin.
The data in this chapter may also provide a further rationale to explain the
findings of the recent study using transgenic mice expressing human elafin
(Sallenave et al., 2003). These mice express elafin cDNA under the control of the
same MCMV promoter incorporated into the Ad-elafin vector used here. In that
study, elafin transgenic mice produced lower levels of serum TNF-a than wild-type
mice, in response to systemic or intratracheal LPS administration. Moreover,
peritoneal macrophages from elafin transgenic mice were hyporesponsive to LPS ex
vivo, in terms of TNF-a, MCP-1 and MIP-2 secretion (Sallenave et al., 2003). The
studies performed here aimed to use serum-containing conditions in order to model
the effects of Ad-elafin on the inflammatory response of macrophages to LPS in the
circulation. The findings described in this chapter appear to corroborate those of
Sallenave et al. (2003), and further suggest that the dampening of systemic
inflammatory responses in elafin transgenic mice may be attributable, at least in part,
to intracellular effects of elafin on the LPS signalling pathway.
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5.4. SUMMARY
The work described in this chapter has demonstrated that adenovirus-
mediated overexpression of elafin in murine macrophages suppresses their
inflammatory response to LPS. These data also suggest that elafin acts intracellularly
to dampen macrophage responsiveness to LPS, since the anti-inflammatory effect of
elafin gene augmentation appeared to be independent of elafin released
extracellularly; while an anti-inflammatory effect of exogenous elafin was
demonstrated in similar conditions and with comparable levels of elafin in Chapter 4,
prior interaction of elafin with LPS was shown to be crucial to this result.
Adenovirus-mediated elafin gene transfer may also provide cells with a negative
feedback mechanism which is amplified during inflammation, since LPS was shown
to upregulate elafin production by Ad-elafin-infected macrophages.
These findings suggest that adenoviral augmentation of elafin may be of
benefit in inflammatory conditions such as sepsis, wherein suppression of
macrophage responses to LPS is a desirable outcome, and provide further evidence
that elafin may play an important role as a modulator of innate immune responses.
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APPENDIX V
Schematic diagram of the proposed LPS signalling pathway in macrophages,
leading to transcription factor activation and gene transcription (including
points of potential elafin interaction)
In serum, LPS-binding protein (LBP) catalyses transfer of LPS monomers to membrane-
bound CD14 (mCD14). Binding of LPS to CD14 leads to association of CD14 with the Toll¬
like receptor 4 (TLR4)-MD-2 complex (potential LPS recognition by intracellular TLR4 and
NOD receptors is also shown). Intracellular signalling depends on interaction of the
intracellular TLR domain, TIR (Toll/IL-1 receptor homology domain), with IRAK (IL-1
receptor-associated kinase); this process is facilitated by the adapter proteins, MyD88
(myeloid differentiation protein 88) and TIRAP (TIR domain-containing adapter protein,
also known as MyD88 adapter-like protein or Mai). IRAK is phosphorylated and associates
with the TNF-receptor-associated factor-6 (TRAF6), leading to activation ofMAP kinases or
the IkB kinase (IKK) complex. To induce NF-kB activation, IKKs phosphorylate IkB at
serine residues, and then IkB undergoes ubiquitination at lysine residues. The
polyubiquitinated IkB subunit remains complexed with NF-kB, but is then selectively
degraded by the nonlysosomal, ATP-dependent 26S proteasome (multicatalytic proteinase)
complex or MPC. On release, NF-kB translocates to the nucleus and induces transcriptional
activation of a host of cytokines and effector molecules, including TNF-a.
Points of potential elafin inhibition are indicated on the diagram. These are discussed in the
'Discussion' section of Chapter 5. Elafin is represented by a red diamond. Question marks
indicate unconfirmed steps or interactions. Red 'X' across an arrow denotes potential elafin-
mediated inhibition of a step in the pathway.
Diagram and diagram description are adapted from reviews by Verma and Stevenson (1997),
O'Neill (2002), Cohen (2002), Kopp and Medzhitov (2003) and Marshall (2003).
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CHAPTER 6
THE EFFECT OF ELAFIN GENE AUGMENTATION ON
ANTIMICROBIAL ACTIVITY OF MURINE EPITHELIAL
CELLS
6.1. AIMS AND BACKGROUND
Having established in the preceding results chapters that elafin, similar to
other antimicrobial peptides with which it shares several biochemical characteristics
(such as low molecular weight, cationicity, heavy disulphide bonding and tissue
distribution at mucosal sites), can bind to and modulate the pro-inflammatory activity
of LPS, it also seemed logical to develop previous studies concerning elafin's
antibacterial activity. Thus the primary aim of the work described in this chapter was
to further investigate the antimicrobial properties of elafin, using the Ad-elafin
vector. As discussed in Chapter 1, it has previously been demonstrated that elafin
peptides possess antimicrobial activity against Staphylococcus aureus and
Pseudomonas aeruginosa in vitro (Simpson et al., 1999; Meyer-Hoffert et al., 2003),
and that adenoviral augmentation of elafin can protect the murine lung against acute
injury mediated by P. aeruginosa in vivo (Simpson et al., 2001b).
Consequently, the experiments described in this chapter were performed in
order to expand and rationalise these findings by using an ex vivo model of airway
epithelium. We wished to investigate whether adenoviral over-expression of elafin
would confer to murine epithelial cells enhanced antimicrobial activity against the
pulmonary pathogens S. aureus and P. aeruginosa, Gram-positive and Gram-
negative organisms respectively. For this purpose, the antimicrobial activities of Ad-
elafin-infected murine Clara cells (DJS2/2) and primary tracheal epithelial cells were
studied. It must be noted at this point that preliminary experiments investigating the
antimicrobial activity of Clara cells were carried out using only P. aeruginosa.
Expertise in the preparation of differentiated murine tracheal epithelium
existed locally within a related research group (Davidson et al., 2000); consequently,
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the majority of the antimicrobial assays described in this chapter were performed in
collaboration with Dr. Alison Maxwell and Dr. Julia Dorin of the MRC Human
Genetics Unit, Western General Hospital, Edinburgh.
For investigation of the antimicrobial activity of Ad-elafin, the bacteria
P.aeruginosa and S. aureus were selected for these studies for five main reasons.
Firstly, both can be considered as versatile and dangerous pathogens in humans, in
particular in the context of pulmonary infection in cystic fibrosis (CF) patients
(Govan and Nelson, 1992; Hutchison and Govan, 1999), in settings of immune
compromise (Maurer et al., 1992; Musher et al., 1994; Dropulic et al., 1995) and in
the pathogenesis of sepsis (Dudley, 1990; Bone, 1994). Secondly, we wished to
study the activity of Ad-elafin-infected cells against both a Gram-negative (P.
aeruginosa) and a Gram-positive (5". aureus) organism. Thirdly, novel strategies to
treat infection caused by these organisms are desirable since they are known to
harbour mechanisms which confer to them resistance to common antimicrobial
agents (Hancock, 1998; Smith and Jarvis, 1999). Fourthly, tremendous experience in
the biology of these organisms exists locally within a related group involved chiefly
in the research of CF microbiology (Govan and Deretic, 1996). Finally, since
synthetic elafin had previously been demonstrated by Simpson et al. (1999) to
possess antimicrobial activity against both P. aeruginosa and S. aureus, it also
seemed prudent to develop our understanding of Ad-elafin using these organisms.
The following sections briefly discuss P. aeruginosa and S. aureus.
6.1.1. Pseudomonas aeruginosa
P. aeruginosa is a ubiquitous environmental non-fermentative Gram-negative
bacillus, found in habitats such as soil, water, plants and vegetables (Green et al.,
1974; Vasil et al., 1986). In the hospital setting, P. aeruginosa can often be cultured
from sites including sinks, respirators and humidifiers, as well as from the hands of
medical personnel (Pitt, 1986). Furthermore, recent findings have indicated that P.
aeruginosa is the fourth leading cause of nosocomial infection and the leading cause
of hospital-acquired pneumonia (Jarvis and Martone, 1992).
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This organism is regarded as an opportunistic pathogen, since it typically
causes disease only in individuals with impaired host defences and has difficulty
accessing healthy tissues and adhering to host cells (Grimwood, 1992). P.
aeruginosa can readily cause infection in patients who are generally
immunosuppressed and therefore predisposed to a variety of bacterial and fungal
infections, such as neutropenic patients undergoing chemotherapy or individuals
suffering from AIDS (Bendig et al., 1987; Franzetti et al., 1992; Kielhofner et al.,
1992). Alternatively, infection may result when the host's defences are artificially
breached as in the case of assisted ventilation or by the presence of an indwelling
urinary catheter (Neu, 1983). P. aeruginosa is also one of the top three pathogens
responsible for sepsis due to Gram-negative bacteria (along with E. coli and K.
pneumoniae) (Dudley, 1990). In terms of conditions more specific to the
pathogenesis of P. aeruginosa, this bacterium is more commonly associated with
bacteraemia in severe burn victims (McManus et al., 1985; Tredget et al., 1992),
acute ulcerative keratitis in users of extended-wear contact lenses (Alfonso et al.,
1986; Zhao and Panjwani, 1995), and chronic lung infection in CF patients (reviewed
by Govan and Deretic, 1996). CF patients in particular are highly susceptible to
pulmonary infections with P. aeruginosa; indeed, over 90% of CF patients are
colonised by P. aeruginosa by the time they reach adulthood (Hutchison and Govan,
1999). Chronic infection with this organism is also the cause of death in over three-
quarters of CF patients (Pier, 2002).
Several host- and bacterial-derived factors contribute to colonisation of the
airways of CF patients by P. aeruginosa. CF is an autosomal recessive disorder
resulting from mutations in the gene encoding the cystic fibrosis transmembrane
conductance regulator (CFTR), a cyclic AMP-dependent chloride ion channel
localised to the apical plasma membrane in epithelial cells (Goldberg and Pier,
2000). The increased pulmonary susceptibility of CF patients to bacterial pathogens
is associated with airway surface liquid (ASL) dehydration, decreased transport
velocity, mucus hypersecretion, and a concomitant deficiency in airway
antimicrobial peptide activity (reviewed by Pier, 2002). Recent findings have
demonstrated that CFTR itself may act as a receptor for P. aeruginosa and mediate
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its epithelial uptake and clearance in healthy lungs (Pier et al., 1996; Pier et al, 1997;
Pier, 2000). Moreover, CFTR has been proposed as an epithelial pattern recognition
molecule (PRM) responsible for the binding, extracting and endocytosis of P.
aeruginosa LPS, leading to activation of NF-kB (Schroeder et al., 2002). CF
epithelial cells may also represent a more attractive substrate for P. aeruginosa
adhesion, due to their increased surface expression of the glycolipid asialo GMi
(Saiman and Prince, 1993).
P. aeruginosa elaborates an array of potent virulence factors which may
contribute to its pathogenicity in the compromised patient. These include LPS,
exotoxin A, leukocidin, exoenzyme S, bacterial elastase, phospholipase C, proteases
and pigments such as pyocyanin (reviewed by Wilson and Dowling, 1998). Perhaps
most strikingly, P. aeruginosa can convert from a non-mucoid phenotype to a
mucoid phenotype, characterised by production of the exopolysaccharide alginate;
this conversion to mucoidy is synonymous with chronic infection in CF following
initial colonisation by non-mucoid strains, and confers to the organism enhanced
antibiotic resistance and protection against host defences (Govan and Deretic, 1996).
The emergence of mucoid P. aeruginosa is often correlated with a poor prognosis
(Pedersen et al., 1992; Koch and Hoiby, 1993), forming the rationale for strategies to
eradicate the organism during the initial non-mucoid stages of colonisation (Valerius
et al., 1991; Frederiksen et al., 1997).
Effective antibiotic therapy of P. aeruginosa is hindered by the high intrinsic
resistance of this organism to antimicrobial agents (Hancock, 1998). The outer
membrane of P. aeruginosa has a low permeability for passage of antibiotics, while
the organism also employs multidrug efflux pumps and antibiotic-inactivating
enzymes such as (3-lactamases (Hancock and Woodruff, 1988; Poole et al., 1993;
Poole et al., 1996; Philippon et al., 1997; Hancock, 1998); the combination of these
factors renders treatment of P. aeruginosa extremely difficult.
Two strains of P. aeruginosa were used in this work, PAOl and J1385,
although the majority of experiments were performed using PAOl; both of these
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strains are non-mucoid. PAOl is the best characterised of all laboratory strains, and
indeed its complete genome sequence has recently been characterised (Stover et al.,
2000). This strain has been demonstrated to generate pulmonary pathology in rodent
models (George et al., 1993). P. aeruginosa J1385 is a CF clinical isolate.
6.1.2. Staphylococccus aureus
S. aureus is a Gram-positive coccus with a characteristic propensity to
arrange into clusters, for which humans may be considered a natural reservoir; S.
aureus is found often as part of the normal microflora of human skin, the upper
respiratory tract and the intestinal tract (Bachert et al., 2002). Between 30-50% of
healthy adults are colonised, with 10-20% persistently colonised, and those persons
colonised with S. aureus are at increased risk for subsequent infections (Casewell
and Hill, 1986; Wenzel and Perl, 1995). Staphylococcal colonisation rates are high
among patients with type 1 diabetes, intravenous drug users, individuals undergoing
haemodialysis, surgical patients and patients with AIDS (Tuazon and Sheagren,
1974; Tuazon et al., 1975; Yu et al., 1986; Weinke et al., 1992; Kluytmans et al.,
1995).
Although S. aureus is a commensal organism, it can also be considered as a
major pathogen with regard to both community-acquired and nosocomial infection.
S. aureus is a prominent causative agent of skin, soft tissue, respiratory, bone, joint
and endovascular disorders (Lowy, 1998), and the majority of these infections occur
in those with multiple risk factors for infection (Musher et al., 1994). The typical
pathological finding of staphylococcal disease is abscess formation, since leukocytes
are the primary host defence against S. aureus infection (Verdrengh and Tarkowski,
1997).
A minority of bacteraemic or local S. aureus infections can lead to sepsis,
and these cases are usually associated with risk factors such as immunosuppression,
chemotherapy or invasive procedures (Lowy, 1998). Pathophysiological effects of
staphylococcal sepsis are similar to those of Gram-negative sepsis, with fever,
hypotension and tachycardia in most cases, and progression to multiple organ failure,
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disseminated intravascular coagulation and death in severe cases (Lowy, 1998). S.
aureus is one of the most prevalent Gram-positive organisms in cases of sepsis
(Bone, 1994).
S. aureus is also closely associated with pulmonary disease in CF (Govan and
Nelson, 1992). S. aureus typically infects the lungs of CF patients in infancy, prior to
colonisation of lungs by P. aeruginosa in adolescence and adulthood (Govan and
Deretic, 1996). Pulmonary infections with S. aureus can usually be controlled with
aggressive antibiotic therapy, but effective clearance of these organisms allows
subsequent colonisation and chronic establishment of P. aeruginosa (Govan and
Deretic, 1996).
This organism exhibits a plethora of potent virulence factors, such as
peptidoglycan, enterotoxins, toxic shock syndrome toxin l(TSST-l), proteases and
hyaluronidase (reviewed by Lowy, 1998). Additionally, the increasing association of
S. aureus with antimicrobial resistance is a major concern for clinicians. While
expression of (3-lactamase by S. aureus confers to the organism resistance against
penicillin, the presence of the mec gene can confer resistance to practically all (3-
lactam antibiotics (reviewed by Hiramatsu et al., 2001). Such organisms are known
as methicillin-resistant S. aureus (MRSA), and are profoundly refractory to treatment
with conventional antibiotics. Indeed, the recent emergence of vancomycin-resistant
MRSA poses a major therapeutic challenge (Hiramatsu et al., 1997a; Hiramatsu et
al., 1997b).
The strain used in this study, S. aureus CI705, is a clinical isolate from a
patient with CF.
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6.2. RESULTS
6.2.1. The effects of elafin gene augmentation on the antimicrobial activity of Clara
cells against P. aeruginosa
It was hypothesised that overexpression of elafin, which in synthetic peptide
form has previously been shown to inhibit bacterial growth in vitro, could enhance
the antibacterial activity of airway epithelial cells against the common pathogens P.
aeruginosa and S. aureus. Initial experiments designed to investigate the effects of
Ad-elafin infection on the antimicrobial activity of epithelial cells used the murine
Clara cell line DJS2/2, described previously in Chapter 4, and assessed only activity
against the P. aeruginosa strain PAOl. These experiments were conducted using
conventional tissue culture conditions as described in the legend below Figure 1.
Several difficulties were encountered in the execution of these assays, and
subsequently the reproducibility of these experiments was poor. For example,
optimisation of the parameters for these investigations was hampered by a profound
inconsistency in initial bacterial numbers; attempts were made to standardise these
counts by measuring the absorbance of bacterial cultures, but this technique itself
was found to yield hyper-variable results. Moreover, numerous conflicting results
were obtained between assays and this hindered attempts to draw any solid
conclusions concerning the effects of Ad-elafin infection.
We initially postulated that infecting Clara cells would enhance their
antimicrobial activity against PAOl, on account of the previous demonstration that
elafin has inherent antimicrobial activity against this organism (Simpson et al.,
1999). On a few occasions Ad-elafin-infected cells seemed to display an enhanced
antimicrobial activity, but these findings were mirrored equally by experiments that
suggested no significant killing of bacteria. Thus, we originally surmised that the
assay conditions may not have been optimal for investigating the antimicrobial
activity of elafin. For instance, elafin secreted by the cells may have been too dilute
to exert an antimicrobial effect; equally, the bacterial numbers may have been too
great and so overwhelming the exogenous elafin. Furthermore, the antimicrobial
activity displayed by several similar peptides such as human P-defensins 1 and 2 has
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been shown to be salt-sensitive (Goldman et al., 1997; Bals et al., 1998b). The salt-
sensitivity of elafin's antimicrobial activity has not been investigated to date, but the
salt concentrations in tissue culture conditions used here may have potentially
affected bacterial killing by elafin. However, the salt concentrations of media were
not measured during these experiments.
To further our understanding of the lack of an observed elafin antimicrobial
activity against PAOl, Western blots were carried out to analyse the elafin content of
medium derived from antimicrobial assays (Figure 1). Firstly, the concentration of
elafin secreted by Ad-elafin-infected cells was shown to increase in a time-dependent
manner post-viral infection (lanes 1 and 2). No elafin was detected in medium taken
from cells that had not been infected with Ad-elafin (lane 4). Incubation of non-
virally-infected cells with PAOl was associated with the detection of an extra band
(demonstrated by an arrow labelled 'PAOl band'), and this band was shown to be
specific to the presence of bacteria in culture medium since it was present in lane 5
but not in lane 4. This band likely represents non-specific antibody interactions with
a bacterial product. Most interestingly, on comparison of media taken from Ad-
elafm-infected cells incubated either in the presence or absence of bacteria, it was
noted that elafin could not be detected in the media of cells that had been exposed to
PAOl (comparing lanes 2 and 3). These findings were supported by analysis of cell
supernatants by elafin ELISA (not shown). The observation that the 'PAOl band'
was present when both Ad-elafin-infected and non-virally-infected cells were
incubated with bacteria rules out the possibility that the band in lane 3 could be due,
for example, to detection of elafin bound to a higher molecular weight protein
derived from PAOl. No other bands were detected on analysis of media taken from
Ad-elafin cells incubated with PAOl. Thus we hypothesised that the lack of an
observed antimicrobial effect, in assays utilising Ad-elafin-infected Clara cells in
vitro, may be attributed to the potential metabolism or destruction of elafin by PAOl.
212
Chapter 6: The effect of elafin gene augmentation on antimicrobial activity of murine epithelial cells
± PAOl
EL 2d EL 6d EL 6d UN 6d UN 6d FL
- - + - + elafin
<—'PAOl' band
<- Elafin 9.9kDa
Lane 2 3 4 5 6
Figure 1. Elafin secreted by Ad-elafin-infected murine Clara cells is eradicated
by Pseudomonas aeruginosa PAOl
Murine Clara cells of the line DJS2-2 were grown to confluence in 96-well plates,
infected with Ad-elafin (moi 100) or vehicle alone and incubated for 2-6 days at
37°C in lOOpl DMEM lacking penicillin-streptomycin. lOOpl samples of medium or
medium containing PAOl were added and incubated with cells for 5 hours at 37°C.
Media were UV-inactivated and subjected to SDS-PAGE/ western blotting using
anti-elafin polyclonal antibody. 2d = medium from cells 2 days post-viral infection,
6d = medium from cells 6 days post-viral infection. + = PAOl added to cells, - =
medium only added to cells. EL = cells infected with Ad-elafin, UN = cells
uninfected with virus. 40ng of synthetic full-length elafin was used as a control (lane
6).
213
Chapter 6: The effect of elafin gene augmentation on antimicrobial activity ofmurine epithelial cells
6.2.2. Adenoviral infection of primary murine tracheal epithelium
In order to advance our understanding of the effects of elafin on the growth
and survival of bacteria, we resolved to use a cell system that eliminated the opacity
intrinsic to the aforementioned tissue culture conditions. Accordingly, primary
culture models of murine tracheal epithelium were generated and grown on semi¬
permeable membranes at an air interface, according to a technique developed by
Davidson et al. (2000), and these cultures were used to further investigate the
potential antimicrobial activity conferred by Ad-elafin.
In the previous section, viral infections of Clara cells were carried out
exclusively in the normal DMEM in which these cells are routinely cultured. It must
be noted that, in chronological terms, our laboratory group became aware of the
benefit of CaPi precipitates in enhancing viral infection efficiency subsequent to
completion of the above experiments. Moreover, the use of techniques to augment
adenoviral infection had been deemed unnecessary due to the presence of the
Coxsackie/adenovirus receptor in lung epithelium (Tomko et al., 1997). However,
several studies have reported poor adenoviral gene transfer to airway epithelia due to
low apical receptor expression, and an improvement in infection efficiency using
CaPi precipitates (Zabner et al., 1997; Fasbender et al., 1998). Hence, following the
success of utilising CaPi precipitates in infection medium for the macrophage
experiments described in Chapter 5, we decided to investigate whether this technique
would also enhance adenoviral infection of primary tracheal epithelium. Using Ad-
lacZ as a reporter construct, infection of tracheal epithelial cells was shown to be
ameliorated by adding virus in an infection medium comprising MEEM plus 4mM
2"F • • • • • • 2+Ca (generating CaPi precipitates formed with a final concentration of 5.8mM Ca
and 0.86mM Pi, as described in Chapter 5) (Figure 2). Infection efficiency was
satisfactory when virus was incubated with cells in the same type of medium used to
feed the cells from beneath the semi-permeable support membrane, Ultroser G
(USG) medium (Panel C). However, infection efficiency was enhanced 2-3-fold by
CaPi (Panel D), and therefore this infection medium was utilised for all subsequent
experiments.
214
Chapter 6: The effect of elafin gene augmentation on antimicrobial activity of murine epithelial cells
Figure 2. Adenovirus efficiently infects primary murine tracheal epithelial cells
and infection is enhanced by calcium phosphate (CaPi) precipitates
Primary tracheal epithelial cells derived from C57BL/6J were treated with vehicle
alone or Ad-lacZ at moi 100, and incubated for 18-20 hours at 37°C. Cells were then
subjected to X-gal staining. Blue colouration indicates expression of the P-
galactosidase gene.
PANEL A - no viral infection of cells, incubated in USG medium
PANEL B - no viral infection of cells, incubated in MEEM plus 4mM Ca2+
PANEL C - cells infected with Ad-lacZ (moi 100) in USG medium
PANEL D - cells infected with Ad-lacZ (moi 100) in MEEM plus 4mM Ca2+
USG medium = Ultroser G medium; MEEM = Minimum Essential Eagle's Medium
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Figure 3. Ad-elafin-infected primary murine tracheal epithelial cells secrete
high levels of elafin
Primary tracheal epithelial cells derived from C57BL/6J or BALB/c mice were
infected with Ad-elafin or Ad-lacZ (moi 100 for each) or vehicle alone and incubated
for 18-20 hours at 37°C. Cell inserts were then washed with both 105pi phosphate
buffer (0.008M K2HP04/ 0.002M KH2P04, pH 7.4) and 105pl phosphate
buffer/0.5% Triton-X. These two samples were then pooled and analysed by elafin
ELISA (see 'Materials and Methods'). Values represent either mean ± SD of n=3
experiments (C57B1/6J) or n=l experiment (BALB/c), each performed in triplicate.
For C57BL/6J cells, *** = significant difference, P<0.001, compared with uninfected
or Ad-lacZ-infected cells. For BALB/c cells, ### = significant difference, P<0.001,
compared with uninfected or Ad-lacZ-infected cells.
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Furthermore, considerable levels of elafin were secreted by Ad-elafin-
infected cells (Figure 3). Cells derived from two different mouse strains, C57B1/6J
and BALB/c, both secreted similar concentrations of elafin; neither of these cell
types secreted a significant level of protein detected by the anti-elafin antibody
unless infected with Ad-elafin (Figure 3), confirming previous observations in our
laboratory that the anti-human elafin antibody does not cross-react with any murine
protein.
6.2.3. The effects of elafin gene augmentation on the antimicrobial activity of
primary murine tracheal epithelium against P. aeruginosa
It should be noted prior to describing these experiments that, while two
strains ofmice were used initially to generate primary culture models, the majority of
experiments described herein were performed using cells derived from C57BL/6J
mice. The decision to persist with only one mouse strain was made due to restrictions
on both time and cost, while C57BL/6 mice were selected since cells derived from
this strain were characterised in the original paper by Davidson et al. (2000).
Moreover, this strain has previously been used in-house to generate both elafin
transgenic (Sallenave et al., 2003) and murine (3 defensin 1-deficient mice (Morrison
et al., 2002a). Antimicrobial assays involving the P. aeruginosa strain PAOl were
carried out exclusively using C57BL/6J cells, whereas those involving the strain
J1385 were performed using both C57BL/6J and BALB/c cells.
The first interesting observation to be drawn from these data is that untreated
tracheal cells were capable of killing PAOl, i.e. following 3-hour incubation with
cells the numbers of PAOl colonies recovered were lower than those added at the
outset (Figure 4). C57B1/6 mice have also been shown to effectively clear PAOl
following lung instillation in vivo (Cressman et al., 1998). In order to demonstrate
this phenomenon, and to illustrate a typical series of results provided by counting
colony forming units (cfu) of PAOl, Figure 4 shows the results of a single
experiment. Figure 5 shows the combined data from two separate experiments, with
cfu values expressed as a percentage of colony growth on uninfected cells. It should
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be noted that Triton-X was incorporated into the second phosphate buffer wash to
ensure removal of bacteria still adhered to the cell surface, following the first wash.
Ad-elafin infection of epithelium resulted in significantly enhanced survival
and growth of PAOl (Figures 4 and 5). In comparison with uninfected cells, PAOl
numbers were increased by approximately 440% on incubation with Ad-elafin-
infected cells (Figure 5). Infection of cells with Ad-lacZ resulted in a notable but
non-significant compromise of the ability of tracheal epithelium to kill PAOl
(Figures 4 and 5).
In order to investigate whether the facilitation of enhanced survival of PAOl
by Ad-elafin was specific to this strain of P. aeruginosa, we also examined the
effects of Ad-elafin on the clinical strain J1385. Although this investigation only
encompassed a single experiment (carried out in triplicate), a similar trend was
observed to that obtained with PAOl (Figure 6). Using cells derived from both
mouse strains, Ad-elafin resulted in an unequivocal augmentation of survival of
J1385 and this was significant compared with bacterial growth on either uninfected
or Ad-lacZ-infected cells (Figure 6). Uninfected BALB/c cells appeared to have
superior ability to kill J1385 (compared with the killing elicited by uninfected
C57BL/6J cells) and, accordingly, the growth of J1385 on Ad-elafin-infected
BALB/c cells was not as pronounced.
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Figure 4. Ad-elafin infection of primary tracheal epithelial cells derived from
C57B1/6J mice compromises their ability to kill Pseudomonas aeruginosa PAOl,
and enhances bacterial survival
Primary tracheal epithelial cells derived from C57BL/6J mice were infected with Ad-
elafin or Ad-lacZ (moi 100 for each) or vehicle alone and incubated for 18-20 hours
at 37°C. 20 nanolitres (nl) of a suspension ofPAOl was added to cells and incubated
for 3 hours at 37°C. Cell inserts were washed with both 105pi phosphate buffer and
105pl phosphate buffer/0.5% Triton-X, and washes plated on PIA. Agar plates were
incubated overnight at 37°C prior to colony counting. Representative data from one
of three similar experiments are shown. Values represent mean ± S.E., carried out in
triplicate except 'Initial no. of bacteria' where twelve replicates were performed. # =
significant difference, P<0.05, compared with uninfected cells.
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Figure 5. Ad-elafin-infected primary tracheal epithelial cells, derived from
C57B1/6J mice, significantly enhance survival of Pseudomonas aeruginosa
PAOl, compared with uninfected or Ad-lacZ-infected cells
Primary tracheal epithelial cells derived from C57BL/6J mice were infected with Ad-
elafin or Ad-lacZ (moi 100 for each) or vehicle alone and incubated for 18-20 hours
at 37°C. 20 nanolitres (nl) of a suspension of PAOl was added to cells and incubated
for 3 hours at 37°C. Cell inserts were washed with both 105pl phosphate buffer and
105pl phosphate buffer/0.5% Triton-X, and washes plated on PIA. Agar plates were
incubated overnight at 37°C prior to colony counting. Values represent mean ± S.E.
of n=2 experiments, each performed in triplicate. # = significant difference, P<0.05,
compared with uninfected cells.
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Figure 6. Ad-elafin infection of primary tracheal epithelial cells derived from
both C57B1/6J and BALB/c mice compromises their ability to kill Pseudomonas
aeruginosa J1385, and enhances bacterial survival
Primary tracheal epithelial cells derived from either mouse strain were infected with
Ad-elafin or Ad-lacZ (moi 100 for each) or vehicle alone and incubated for 18-20
hours at 37°C. 20 nanolitres (nl) of a suspension of J1385 was added to cells and
incubated for 3 hours at 37°C. Cell inserts were washed with both 105pl phosphate
buffer and 105pi phosphate buffer/0.5% Triton-X, and washes plated on PIA. Agar
plates were incubated overnight at 37°C prior to colony counting. Data are
representative of a single experiment. GRAPH A - cells derived from C57B1/6 mice.
GRAPH B - cells derived from BALB/c mice. Values represent mean ± S.E., carried
out in triplicate except 'Initial no. of bacteria' where twelve replicates were
performed. * = significant difference, P<0.05, compared with Ad-lacZ-infected cells.
# = significant difference, P<0.05, compared with uninfected cells.
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6.2.4. The effects of elafin gene augmentation on the antimicrobial activity of
primary murine tracheal epithelium against 5". aureus
Taking into account the previous demonstration by Simpson et al. (1999) that
synthetic elafin peptides possess antimicrobial activity against S. aureus CI705, it
seemed appropriate to investigate whether Ad-elafin infection of tracheal epithelium
would enhance killing of this organism.
Figure 7 shows the results of a single experiment using cells derived from
C57BL/6J mice, with data provided as colony counts of S. aureus. In contrast to the
observed antimicrobial activity of epithelium against PAOl (Figure 4), untreated
tracheal epithelial cells were unable to prevent growth of CI705 (Figure 7). Most
notably, Ad-elafin infection of C57 BL/6J tracheal epithelium resulted in enhanced
antimicrobial activity against CI705, and this effect was significant over three
experiments (Figure 7 and Figure 8); compared with uninfected cells, Ad-elafin-
infected cells reduced bacterial numbers by an average of 63% (Figure 8). Likewise,
Ad-elafin infection of tracheal epithelium derived from BALB/c mice resulted in
recovery of a significantly decreased number of colonies of CI705 (Figure 9). In the
case of BALB/c cells, the effects of Ad-elafin were not as pronounced, but still
resulted in an approximately 30% reduction in survival of CI705 (compared with
uninfected cells). It is worthy to note that the enhanced antimicrobial activity
conferred by Ad-elafin was insufficient to reduce bacterial numbers below those
added to the cells at the outset, as demonstrated using C57BL/6J cells (Figure 7). A
further interesting observation was that, in several assays, infection of cells with Ad-
lacZ augmented their antimicrobial activity (Figure 7 and Figure 9).
Finally, analyses of the phosphate buffer used to collect bacteria from the
surface of Ad-elafm-infected tracheal epithelium demonstrated that incubation of
CI705 with these cells caused a significant up-regulation in the level of elafin
secreted (Figure 10). Regrettably, similar data regarding elafin levels secreted by
cells following incubation with PAOl are unavailable, as a result of alterations to the
assay protocol as these experiments progressed.
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Figure 7. Ad-elafin infection of primary tracheal epithelial cells derived from
C57B1/6J mice enhances their antimicrobial activity against Staphylococcus
aureus C1705
Primary tracheal epithelial cells derived from C57BL/6J mice were infected with Ad-
elafin or Ad-lacZ (moi 100 for each) or vehicle alone and incubated for 18-20 hours
at 37°C. 20 nanolitres (nl) of a suspension ofCI 705 was added to cells and incubated
for 3 hours at 37°C. Cell inserts were washed with both 105pi phosphate buffer and
105pl phosphate buffer/0.5% Triton-X, and washes plated on nutrient agar. Agar
plates were incubated overnight at 37°C prior to colony counting. Representative
data from one of three similar experiments are shown. Values represent mean ± S.E.,
carried out in triplicate except 'Initial no. of bacteria' where twelve replicates were
performed.
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Figure 8. Ad-elafln-infected primary tracheal epithelial cells, derived from
C57B1/6J mice, exhibit significantly greater antimicrobial activity against
Staphylococcus aureus C1705 than Ad-lacZ-infected cells
Primary tracheal epithelial cells derived from C57BL/6J mice were infected with Ad-
elafin or Ad-lacZ (moi 100 for each) or vehicle alone and incubated for 18-20 hours
at 37°C. 20 nanolitres (nl) of a suspension ofC1705 was added to cells and incubated
for 3 hours at 37°C. Cell inserts were washed with both 105pi phosphate buffer and
105pl phosphate buffer/0.5% Triton-X, and washes plated on nutrient agar. Agar
plates were incubated overnight at 37°C prior to colony counting. Values represent
mean ± S.E. of n=3 experiments, each performed in triplicate. * = significant
difference, P<0.05, compared with Ad-lacZ-infected cells.
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Figure 9. Ad-elafin-infected primary tracheal epithelial cells, derived from
BALB/c mice, exhibit significantly greater antimicrobial activity against
Staphylococcus aureus C1705 than either uninfected or Ad-lacZ-infected cells
Primary tracheal epithelial cells derived from BALB/c mice were infected with Ad-
elafin or Ad-lacZ (moi 100 for each) or vehicle alone and incubated for 18-20 hours
at 37°C. 20 nanolitres (nl) of a suspension ofCI705 was added to cells and incubated
for 3 hours at 37°C. Cell inserts were washed with both 105pi phosphate buffer and
105pl phosphate buffer/0.5% Triton-X, and washes plated on nutrient agar. Agar
plates were incubated overnight at 37°C prior to colony counting. Values represent
mean ± S.E. of n=2 experiments, both performed in triplicate. # = significant
difference, P<0.05, compared with uninfected cells. ** = significant difference,
P<0.01, compared with Ad-lacZ-infected cells. ### = significant difference,
P<0.001, compared with uninfected cells.
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Figure 10. Staphylococcus aureus C1705 up-regulates elafin secretion from Ad-
elafin-infected tracheal epithelial cells
Primary tracheal epithelial cells derived from C57B1/6J mice were infected with Ad-
elafin and incubated for 18-20 hours at 37°C. 20 nanolitres (nl) of a suspension of
CI705 was added to cells and incubated for 3 hours at 37°C. Alternatively, cells
were incubated with 20nl of phosphate buffer. Cell inserts were washed with both
105pl phosphate buffer and 105pi phosphate buffer/0.5% Triton-X, samples pooled
and centrifuged at 8000rpm for 10 mins. Pellets were resuspended in 200pl
phosphate buffer and plated onto nutrient agar for colony counting, while
supernatants were analysed by elafin ELISA (see 'Materials and Methods'). Values
represent mean ± S.E. of n=3 experiments, each performed in triplicate. * =
significant difference, P<0.05, compared with 'Ad-elafin alone'.
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6.3. DISCUSSION
The principal conclusion arising from these data is that Ad-elafin infection of
primary murine tracheal epithelium modulates the antimicrobial activity of these
cells against P. aeruginosa and S. aureus. Interestingly, while infection of epithelial
cells with Ad-elafin significantly enhanced their antimicrobial activity against S.
aureus (Figures 7-9), the inherent ability of cells to kill P. aeruginosa was greatly
compromised by Ad-elafin infection and this treatment in fact augmented bacterial
survival (Figures 4-6).
The primary culture model of differentiated murine tracheal epithelium
described in this chapter was chosen for use in these studies for a number of reasons.
Firstly, we deemed the murine tracheal epithelium to be an appropriate physiological
model for bacterial invasion of the airways, in particular since both P. aeruginosa
and S. aureus are known to cause infection of the trachea in vivo (Vishwanath and
Ramphal, 1984; Baltimore et al., 1989; Hutchison and Govan, 1999; Kobashi and
Matsushima, 2003); moreover, tracheal epithelium is known to be an important site
for initial colonisation of the upper respiratory tract of CF patients by non-mucoid P.
aeruginosa (Fegan et al., 1990; Grimwood, 1992). Secondly, since these culture
models are grown on semipermeable membranes at an air-liquid interface, no culture
medium bathes the cells apically; these cells thus form a confluent, polarised, ciliated
epithelia, lined only by a small volume of secreted airway surface liquid as observed
in vivo (Davidson et al., 2000). For our purposes, this meant that not only could we
more accurately reproduce the in vivo situation, but also that we could eliminate the
difficulties we had experienced in performing antimicrobial assays using more
conventional tissue culture conditions, in which rich media considerably augments
bacterial growth (as discussed in section 6.2.1.). Finally, with regards to the potential
use of adenoviral gene transfer techniques to modulate lung defence mechanisms, the
tracheal epithelium may be considered as a fundamental target in the proximal
airways.
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Furthermore, we considered murine cells as an ideal choice for these gene
transfer studies since no murine homologue of elafin has been identified to date, and
our anti-elafin antibody does not appear to cross-react with any murine protein; thus,
the introduction of this entirely foreign gene could allow us to study the effects of
elafin without the contribution of a homologous native molecule. However, although
no expression of elafin has been demonstrated in mice, elafin has previously been
localised in the trachea of other species, including man (Nara et al., 1994; Suzuki et
ah, 2000).
Discussion of the results of these antimicrobial assays will be divided into
separate sections for each organism, with slightly more emphasis on P. aeruginosa
since the results obtained with this bacterium necessitate more detailed analyses.
6.3.1. The effects of elafin gene augmentation on the antimicrobial activity of
primary murine tracheal epithelium against P. aeruginosa
The experiments using primary murine tracheal epithelium were prompted by
an inability to gain consistent or informative results regarding the antimicrobial
activity of adenovirally-infected Clara cells against PAOl, using standard tissue
culture techniques. Nevertheless, an interesting observation arising from these initial
Clara cell assays was that P. aeruginosa PAOl appeared to degrade or metabolise
elafin protein secreted by Ad-elafin-infected cells (Figure 1). Thus, at this point we
postulated that the lack of an observed Ad-elafin-mediated antimicrobial effect may
be attributable to inactivation of elafin by the bacteria, thus masking any underlying
microbicidal action.
These findings were corroborated by the remarkable finding that, not only did
Ad-elafin infection of tracheal epithelium compromise the inherent ability of cells to
exert a bactericidal effect against PAOl, this treatment in fact significantly enhanced
bacterial survival (Figures 4 and 5). We also demonstrated that this phenomenon was
not restricted to the P. aeruginosa strain PAOl, since the clinical P. aeruginosa
strain J1385 also exhibited improved subsistence on Ad-elafin-infected cells (Figure
6). This augmentation of P. aeruginosa survival was certainly associated with
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secretion of high concentrations of elafin into the airway surface liquid of Ad-elafin-
infected tracheal epithelium, and the complete absence of elafin secretion by
uninfected or Ad-lacZ-infected cells (again confirming no cross-reactivity of the
anti-human elafin antibody with a similar murine molecule) (Figure 3). It should be
noted that figure 3 shows elafin levels secreted by Ad-elafin-infected epithelium
following incubation without P. aeruginosa; unfortunately, no reliable ELISA data
were obtained during these experiments regarding elafin levels following incubation
with this organism.
Although both Simpson et al. (1999) and Meyer-Hoffert et al. (2003) have
previously demonstrated that elafin peptides display antibacterial activity against P.
aeruginosa, these studies produced slightly differing results. While the strains of P.
aeruginosa used by the two groups were different (PAOl in the study carried out by
Simpson et al., three ATCC strains in the study carried out by Meyer-Hoffert et al.),
potentially contributing to discrepancies between the results, the concentrations of
elafin tested in both investigations were in a similar micromolar range. The more
recent study described by Meyer-Hoffert et al. (2003) demonstrated that elafin's
antimicrobial acitivity against all three P. aeruginosa strains was dose-responsive,
and was therefore maximal at the highest elafin concentration tested. Contrastingly,
the study carried out by Simpson et al. (1999) demonstrated an inverse dose-response
relationship for elafin's antimicrobial activity against PAOl, in that elafin's effects
were maximal at a low intermediate concentration in the dose range and considerably
reduced at higher concentrations. However, it must still be noted that Simpson et al.
(1999) observed significantly decreased bacterial numbers over all elafin
concentrations, as compared with bacterial growth in controls, and these findings are
also in disagreement with those ofMeyer-Hoffert et al. (2003). A critical difference
between the studies, and one not taken into account in the discussion of the paper by
Meyer-Hoffert et al., is that the elafin peptides used by the two groups were
different; while the study by Simpson et al. used synthetic full-length elafin (95
amino acids), the NH2-terminal domain (50 amino acids) and the COOH-terminal
domain (45 amino acids), Meyer-Hoffert et al. used a recombinant 57 amino acid
form of elafin consisting predominantly of elafin's COOH-terminal domain (Wiedow
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et al., 1990; Meyer-Hoffert et al., 2003). Nevertheless, Simpson et al.'s study
additionally demonstrated an inverse dose-response relationship for the antimicrobial
activity of the COOH-terminal domain against P aeruginosa, adding further to the
intriguing comparison between these studies. Neither study provided evidence of a
microbicidal effect of elafin against P. aeruginosa i.e. a reduction in bacterial
numbers below those added at the outset of the assays.
Therefore, it seems reasonable to suggest that the findings of our study bear a
stronger relationship with those of Simpson et al. (1999). Importantly, the elafin
protein secreted by Ad-elafin-infected cells is the same as the 9.9kDa (95 amino
acid) full-length synthetic elafin peptide used in that study. As mentioned, while this
previous investigation demonstrated an increase in bacterial numbers as elafin
concentration increased, at no point did the number of PAOl colonies exceed those
in controls (Simpson et al., 1999). Here, Ad-elafin-infection of tracheal epithelium
resulted in impairment of cellular clearance of PAOl (and indeed J1385), coupled
with a significant augmentation of bacterial survival compared with controls (Figures
4-6). While it must be pointed out that Ad-lacZ infection generally caused a slight
hindrance of cellular bactericidal activity, these effects were not significant (Figures
4-6).
The observation that Ad-elafin-infected cells encourage growth of
P.aeruginosa is most interesting, and the reasons for this phenomenon are not
entirely clear.
One potential explanation could be that this organism is capable of using
elafin as a nutrient for growth, and is therefore able to thrive in the airway surface
liquid of cells secreting elafin. P. aeruginosa is known to have both a broad
metabolic diversity, for example its use of crude oil hydrocarbons as an energy
source in the environment, and a propensity to survive and grow in the presence of
limited nutritional resources (Juffs, 1976; Clarke, 1982; Terry et al., 1991; Alonso et
al., 1999). In seeking an explanation for the inverse dose-response relationship
observed during their investigations, Simpson et al. (1999) suggested that there may
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exist a critical balance between elafin exerting an antimicrobial effect at lower
concentrations, and providing a source of nutrition for P. aeruginosa at higher
concentrations. This hypothesis may also be applicable to our studies. Elafin levels
recovered from the airway surface fluid of Ad-elafin-infected cells were typically
around 3.5pg/ml, equivalent to 350nM elafin (Figure 3) (this figure in itself can only
be approximate, since in its calculation we assumed the total volume ofASL bathing
cells to be 1 pi). Although this concentration would be at the low end of the range
used by Simpson et al. (the lowest concentration assayed in their study was 1 pM),
the very small volume of ASL produced by cells may mean that extracellular elafin
is in fact highly concentrated on the epithelial cell surface. Considerable differences
in the numbers of bacteria used in the two studies also make direct comparisons
difficult, but it seems plausible that P. aeruginosa may be able to thrive on the high
concentrations of elafin secreted by Ad-elafm-infected cells. Unfortunately,
constraints dictated that we have no data pertaining to the levels of elafin recovered
from Ad-elafin-infected tracheal epithelium incubated with P. aeruginosa. The
enhanced survival of bacteria in the presence of elafin observed here does, however,
add further substance to our earlier hypothesis to explain disappearance of the elafin
band produced by Ad-elafin-infected Clara cells on incubation with PAOl (Figure
1). The complete 'removal' of detectable elafin by PAOl from the culture media of
Ad-elafin-infected cells may be considered even more remarkable in view of the fact
that Gram-negative LPS has previously been shown to up-regulate elafin production
by Ad-elafin-infected cells (Simpson et al., 2001a). Additionally, it is possible that
elastase produced by P. aeruginosa could inactivate elafin directly, as has previously
been demonstrated in the case of the other member of the ALP superfamily, SLPI
(Sponer et al., 1991).
Interestingly, these findings may help to explain the previous observation that
elafin levels are down-regulated in sputa from cystic fibrosis patients (Sallenave et
al., 1999b). The presence in sputum of large numbers of P. aeruginosa, and
potentially other pathogens such as the pseudomonad Burkholderia cepacia, may
lead to degradation of elafin in vivo, and thus contribute to enhanced colonisation
and reduced antimicrobial activity against organisms such as S. aureus. SLPI levels
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were contrastingly shown to be increased in CF sputa (Sallenave et al., 1999b), and
therefore it would be of interest to investigate the effects of adenoviral
overexpression of SLPI on the antibacterial activity of tracheal epithelium in the
same model used here.
In concert with the aforementioned hypotheses to explain increased P.
aeruginosa survival, adenoviral gene transfer of elafin to tracheal epithelium may
potentially affect the cellular production of endogenous antimicrobial peptides. The
murine lung is known to produce a range of cationic antimicrobial peptides known as
the murine P-defensins (Huttner et al., 1997; Bals et al., 1998a; Morrison et al.,
1998; Morrison et al., 1999; Bals et al., 1999a; Jia et al., 2000; Bauer et al., 2001;
Yamaguchi et al., 2001; Morrison et al., 2003); in several cases expression of these
peptides has been specifically demonstrated in the trachea (Bals et al., 1998a;
Morrison et al., 1998; Morrison et al., 1999; Jia et al., 2000; Yamaguchi et al., 2001).
Murine p-defensins have been shown to possess antimicrobial activity against Gram-
positive and Gram-negative bacteria, including P. aeruginosa and S. aureus, and
therefore any disruption in the activity of these peptides could potentially weaken the
antimicrobial profile of airway epithelium (Bals et al., 1998a; Morrison et al., 1998;
Bals et al., 1999a; Bauer et al., 2001; Yamaguchi et al., 2001; Morrison et al., 2002a;
Morrison et al., 2002b).
Posttranslational proteolytic processing is required in order to convert P-
defensins from a precursor (prepropeptide) form into their mature antimicrobial form
(Martin et al., 1995; Lehrer and Ganz, 2002). Other cationic antimicrobial peptides
also rely on proteolytic cleavage for liberation of the fully functional molecule; for
example, cryptdins of murine Paneth cells are processed by the matrix
metalloproteinase matrilysin, while neutrophilic cathelicidins such as porcine
protegrin-3 and human LL-37 require extracellular processing by the serine proteases
elastase and proteinase-3 respectively (Panyutich et al., 1997; Wilson et al., 1999;
Sorensen et al., 2001). With regards in particular to the last two examples, it is
apparent that epithelial overexpression of a serine proteinase inhibitor such as elafin
may potentially inhibit cleavage of endogenous antimicrobial peptides to their
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mature form. Although little is currently known about the enzymes required for
processing ofmurine P-defensins, serine proteinases such as those inhibited by elafin
could potentially be involved. As discussed in Chapter 1, elafin has a narrow
spectrum of protease inhibitory activity and in humans has been shown to inhibit
only neutrophil elastase (HNE) and proteinase-3 (Wiedow et al., 1990; Sallenave and
Ryle, 1991; Wiedow et al., 1991). While these proteases are well characterised as
neutrophilic enzymes, epithelial cells may also be a source of proteinase-3 or
elastase-like activity (Schwarting et al., 2000; Achilles and Bednarski, 2003). HNE
preferentially hydrolyses bonds adjacent to small aliphatic amino acids such as valine
or alanine, while proteinase-3 preferentially cleaves alanine, serine and valine (Bode
et al., 1989; Rao et al., 1991). Analysis of peptide sequence alignments ofmurine P-
defensins (provided by Morrison et al. (2003)) reveals that several peptides,
including murine p-defensin-2, have an alanine residue adjacent to the bond cleaved
to form the mature peptide (see murine p-defensin-2 sequence below this paragraph;
putative cleavage site indicated by an arrow); such sites could potentially be a target
for elastolytic activity. Therefore, it is also feasible that Ad-elafin infection ofmurine
epithelium could hinder the innate ability of cells to kill P. aeruginosa by inhibiting
processing of endogenous antimicrobial peptides. However, such a hypothesis is
entirely speculative and warrants further investigation. It would thus be of interest in
future studies to investigate levels of defensin production by these tracheal epithelia
models, prior to and following infection with Ad-elafin, to determine whether
antiproteinase overexpression can interfere with their processing (and function).
)— signal sequence —|— pro-piece —|— mature peptide —|
|MRTLCSLLLICCLLFSYTTPl\VGSLKSIGYEA|ELDHCHTNGGYCVRAICPPSARRPGSCFPEKNPCCKYMKl
t
Finally, it has previously been demonstrated that serine proteinase inhibitors
such as a 1-proteinase inhibitor and al-antichymotrypsin can interact with and
inactivate the a-defensin human neutrophil peptide (HNP)-l (Panyutich et al., 1995).
The same study also observed that SLPI did not interact with HNP-1, and
hypothesised that this may be due to the cationic nature of both molecules. While
elafin has a similar cationic character to SLPI, and a direct interaction between elafin
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and defensins thus seems unlikely, any complex formation between elafxn and
endogenous cationic antimicrobial peptides could have potentially compromised
bacterial killing in these experiments.
It is important to note that these assays, while providing an interesting ex vivo
model for the effects of Ad-elafm on the antimicrobial activity of murine tracheal
epithelium against P. aeruginosa, are indubitably insufficient to recreate the complex
interactions which take place during bacterial infection in vivo. This is highlighted by
comparison with the study performed by Simpson et al. (2001), which demonstrated
that adenoviral augmentation of elafin in the murine lung was protective against
acute injury mediated by P. aeruginosa PAOl, and resulted in significantly reduced
bacterial numbers in the airways. Evidently the immune responses employed to
combat and clear P. aeruginosa infection in vivo are far more complex than can be
modelled in our system, and the effects of elafin augmentation in the host are more
extensive than can be attributed to its antimicrobial activity alone.
6.3.2. The effects of elafin gene augmentation on the antimicrobial activity of
primary murine tracheal epithelium against S. aureus
In contrast to the results obtained with the Gram-negative organism P.
aeruginosa, Ad-elafm infection significantly enhanced the antimicrobial activity of
murine tracheal epithelium against the Gram-positive organism S. aureus CI705
(Figures 7-9). Also of interest was the finding that tracheal epithelium was unable to
exert a bactericidal effect against CI705, such that bacterial numbers typically
increased by an average of around 20-fold following 3-hour incubation with cellular
inserts (Figure 7). This suggests that production of endogenous defensins by tracheal
epithelium, such as murine p-defensins 1, 2, 4 and 6 (Bals et al., 1998a; Morrison et
al., 1998; Morrison et al., 1999; Jia et al., 2000; Yamaguchi et al., 2001), may be
insufficient to kill S. aureus C1705, despite demonstrable activity of at least murine
P-defensin 1 against S. aureus in vitro (Bals et al., 1998a). The mechanism of S.
aureus resistance to defensin activity in tracheal cultures may be complex, but could
be due to its capacity to modify phosphatidylglycerol, one of its major membrane
phospholipids, with Z-lysine, giving the molecule a net positive charge and thus
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resistance to cationic defensins (Peschel, 2002). A recent study has also described an
exoprotein produced by S. aureus, known as staphylokinase, which can bind to and
neutralise the antimicrobial activity of human a-defensins (Jin et al., 2004). This
strain of S. aureus can, however, be cleared effectively by murine lungs in vivo
(Morrison et al., 2002a).
The effects of elafin in this model cannot be described as bactericidal, since
the cfu of S. aureus recovered following incubation with Ad-elafin-infected cells
were not lower than those added at the outset (Figure 7). However, compared to
uninfected and Ad-lacZ-infected cells, cells producing elafin exerted a considerably
enhanced antimicrobial activity (Figures 8 and 9). Elafin secretion is therefore
associated with significant inhibition of growth of S. aureus, although it is unclear
from these studies whether elafin acts to slow the growth of the organisms, directly
kills a proportion of the organisms, or a combination of both. Moreover, a synergistic
activity of elafin with endogenous antibacterial peptides (which may be inadequate to
combat infection alone) cannot be ruled out; synergism between neutrophil defensins
and cathelicidins has previously been demonstrated against S. aureus (Nagaoka et
al., 2000).
Cationic antimicrobial peptides can interact directly with components of S.
aureus, such as teichoic acid and lipoteichoic acid (Scott et al., 1999a; Vorland et al.,
1999), and it is tempting to speculate that elafin may also be capable of direct
interaction with similar structural determinants of Gram-positive bacteria. Elafin can
be included among a wide range of antimicrobial peptides which have been shown to
display antimicrobial activity against S. aureus (Giacometti et al., 1998; Severina et
al., 1998; Turner et al., 1998; Friedrich et al., 2000; Travis et al., 2000; Midorikawa
et al., 2003). SLPI, the other member of the antileukoprotease superfamily of
proteinase inhibitors, has also been demonstrated to possess antimicrobial activity
against several common bacterial pathogens, including S. aureus and P. aeruginosa
(Hiemstra et al., 1996; Wiedoweta/., 1998).
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With regards to the adenoviral gene transfer techniques used to confer elafin
production to epithelial cells in our investigations, recent studies have demonstrated
similar enhancement of antimicrobial activity by overexpression of the human
cathelicidin antimicrobial peptide hCAP18/LL-37. While administration of a
synthetic hCAP18/LL-37 peptide could protect mice against the effects of P.
aeruginosa (Kirikae et al., 1998), overexpression using adenovirus vectors
containing the cDNA for hCAP18/LL-37 were shown to significantly augment
bacterial killing in two separate studies (Bals et al., 1999b; Bals et al., 1999c). In
vitro, adenoviral overexpression of this cathelicidin in a cystic fibrosis bronchial
xenograft model augmented the antimicrobial activity of ASL against both S. aureus
and P. aeruginosa (Bals et al., 1999b). In mouse models, intratracheal administration
of these adenoviral vectors conferred protection against the effects of pulmonary
challenge with P. aeruginosa, and was associated with a lower bacterial load (Bals et
al., 1999c). It is therefore apparent that adenoviral gene transfer of antimicrobial
peptides may provide protection against certain bacterial pathogens.
A further interesting observation made during our studies was that incubation
of S. aureus with Ad-elafin-infected tracheal epithelium actually enhanced secretion
of elafin (Figure 10). This also contrasts with the previous finding that P. aeruginosa
appeared to eradicate elafin secreted by cells (Figure 1), perhaps reflecting elafin-
mediated antimicrobial action against S. aureus on one hand and metabolism of
elafin by P. aeruginosa on the other. Although the mechanisms by which S. aureus
upregulates elafin secretion are unclear, it may be possible that components of this
organism, such as lipoteichoic acid, can regulate elafin transgene expression in a
similar fashion to that demonstrated by LPS (Simpson et al., 2001a). As per Simpson
et al. (2001a), up-regulation may be due to stimulatory effects of bacterial products
on the mCMV promoter at the transcriptional level; however, no mRNA data was
obtained in order to support this hypothesis.
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6.4. SUMMARY
The work in this chapter has demonstrated that Ad-elafin infection of primary
murine tracheal epithelium can modulate the antimicrobial activity of these cells
against common respiratory pathogens. However, the effects of Ad-elafin were
highly dependent upon the type of organism used to model infection. Ad-elafin
infection conferred significant antimicrobial activity against the Gram-positive
organism S. aureus, but compromised the inherent ability of cells to kill Gram-
negative P. aeruginosa, and in fact greatly enhanced its survival.
While Bals et al. (1999b) demonstrated that adenoviral overexpression of the
cathelicidin hCAP18/LL-37 could reverse the bacterial killing defect against both S.
aureus and P. aeruginosa in a cystic fibrosis bronchial xenograft model, the data
presented here suggest that the therapeutic advantage of elafin augmentation may be
more pathogen-specific. Elafin overexpression may be of benefit in eliminating
pathogens in conditions such as CF when the spectrum of pathogens is clearly
defined, for example in infancy prior to colonisation with P. aeruginosa-, however,
caution is undoubtedly warranted in the design of treatments for such a complex
clinical condition.
In conclusion, these findings contribute to the knowledge surrounding
potential roles for elafin in the innate immune response to bacterial infection, and
emphasise the need for further characterisation of the effects of elafin overexpression
in vivo.
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CONCLUDING REMARKS AND FUTURE DIRECTIONS
The experiments described in this thesis have shown that elafin can bind
directly to Gram-negative bacterial lipopolysaccharide, a potent immunomodulatory
molecule and key instigator of the pathophysiology of Gram-negative septic shock.
Furthermore, binding of elafin to LPS appears to occur within the conserved lipid A-
core portion of the LPS molecule, suggesting that elafin may recognise a broad range
of bacterial lipopolysaccharides. Elafin bound to LPS can prevent subsequent
interaction of LPS with the serum lipid transfer protein LBP, a critical step in LPS-
mediated cellular activation.
This observation led to experiments suggesting that binding of elafin to LPS
may provoke contrasting roles in inflammatory immune responses. In the presence of
serum, exogenous elafin dampened LPS activation of macrophages, whereas LPS-
induced responses were augmented by elafin in the absence of serum. These findings
have suggested that inhibition of LPS interaction with serum factors such as LBP
may confer to elafin a net anti-inflammatory role in macrophage activation while, in
conditions short of serum reactants, elafin may itself function as an LPS 'transfer'
molecule.
Elafin gene augmentation was found to suppress the inflammatory response
of macrophages to LPS in serum-containing milieu, and further experiments
demonstrated that these effects were not mediated by extracellular elafin. These
findings infer an important role for intracellular elafin in dampening macrophage
responsiveness by interfering with the LPS signalling pathway.
Together these observations suggest that elafm may fulfil a dual role in innate
immunity, enhancing immune responses in sites of local inflammation, such as the
airways, but dampening potentially deleterious systemic inflammatory responses in
the circulation.
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The characteristics of elafin suggest intrinsic antimicrobial properties, and
adenovirus-mediated elafin overexpression in murine tracheal epithelium ex vivo was
shown to confer antimicrobial activity against Staphylococcus aureus, but
compromised the inherent ability of cells to kill Pseudomonas aeruginosa. Ad-elafin
infection may thus confer pathogen-specific augmentation of antimicrobial defences
in cells constantly exposed to microbial challenge.
These experiments advance our understanding of elafin biology and of
potential activities for elafin in modulating inflammation in vivo, but a great many
findings require further definition and could form the subject of future research.
It would be of interest to determine whether elafin can also inhibit
interactions of LPS with other molecules of the LPS receptor complex, such as
CD 14, or indeed prevent formation of the LPS-CD14-TLR4-MD-2 complex. Such
inhibitory activities could potentially contribute to the anti-inflammatory effects of
elafin on macrophage activation in the presence of serum. However, since elafin was
found to play divergent roles in LPS-mediated activation, a potential role for elafin in
accelerating binding of LPS to CD14 or to TLR4-MD-2 is also a possibility, and
should be addressed. As previously suggested in Chapter 4, the use of adenovirus
techniques to overexpress TLR4-MD-2 and CD14, perhaps even in cells which do
not normally express these molecules, may be of benefit in investigating elafin's
putative function in facilitating LPS transfer to the receptor machinery. Additionally,
experiments aimed at investigating the key serum factors that contribute to elafin
acting either as LPS agonist or antagonist may involve blockade of LBP and/or
sCD14 in serum, but could equally encompass cellular overexpression of these
molecules in serum-free conditions.
Although not performed here, an investigation of the kinetics of elafin-LPS
interaction would be useful in order to compare specifically the LPS-binding
affinities of elafin with those of the LPS receptor complex. The identification of a
putative cellular elafin receptor would also contribute to knowledge surrounding
roles for elafin during inflammation, since elafin uptake could potentially dampen
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LPS-mediated inflammation intracellularly, or lead to elafin-LPS internalisation.
Furthermore, identification of such an elafin receptor may also provide a mechanism
by which elafin can mediate its chemotactic activity for neutrophils; for example, the
human cathelicidin LL-37 has been shown to use the formyl peptide receptor-like 1
(FPRL1) to chemoattract neutrophils, monocytes and T cells (Yang et al., 2000).
In terms of the effects observed in this study of elafin gene augmentation in
macrophages, creation and overexpression of a non-secretory form of elafin could
potentially help to answer questions regarding its intracellular role in modulating
LPS responses. Likewise, it would be of interest to mutate or oxidise elafin's active
site in order to investigate whether antiproteinase activity is important for the anti¬
inflammatory effects observed here. Elafin's effects on components of the LPS
signalling pathway upstream of IkB, such as MyD88, IRAK and the IKK complex,
also remain to be elucidated.
With regard to elafin's antimicrobial activity, it would be of interest to
investigate potential synergism with other cationic antimicrobial peptides, and even
with conventional antibiotics. Elafin could potentially bind systemic LPS released by
bacteria following antibiotic-mediated killing and prevent subsequent inflammation,
as shown previously using co-administration of BPI with antibiotic treatment.
Interactions of elafin with cell surface components of Gram-positive bacteria, such as
lipoteichoic acid, also merit investigation. Moreover, the effects of adenovirus-
mediated cellular overexpression of elafin on the production of endogenous
antimicrobial peptides, as discussed in Chapter 6, is worthy of further attention to
help explain the findings made here. The potential salt-sensitivity of elafin's
antimicrobial action additionally remains to be clarified, since this could abolish the
molecule's activity in vivo in inflammatory conditions such as cystic fibrosis.
In conclusion, the findings described in this thesis may further contribute to
the understanding of roles played by elafin in the innate immune response. The
activities ascribed to elafin thus far, including antiproteinase, antimicrobial,
neutrophil-chemoattractant and anti-endotoxin activities, have suggested a range of
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functions for this molecule in mediating inflammatory responses. Due to its
widespread distribution within skin, mucosal epithelial tissues and cells of myeloid
lineage, and upregulation in response to early inflammatory stimuli, elafin may be
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